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Summary 
Background and aims: Familial hypercholesterolemia (FH) is a metabolic autosomal 
dominant disorder. It is characterised by elevated plasma total cholesterol and low 
density lipoprotein (LDL) cholesterol levels usually due to a genetic mutation in the 
LDL receptor gene and have therefore a higher risk of non-fatal or fatal coronary 
heart disease (CHD). Yet, there is a substantial variation between individuals with 
FH, even among FH subjects with the same genetic mutations, in susceptibility to 
CHD in terms of the age of onset and severity. The aim of this thesis was to increase 
the knowledge about which factors that may affect the onset of CHD in FH subjects. 
This is an important knowledge in order to determine how intense the treatment the 
various patients should be offered and how early treatment should be initiated.  
Subjects and methods: Two different studies were included in this thesis. The first 
study, a retrospective data collection study, characterised and compared clinical and 
biochemical parameters from the medical records of  71 FH subjects with early CHD 
event and 76 FH subjects with late or no CHD event. In addition, 14 deceased FH 
subjects with early CHD event and 14 deceased FH subjects with late or no CHD 
event were compared with each other and with the non-deceased FH groups. In the 
second study, a case-control study administered by the master student, clinical and 
biochemical parameters in a smaller group of FH subjects with more strict inclusion 
criteria than the first study were compared, with special regard to different 
coagulation factors, CRP and fibrinogen. The case-control study included 19 FH 
subjects with early CHD event, 15 FH subjects with late or no CHD event and 10 
control subjects. All groups except from the control group were subdivided into 
gender. 
Results: FH subjects with early onset of CHD seems to have a more severe risk factor 
profile compared with FH subjects with late or no CHD event, even though they are 
more intensively medically treated. Female FH subjects seem to have a more severe 
risk factor profile in comparison with male FH subjects, suggesting that they are not 
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well enough medically treated. However, in general, today’s lipid-lowering treatment 
seems to be more effective than the lipid-lowering treatment ten years ago, reducing 
the risk of fatal CHD in FH subjects. In our study, coagulation markers do not appear 
to play a determining role in susceptibility to CHD in FH subjects. 
Conclusion: Even though the treatment in FH subjects seems to have improved 
substantially, there is still a potential for improvement concerning reaching the 
treatment goals for blood lipid levels. Our results may also indicate that female FH 
subjects may need to be followed up more closely, and to be more extensively treated 
with lipid-lowering medication and combination medication. The contribution of 
lipoprotein (a) in particular but also supplementation with omega-3 fatty acids with 
regard to CHD risk and death in FH subjects should be examined to a greater extent. 
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1. Introduction 
1.1 Coronary heart disease 
Coronary heart disease (CHD) is one of the leading causes of deaths worldwide (1, 2). 
In Norway, CHD accounts for approximately 32 % of all deaths in men and 35 % of 
all deaths in women (3). CHD, also called coronary artery disease (CAD), is a 
subgroup of cardiovascular disease (CVD). CVD includes all diseases of the heart and 
circulatory system while CHD primarily affects the coronary arteries and the arteries 
through the progress of atherosclerosis. 
Scientific evidence suggests that the vast majority of coronary events can be 
explained on the basis of different risk factors for CHD (2). Risk factors are often 
classified into two groups; modifiable or non-modifiable. Examples of modifiable risk 
factors are high blood pressure, obesity, diabetes, unhealthy diet, smoking, low 
physical activity and elevated plasma cholesterol levels. Examples of non-modifiable 
risk factors are age, gender and genetic susceptibility (4).  
The prevalence of CHD increases with increasing age and in the general population 
clinical manifestations of CHD seldom appear before the fourth decade of life (5). 
Nevertheless, evidence indicates that atherosclerosis, the major cause of CHD, begins 
early in life and progresses silently for decades (5, 6).  
1.2 Cholesterol metabolism 
All cell membranes contain cholesterol (7). Cholesterol is also a precursor of bile 
acids and steroid hormones. Its distribution is mediated through the blood system. The 
cholesterol molecule itself is insoluble in blood. Lipoproteins make cholesterol 
molecules soluble by binding them to form a lipid droplet. Then the insoluble parts 
point inwards to the core of the lipid droplet and the soluble parts point towards the 
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blood. There are different types of lipoproteins, some transport mainly fatty acids 
(FA) in the form of triglycerides (TG), others transport mainly endogenously 
synthesised cholesterol or absorbed dietary fat (7).  
1.2.1 Cholesterol homeostasis 
Cholesterol homeostasis in the body is assured through the actions of two major 
groups of lipoproteins; those containing apolipoprotein B (ApoB) such as 
chylomicrons, very low density lipoprotein (VLDL) and VLDL remnants, 
intermediate density lipoprotein (IDL) and low density lipoprotein (LDL), and those 
containing apolipoprotein A1, principally high density lipoprotein (HDL) (8).  
1.2.2 Lipoprotein metabolism 
As shown in figure 1, dietary cholesterol is absorbed in the gut and transported to the 
liver in TG-rich chylomicrons (9). Cholesterol and TGs synthesized in the liver are 
secreted into the circulation in VLDL particles. Chylomicrons and VLDL ensure the 
distribution of energy in the form of TGs and FAs to peripheral tissues (10). In the 
circulation, the enzyme lipoprotein lipase releases TGs from VLDL. The VLDL 
remnants are either removed from the circulation by the liver or converted via IDL 
into LDL particles by the enzyme hepatic lipase. LDL distributes cholesterol to 
peripheral cells mediated with the help of LDL receptors (LDL-Rs). HDL transport 
excess cholesterol back to the liver for degradation and/or and excretion in bile acid. 
This process is facilitated either directly by a HDL specific receptor in the liver or 
indirectly through conversion of HDL by the enzyme cholesteryl ester transfer protein 
to VLDL and LDL followed by uptake in the liver facilitated by LDL-Rs on the liver 
cells. LDL-C account for 60-70 % of the total serum cholesterol (11). 
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Figure 1. Lipoprotein metabolism. From Bhatnagar et al (9). 
1.3 Atherosclerosis 
Atherosclerosis can be considered to be a form of multi-step chronic inflammation in 
the artery walls (12-14). The different risk factors of CHD contribute to cause 
endothelial injury in the vessels (15). In healthy vessels, the endothelium maintains 
vascular tone and blood pressure (16). In time, the stress from CHD risk factors leads 
to endothelial dysfunction and inhibits endothelial production of nitric oxide (NO) 
(13). NO is a potent vasodilator and anti-inflammatory molecule. The endothelium 
binds monocytes and T lymphocytes, which migrate into the subendothelial space. 
There they initiate and maintain the inflammatory process, and the monocytes 
transform to macrophages (12). LDL particles also bind to endothelial cells and 
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migrate to the subendothelial space. In the vascular wall the LDL particles are subject 
to oxidative modifications, and recruit more monocytes from the blood (8, 16). The 
macrophages take up oxidized LDL in the subendothelium and are transformed into 
foam cells. This process results in the development of so-called fatty streaks (13).  
Macrophages, T lymphocytes and proinflammatory molecules further promote the 
deposits of cholesterol, cellular waste products of among others smooth muscle cells, 
calcium and other substances in the arteries (8, 13). The result is fibrous lipid-filled 
plaques. The plaques may rupture and, if an occluding thrombus is formed, different 
outcomes such as a heart attack or a stroke may be seen (12, 17). 
1.3.1 Cholesterol as a CHD risk factor 
While LDL cholesterol (LDL-C) has an essential physiological role in distributing 
cholesterol to peripheral tissues, increased LDL-C levels are associated with 
increased CHD risk (11, 12). Increased total cholesterol and LDL-C is considered a 
CHD risk factor of crucial importance (4). In the dyslipidemic state, subendothelial 
uptake and oxidation of LDL increases; oxidized lipids stimulate production of 
adhesion molecules and inflammatory cytokines and may have antigenic properties, 
promoting a T lymphocyte–mediated immune response and inflammation in the 
arterial wall (15).  
The atheroprotective role of HDL 
 HDL protects against atherosclerosis. Some of the atheroprotective function is 
mediated via reverse cholesterol transport (15). However, HDL particles also 
transport antioxidant enzymes, which can break down oxidized lipids and neutralize 
their proinflammatory effects (18). Hence, a low HDL cholesterol (HDL-C) level is 
strongly and inversely associated with CHD risk (11).  
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1.4 Familial hypercholesterolemia 
1.4.1 History and prevalence 
Heterozygous familial hypercholesterolemia (FH) is a metabolic autosomal dominant 
disorder (19).  
The condition is caused by defects in one of at least three different genes that code for 
proteins that affects the normal control of lipoprotein metabolism, and are involved in 
hepatic clearance of LDL (20). These include, most commonly, different mutations in 
the LDL-R gene (7, 19, 20). The LDL-R mediates feedback control of cholesterol 
synthesis (7). Much less common are mutations in the gene coding for ApoB, the 
major protein of the LDL particle. Rarely, FH also results from mutations in the gene 
coding for proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme 
involved in LDL-R turnover (20).  
Expression of LDL-Rs is subject to feedback control by intracellular cholesterol 
levels (12). Low levels of intracellular cholesterol activate the sterol regulatory 
element binding protein-2 (SREBP-2) transcription factors which again stimulate 
transcription of the LDL-R gene and other genes involved in cholesterol synthesis 
(12). LDL-R has a dual role in LDL metabolism (7). As shown in figure 2, when the 
LDL-Rs are genetically defective they impede the liver cells from LDL uptake and 
thereby degradation. At the same time the liver cells produce more LDL through 
VLDL and IDL. Both processes contribute to increased LDL-C plasma levels.  
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Figure 2. LDL-R controls both production and catabolism of LDL in plasma. From Brown 
and Goldstein (7).  
 
Hypercholesterolemia in FH subjects is present from birth (21). The mutations result 
in accumulation of both total cholesterol and LDL-C in the blood plasma and in 
peripheral tissues and arterial walls which again leads to increased risk of premature 
CHD (20). Premature CHD is by many defined as CHD event occurring <55 years in 
men and <65 years in women, respectively (11, 22-24). With a frequency of one in 
500, heterozygous FH on a world basis is one of the most common inborn errors of 
metabolism (19, 25). The prevalence of homozygous FH is one in one million 
persons. Heterozygous FH affects about one in 300 individuals in the Norwegian 
population (26), estimated from a study in the county of Østfold, Norway (27).  
Worldwide, there have by 25 May 2010 been identified 1,739 allelic variants and 
1,120 unique allelic LDL-R mutations (28).  
According to Leren et al (26), by May 2007 a total of 3,900 Norwegians had been 
genetically diagnosed with FH. As of May 2010, unpublished data provided by Leren 
suggest that the number now has exceeded 4,750 persons. Approximately 130 LDL 
 22 
receptor mutations were by May 2007 (May 2010: unpublished data suggest 140) 
identified in Norway (26). 
1.4.2 The genetic basis of FH 
The LDL-R locus is located on the distal part of the short arm on chromosome 19, on 
band p13.1 to p13.3 (7, 29). On basis of the LDL-R gene mutations’ disturbance in 
function, the mutations are classified into different groups. There are five classes of 
mutations that disrupt the structure and function of the LDL-R and cause FH (21), as 
shown in figure 3. Each class of mutations affect different gene sites in the LDL-R 
metabolism. In class one, so-called receptor-negative or null-allele mutations, no 
LDL-Rs are synthesized. The receptors are synthesized in class two, but there is a 
disruption on the transport from the endoplasmic reticulum to the Golgi apparatus. In 
class three mutations LDL-Rs fail to bind LDL molecules properly even though they 
reach the liver cell surface. Class four mutations are characterised by the failing of 
clustering of LDL-Rs into coated pits after binding the LDL molecules. Finally, class 
five mutations prevent the LDL-Rs from being recycled to the cell surfaces and/or the 
LDL particles from being released in the endosomes for degradation. In consequence, 
FH subjects experience few, if any, functional LDL-Rs (30).  
In a large cohort study of FH subjects and their unaffected relatives, Umans-
Eckenhausen et al (31) found significant variation in LDL-C levels depending on the 
mutation type. FH persons with receptor-negative mutations appear to have higher 
LDL-C levels and also elevated risk of CHD (16, 31). 
 23 
 
Figure 3. Five classes of LDL-R gene mutations. From Kumar et al (32). 
 
Different LDL-R gene mutations prevail in different populations. A relatively large 
number of mutations seem to cause FH in most populations. Yet, in a few populations 
there are founder mutations (33). In Norway, for instance, three mutations account for 
approximately 40 % of the mutations among FH subjects (34). The most frequent 
mutations are FH-Elverum, FH-Svartor and C210G, respectively.  
Many clinically diagnosed FH subjects do not have a monogenic cause of their 
hypercholesterolemia and the existence of a LDL-R mutation is not always detected. 
The detection rate of LDL-R gene mutations vary mainly depending on the clinicians’ 
criteria for using the test and also on the methods used in various laboratories (25). 
According to this, a higher mutation detection rate has been reported in FH patients 
with tendon xanthomas than in those without tendon xanthomas. This illustrates that 
very strong clinical criteria for performing the test naturally will result in a higher 
detection rate (35). Patients with other types of lipid disorders could have clinical and 
biochemical characteristics much alike FH, for instance in familial defective 
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ApoB100 (36), familial combined hyperlipidemia (37) or polygenic 
hypercholesterolemia (26). 
1.4.3 Characteristic clinical features and diagnosis of FH 
Characteristics of FH  in addition to elevated total cholesterol and LDL-C from birth 
onwards, is the appearance of tendon xanthomas and premature CHD in the third or 
fourth decade of life if untreated (21). As shown in figure 4, tendon xanthomas 
typically appear in extensor tendons, such as in the Achilles tendons (most common 
location) and tendons on the dorsum of the hands. Furthermore, several FH subjects 
experience xanthelasms on the upper and/or lower eye lid and/or corneal arcus (19, 
25). The occurrence of carotid and/or aortic stenosis is frequently seen in persons with 
FH (21, 38). In comparison, in homozygote FH subjects development of CHD is 
rapidly progressive and generalized atherosclerosis may develop even before the age 
of four. This often results in myocardial infarction (MI) and possible death before the 
age of 30 (19, 30).   
 
 
 
 
 
 
 
 
Figure 4. Characteristic clinical features of FH. A. Xanthelasm above the eyelid; B. 
Xanthomata on the dorsum of the hand; C. Corneal arcus; D. Xanthomata on the Achilles 
tendon; E. Xanthomata on Tuberositas Tibiae. All pictures are used with permission from the 
owners Leiv Ose (A-D) and Kjetil Retterstøl (E), respectively. 
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Biochemically, in addition to raised total cholesterol and LDL-C levels, other lipid 
and non-lipid parameters are often measured in FH subjects. HDL-C levels are 
generally low in patients with FH (39). Lipoprotein (a) (Lp(a)) levels have been 
shown to be elevated in FH subjects (40-42). FH subjects often have normal serum 
TG levels (30).  
There are several sets of diagnostic criteria and/or screening recommendations 
commonly used in order to clinically verify the presence of FH, among others the UK 
Simon Broome Register Group (25), the USA Make Early Diagnosis to Prevent Early 
Death (MEDPED) Program (43) and the Dutch Lipid Clinic Network (44). The major 
difference between the three mentioned here is the use of different cut-offs for 
premature CHD. The Simon Broome Register group recommends the use of CHD, 
<60 years in first-degree relatives and, <50 years in second-degree relatives. The 
MEDPED criteria recommend a cut-off at age 65, while the Dutch Lipid Clinic 
Network suggest <55 years for men and <65 years for women. At the Lipid Clinic in 
Norway, the Dutch criteria shown in table 1 are used. 
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Table 1. The Dutch Lipid Clinic Network criteria for FH. Adapted from Bhatnagar (21) and 
World Health Organization (44). 
                Criteria       Points* 
                        Family history       
First-degree relative with known premature** coronary and vascular disease, 1 
or first-degree relative with known LDL-C  >95th percentile  
First-degree relative with tendon xanthomas and/or corneal arcus, 2 
or children aged less than 16 years with LDL-C >95th percentile 
        Clinical history       
Patient with premature coronary artery disease   2 
Patient with premature cerebral or peripheral vascular disease  1 
        Physical examination      
Tendon xanthomas      6 
Corneal arcus prior to age 45 years    4 
        Laboratory analysis (mmol/L)***     
LDL-C  >8.5      8 
LDL-C  6.5 - 8.4      5 
LDL-C  5.0 - 6.4      3 
LDL-C  4.0 - 4.9      1 
        DNA analysis       
Functional mutation in the LDL-R gene present   8 
                
* Diagnosis is based on the total numbers of points obtained: a 'definite' FH diagnosis  
requires more than 8 points, a 'probable' diagnosis requires 6-8 points, a 'possible' diagnosis 
requires 3-5 points       
** Men: <55 years; women: <60 years     
*** HDL-C and TGs are normal      
 
There are different ways of screening for FH. One could genetically screen the entire 
population in a country. Taking into consideration the prevalence of FH (relatively 
low even though it is reckoned one of the most common inborn errors of metabolism), 
the different expressions of physical and biochemical characteristics and also the wide 
variety of mutations, population screening is not cost-effective. One could also screen 
patients in clinical setting with clinical signs on hypercholesterolemia or persons with 
premature CHD. However, the most cost-effective way to detect cases across the 
whole population is so-called cascade screening; to investigate first-degree relatives 
of already clinically or genetically diagnosed FH subjects (21, 45). Subjects detected 
by cascade screening have one or more relatives that already have a LDL-R mutation 
and have a 50 % a priori risk of FH.  
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In cascade screening FH diagnosis based on genetic verification of a LDL receptor 
gene mutation has a sensitivity and specificity of 1.0. In clinical or biochemical 
verification of the disorder, the sensitivity and specificity reaches 0.80-0.85 (26, 43, 
46, 47).  
Recently, Civeira et al (48), in a cross-sectional study of 825 FH subjects in Spain, 
suggested that tendon xanthomas and age-adjusted LDL-C cut-off values have the 
highest value for clinical diagnosis and indication of genetic testing of FH. Recent 
studies investigating the relevance of genetic testing in FH have found that 52.3 % 
(49) and 57.7 % (50) of those with clinically defined FH had an LDL-R mutation. As 
LDL-R gene mutations are not found in all FH families it is important to use 
combination of LDL-C level and family history to diagnose FH subjects, especially 
children. 
Rees (51) argues in an editorial referring to Neil et al and their cohort study of 3,382 
FH subjects in Britain (52) that FH is underdiagnosed and undertreated. Indeed, 
global estimates suggest 200,000 heterozygous FH subjects die each year of 
preventable MIs (30). 
1.4.4 Treatment 
Medical treatment 
In contrast to most genetic disorders, efficient therapy is available for FH patients. 
Before the invention and availability of statins, treatment of FH consisted of resins 
and dietary advice (25). Some also advocated the use of niacin and fibrates. The 
therapy only had small effects on plasma cholesterol levels, and the risk of CHD 
remained high (25).  
Most people with FH are diagnosed too late, after their first coronary event. The high 
prevalence of FH and the associated CHD morbidity and mortality support aggressive 
screening and treatment (53).  
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Graham et al argue in the newest version of European guidelines on cardiovascular 
disease prevention in clinical practice (54, 55) that reduction of plasma cholesterol 
levels is crucial in reducing CHD risk. Table 2 shows the optimal cholesterol 
treatment goals when considering FH an a priori high risk for CHD. In a recent 
guideline for primary prevention of CHD the Norwegian Directorate of Health 
recommends LDL-C levels to be lower than 3.0 mmol/L in all individuals 
independent of CHD risk (23). The Norwegian Directorate of Health follows the 
European guidelines on cardiovascular disease prevention in clinical practices’ 
recommendations (23, 54, 55). 
Table 2. Optimal cholesterol treatment goals in high risk individuals. Adapted from Graham 
et al in the European guidelines on cardiovascular disease prevention in clinical practice (54, 
55). 
    Treatment goals 
       Optimal  Optional* 
                  Blood lipid component      
      Total cholesterol <4.5 mmol/L  <4.0 mmol/L 
      LDL-C <2.5 mmol/L  <2.0 mmol/L 
      HDL-C    
      Male >1.0 mmol/L   
      Female >1.2 mmol/L   
      TGs <1.7 mmol/L   
            
* If feasible      
 
A number of scientists suggest that treatment of FH subjects should start already in 
childhood (56-58), especially in those with a family history of premature CHD (25). 
Endothelial cell dysfunction, which is an early reversible stage in the development of 
atherosclerosis,  has been observed in children with FH (56). With cholesterol-
lowering statin therapy it is possible to reverse the endothelial cell dysfunction (25, 
56). Also, one could reverse the inter-media thickening in the carotid arteries seen in 
children with FH (59). 
According to Neil et al (52), on behalf of the Simon Broome Familial 
Hyperlipidaemia Register Group, mortality is not significantly higher in FH subjects 
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who are identified before they develop CHD symptoms than in the general 
population.  
It is not ethical to conduct placebo-controlled randomised trials on FH patients (25, 
60). Nevertheless, the safety and efficacy of statin use is well documented in both 
primary and secondary prevention of patients with hypercholesterolemia of various 
causes (11, 61-63). Based on evidence from other high risk groups, such as post-MI  
patients, one could assume similar effects of reduction of total and myocardial 
mortality of for instance statins and other lipid-lowering drugs to persons with FH 
(60). Treatment with statins is effective in FH patients (64) and it delays or prevent 
the onset of CHD (25, 61). 
There are five major groups of LDL-C lowering drugs available (65). So-called 
statins are 3-hydroxy-3-methyl-glutaryl Co-enzyme A (HMG CoA) reductase 
inhibitors; they inhibit production of cholesterol in the liver by inhibiting the enzyme 
HMG CoA reductase. Bile acid sequestrants, or commonly called resins, bind bile 
acid and prevent the body from reabsorbing bile acid containing cholesterol from the 
gastrointestinal tract. As a result the liver cells produce more LDL-Rs, which again 
lower the LDL-C levels in serum (23). The cholesterol-lowering function of statins 
and resins are shown in figure 5. The third lipid-lowering drug, ezetimibe, inhibits 
intestinal uptake of cholesterol from dietary and biliary sources (66). The fourth group 
of drugs is nicotinic acid (also called niacin), and the fifth group is fibric acids 
derivates (also called fibrates) (67). Ezetimibe, resins, niacin and/or fibrates are often 
used in combination with statins, if the treatment goal is not reached with statins 
alone. They are less potent than statins; hence statins are a first choice. Combined 
with lowering of LDL-C, all the groups of LDL-C lowering drugs also contribute on 
lowering TGs and to increase HDL-C levels (11, 23).  
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Figure 5. Treatment with statins and resins. From Brown and Goldstein (7). 
 
Some patients are intolerant to statins. An alternative is red yeast rice, which is a 
product of yeast grown on rice. It naturally contains a small dose of a statin-like 
substance called monacolin in combination with unsaturated FAs and phytosterols 
(68, 69), all capable of lowering LDL-C levels to some extent (68, 70). Red yeast rice 
also alters the TG levels and the total cholesterol levels in a positive direction. 
However, the HDL-C level is to some extent reduced, and the cholesterol-lowering 
effect is considered to be less potent than statins (68). Furthermore, monotherapy with 
ezetimibe is shown to be a good alternative when statins are not suitable (71). 
In most FH subjects LDL-C levels need to be reduced about 40-50 % to reach 
treatment goal (54, 55, 65, 72). A common drug treatment approach is to begin with a 
moderate dose of statins. If treatment goal is not reached the statin dose should be 
increased. Resins or ezetimibe can be added if maximal dose of statins is not 
tolerated. If treatment goal still is not reached the statins should be given in full dose 
and addition of niacin should be considered in addition (65). At present, however, the 
combined use of statins, ezetimibe and low dose resins are well tolerated and have 
been shown to reduce LDL-C levels by almost 70 % in a FH population (73). Tendon 
xanthomas can regress significantly and even disappear with cholesterol-lowering 
therapy (21, 74). The lipid-lowering effect of different drugs is shown in table 3. 
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Table 3. Comparison of efficacy of various lipid-lowering drugs in patients with FH (11, 30, 
65, 68, 71). 
    Influence on blood lipids 
         Decrease in LDL-C Increase in HDL-C Decrease in TGs 
            Drug    
    Statins 18 - 55 % 5 - 15 % 7 - 30 % 
    Resins 10 - 30 % 3 - 5 % No change 
    Ezetimibe* 5 - 25 % 1 - 6 %** 0 - 14 % 
    Red yeast rice  ~ 21 % No change*** ~ 6 % 
    Niacin/nicotinic acid 5 - 30 % 15 - 35 % 20 - 50 % 
    Fibric acids 5 - 30 % 10 - 20 % 20 - 50 % 
        
* Ezetimibe effect in combination with statins and not in monotherapy 
** A few studies showed a small decrease in HDL-C  
*** There was a non-significant (-0,5 %) decrease in HDL-C  
 
Dietary recommendations 
Importantly, a genetic cause does not imply that diet and life style habits are without 
influence (23, 44). Although dietary treatment always is implemented in management 
of FH, very few randomized controlled trials have been performed on patients with 
FH and diet (75). In 2010, Shafiq et al (75) in a Cochrane review on 11 randomised 
trials suggested that no conclusion can be made about the effectiveness of cholesterol-
lowering diet in reducing CHD and lowering cholesterol due to lack of adequate data. 
Nor can their findings support any other dietary intervention considered for FH, like 
the addition of omega-3 FAs or soya protein (75). However, they found a significant 
reduction of plasma cholesterol with plant sterols and/or stanols (75).  
On the other hand, World Health Organization (WHO) recently proposed that there is 
convincing evidence that replacing saturated fat with unsaturated fat will contribute to 
reduce CHD in the general population as well as in high risk subjects (76). Others 
have suggested that a change in diet to a cholesterol-lowering alternative could reduce 
plasma LDL-C levels by 15 to 20 % in FH subjects (77).  
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Nevertheless, diet alone is not a sufficiently effective treatment in FH (30). However, 
diet is recommended to be the first-line treatment of FH in addition to lifestyle 
changes like smoking cessation and increased physical activity (5, 30). 
In dietary intervention, the main objective is to reduce the LDL-C levels by restriction 
of the amount and type of fat from the diet (75, 76, 78). In the general population, 
also including the FH population, the total intake of fat should not exceed 30-35 % of 
the total energy intake (25, 76, 79). Also, the dietary sources of saturated fat should be 
limited to a minimum – and substituted by foods containing unsaturated fat (54, 55). 
As figure 6 shows, saturated fat reduces hepatic LDL-R expression and increases 
VLDL synthesis (7, 65). Omega-3 FAs from marine sources are also recommended 
due to their TG lowering and HDL-increasing effect (80), both through increased 
dietary intake of seafood and through intake of concentrated omega-3 in capsules. 
However, the North American National Cholesterol Education Program (NCEP ATP 
III) guidelines suggest that the use of omega-3 FA supplements is optional and does 
not recommend a specific amount of omega-3 (11, 81). Other dietary 
recommendations include a reduction of the dietary cholesterol, an increase of 
antioxidants through fruits and vegetables and an increase of fibre intake through 
fruits, vegetables, legumes and whole-grain products. A high amount of soluble fibre 
in the diet binds bile acid in the colon and retains it from being reabsorbed by the 
body (82).  
 
Figure 6. Contribution of high fat diet on LDL-C levels. From Brown and Goldstein (7). 
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In subjects with FH, as in all people, a high fat diet contributes to elevated LDL-C 
levels. Since FH patients also have the genetic disposition of elevated LDL-C levels, 
avoidance of a diet rich in fat, and saturated fat especially, generally is recommended 
(19). However, effects of dietary changes vary on basis of the initial level of plasma 
cholesterol and the patients’ initial dietary habits. 
1.5 Familial hypercholesterolemia and coronary heart 
disease 
According to Oosterveer et al (83) most CVD incidences in FH are CHD. Extensive 
epidemiologic studies in numerous populations in many countries strongly associates 
increased plasma total cholesterol and LDL-C levels with CHD (11, 65).  
Patients with FH have a higher risk of fatal or non-fatal CHD than persons without 
FH (25). FH is also associated with premature death (16). The disorder is considered a 
world public health problem due to the high incidence of premature CHD and 
reduction of life expectancy (65). Yet, studies of mortality and morbidity of untreated 
FH subjects are based on register-data and probably over-estimate the CHD risk (84). 
In men, the mean age of onset of CHD characteristically is between 40 and 45 years, 
and in female FH subjects approximately ten years later (22). The cumulative risk is 
more than 50 % by age 50 years in men and at least 30 % in women aged 60 years 
(25). By the age of 65, approximately 85 % men and 50 % women with FH will 
experience a coronary event if they are not treated (65). 
Yet, there is a substantial variation between individuals with FH, even among FH 
subjects with the same genetic mutations, in susceptibility to CHD in terms of the age 
of onset and severity (22, 40, 65, 85). The fact that all phenotype variations cannot be 
explained only on basis of the LDL-R mutation suggests that other factors may 
influence the progression and development of atherosclerosis. A large, retrospective 
cohort study by Jansen et al (86) recently showed that the traditional risk factors may 
explain less than 20 % of the variation in the prevalence of CVD in FH subjects. 
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Thus, increased risk of CHD in FH subjects is not solely due to elevated LDL-C 
levels, but also other risk factors (87). However, the fact that hypercholesterolemia 
persists from birth in FH is different from other forms of hypercholesterolemia. It 
should be recognized that polygenetic and life style induced hypercholesterolemia 
diagnosed in adults may have not persisted that long. Thus, the cholesterol “burden” 
during years is not as heavy in polygenic hypercholesterolemia as in FH and hence of 
less importance for the atherosclerotic process than in FH patients. This underlines 
the need of more specific prognostic tools focused on a FH population exclusively. 
In the last ten years, different studies, mainly case-control studies, have analysed the 
main risk factors associated with CVD and CHD in heterozygous FH in different 
populations (22, 40, 64, 86-91). Both traditional risk factors for CHD such as 
smoking, gender, hypertension and diabetes and/or clinical or molecular features 
specific to FH are analysed (65, 86). Many of the studies show that traditional risk 
factors play an important role in heterozygous FH, both as risk factors in themselves 
and on top of the risk factors specific to the condition (16). For instance, risk of 
premature CHD is much higher in FH subjects than in the general population, but it is 
also two to five times more frequent in FH men than in FH women (87). In table 4, 
eight major risk factors for CHD in heterozygous FH subjects are presented. 
Considering the presence or absence of the listed risk factors Civeira et al (65) argues 
that one can calculate an absolute risk for a person with FH – and use that as a 
guiding tool for optimal treatment. According to Jansen et al (86) LDL-C is not 
reckoned a risk factor in their and many other studies of risk factors within a FH 
population group. Their argument supporting this theory is that the FH group as a 
whole are hypercholesterolemic and hence the small differences in the elevated range 
do not confer any greater risk (86). 
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Table 4. Major risk factors for CHD in heterozygous FH. Adapted from Civeira et al (65). 
  CHD risk factors 
  
Age 
 Men: ≥30 years 
 Women: ≥45 or postmenopausal 
 Cigarette smoking: active smokers 
 Family history of premature CHD 
 CHD in male first-degree relative <55 years 
 CHD in female first-degree relative <65 years 
 Very high LDL-C: >8.5 mmol/l 
 HDL-C: <1.0 mmol/l 
 High blood pressure ( >140/90 mmHg) 
 Diabetes mellitus 
 Lp(a): >600 mg/l 
  
 
1.5.1 Different manifestation of coronary heart disease in FH 
subjects 
There is inconsistency in the physical and biochemical features in FH patients and not 
all the characteristic clinical features of FH are shown in all patients (92). Also, the 
nature and onset of CHD in heterozygote FH persons is variable (93, 94). The 
literature suggests that environmental, genetic and phenotypic variations could 
influence on the differences between persons with FH (20, 21, 84). One could 
especially see this in studies on FH reported from different countries or geographical 
areas (84, 95), even when controlling for differences in the underlying mutations (16). 
Different classes of LDL-R defects could be associated with a ‘severe’ or ‘mild’ 
physical and biochemical characteristics of FH (31). According to de Sauvage Nolting 
et al (94), even FH subjects with identical mutations and LDL-C levels can have 
significant differences in clinical outcome. Increased LDL-C levels and premature 
CHD, the two most typical characteristics of FH, are also significantly influenced by 
environmental factors (21, 96). For instance, the specificity of family history of CHD 
as an indicator of a possible genetic risk depends on the prevalence of CHD in the 
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population being studied (25). Possible causes of different manifestations in FH are 
shown in table 5. 
Table 5. Some causes of variability in physical and biochemical characteristics of FH. 
Adapted from Bhatnagar (21). 
    Cause Example 
      Genetic Specific mutations leading to FH phenotype 
 Genetic factors that influence lipoprotein metabolism 
 Genetic factors that influence CHD 
 Gender                      
  Environmental Diet 
 Smoking 
 Prevalence of CHD in community 
 Drugs affecting lipoprotein metabolism used without identifying FH 
  Metabolic Hormonal 
 Diet and body weight 
 Lipoproteins and enzymes and apolipoproteins modulating their 
metabolism, amongst others Lp(a) levels, LDL particle size, HDL-
C levels, ApoB/ApoA1 ratio  
 Factors involved in inflammation, clotting and thrombosis, 
amongst others plasma fibrinogen* and C-reactive protein*  
    
* Are shown to increase risk of CVD in the general/non-FH population,  
but their role in FH and CHD risk is uncertain 
 
However, solid data addressing the contribution of environmental and genetic factors 
to the variable physical and biochemical characteristics of FH are scarce.  
Lipoprotein(a) as a CHD risk factor in FH 
Lp(a) is a LDL-like particle which contains apolipoprotein (a) in addition to ApoB 
(97, 98). Several epidemiologic studies have suggested that elevated levels of Lp(a) 
are a strong risk factor for CHD (97, 99), also in FH persons (40, 42, 100). In a recent 
large-scale prospective data study Bennet et al argue that Lp(a) is not only a CHD risk 
factor, but an independent risk factor of CHD (97). This finding is supported by 
others (42, 101, 102). A Lp(a) concentration of >300 mg/L is considered elevated 
(103-106). 
 37 
Low HDL concentration in FH 
Low HDL-C is a risk factor for CHD in FH (39). Indeed, low HDL-C levels are 
considered a CHD risk factor at all LDL-C concentrations (107, 108). For plaque 
regression in atherosclerosis, a minimal elevation of HDL-C in addition to reduction 
of LDL-C, is by Nicholls et al estimated to be 7.5 % (109). Some statins contribute to 
such a level of HDL-C increase, but most patients need combination treatment with 
fibrates and/or niacin to enhance the HDL-C increase (110).  
ApoA1, ApoB and ApoB/ApoA1 ratio in FH 
Clinical trials have reported that ApoB and ApoA1 are important predictors of CHD 
risk (2, 111, 112). In the INTERHEART study, with 15,000 cases and controls, 
ApoA1 and ApoB have been used as surrogate for anti-atherogenic HDL-C and 
atherogenic LDL-C and VLDL-C, respectively (2). In the Swedish Apolipoprotein 
Mortality RISk (AMORIS) study measurement of ApoB and ApoA1 improved the 
prediction of fatal MI at all levels of total cholesterol, LDL-C and TGs (111).  
Due to the fact that ApoB and ApoA1 have opposite effects on atherogenic risk, the 
ratio between the two values appears to be a useful indication of cardiovascular risk 
(2, 8, 112-114). In an AMORIS follow-up from 2008 (115), ApoB/ApoA1 was found 
equally predictive with LDL-C on CHD. 
Factors involved in inflammation, clotting and thrombosis 
C-reactive protein 
It is recognized that CHD could be considered an inflammatory process in the body 
(17, 116). Inflammation is often assessed by measurements of the inflammatory 
marker C-reactive protein (CRP) (71, 117, 118). Elevated CRP is associated with 
increased CHD risk (8, 117, 119-121). CRP is an acute phase reactant protein 
produced primarily in the liver and is released in response to inflammatory processes 
such as infection or acute injury. NCEP ATI III considers CRP to be an emerging 
marker for the diagnosis and management of CHD (11, 71). However, CRP was by 
Drakopoulou et al in a recent review considered more of a nonspecific systemic 
 38 
marker of infection and tissue damage than a CHD marker (118). Others’ findings 
support those findings (122, 123). Both Ridker et al (124) and Nissen et al (125) 
suggest that the reduced CHD risk observed after statin treatment correlates with 
reductions in CRP levels. In the Justification for the Use of Statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, one outcome was that 
CRP independently predicts vascular events regardless 
A specific range of CRP levels is commonly used to predict CVD. The 2002 joint 
American Heart Association and Centers for Disease Control Consensus Report (129) 
suggested that CRP levels <1.0 mg/L indicate a low risk of developing CVD. If CRP 
levels are between 1.0 and 3.0 mg/L, there is an average risk, whereas CRP levels 
>3.0 mg/L indicate high risk. 
of LDL-C level (126-128). 
Also, one can see an additive effect on CRP level reduction with a combination of 
statin and ezetimibe (71). Although there is conflicting information regarding the role 
of CRP in premature CHD, most of the available evidence is in favour of their use in 
assessing the prognosis of atherosclerosis and suggest the inclusion of CRP in the 
standard assessment of cardiovascular risk (8). 
Fibrinogen 
Fibrinogen has a pivotal role in haemostasis; it promotes fibrin formation and is a 
major contributor to platelet aggregation and coagulation (8, 130). Increased 
fibrinogen levels are associated with CHD (8, 119, 131-134). Fibrinogen is useful in 
the prediction of atherosclerosis (132, 135), and in patients with manifested 
atherosclerosis (136). In a recent meta-analysis including 154,211 apparently healthy 
subjects, the Fibrinogen Studies Collaboration (FSC) registered correlation between 
fibrinogen and several established CHD risk factors (130). However, it is unclear 
whether plasma fibrinogen is an independent risk factor for CHD (137), also in FH 
(21). 
Protein C, Activated Protein C resistance and Protein S 
The Protein C system is important in anticoagulation by its regulation of the activities 
of the coagulation factors Factor Va and Factor VIIIa (138). Protein S is a cofactor to 
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activated Protein C (APC) (139, 140). In addition to its anticoagulant properties, APC 
has anti-inflammatory functions (138). There are two forms of Protein S, one free and 
one bound form. The free form acts as a cofactor in anti-coagulation in the 
inactivation of coagulation factors Factor Va and VIIIa. Protein S also expresses anti-
coagulant activity in the absence of APC (139, 141, 142). In inflammatory processes 
the bound form of Protein S increases and the free form decreases. Consequently, 
Protein S deficiency – either inherited or as a result of inflammation – could increase 
the risk of thrombosis and hence CHD (139). A low concentration of Protein C in the 
form of APC resistance and/or a low concentration of Protein S are clinically 
interesting; with values below the reference range the risk of thrombosis increases 
(138). 
von Willebrand factor  
von Willebrand factor (vWF) plays a central role in haemostasis (143). vWF’s 
primary function is binding to other proteins in the coagulation cascade, in particular 
Factor VIII (144). It is important in platelet adhesion to wound sites. Deficiency of 
vWF is associated with increased bleeding tendency. Conversely, increased vWF 
level and activity could be considered a predictor of cardiovascular disease (144, 
145). 
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2. Aims of the study 
2.1 Study rationale 
This thesis aims to identify important risk factors for CHD and death in a FH 
population. It aims to identify which clinical and biochemical factors that could be 
responsible for the “protection” of a subgroup of heterozygous FH subjects and, on 
the contrary, to identify the most important risk factors existing in a FH population 
exclusively. A study by Sijbrands et al (84) which was conducted in a large pedigree 
without selection for CHD showed that approximately 60 % of untreated persons with 
FH suffered from a premature death whereas 40 % of the FH subjects had a normal 
life expectancy. The search for factors that affect the onset of CHD in FH subjects is 
potentially important for how intense treatment the various patients should be offered 
and how early treatment should be initiated.   
2.2 Study objective 
2.2.1 Specific aims of this thesis 
Specific aims of this thesis were  
a. to retrospectively characterise and compare clinical and biochemical parameters 
from the medical records of FH subjects with early CHD event (‘susceptible’) and 
FH subjects with late or no CHD event (‘resistant’) 
b. to characterise and compare clinical and biochemical parameters from the medical 
records of deceased FH subjects with premature CHD event or with late or no 
CHD event with susceptible and resistant FH subjects 
c. to further characterise and compare the differences between a smaller group with 
more strict inclusion criteria of susceptible and resistant FH subjects and healthy 
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controls with focus on different coagulation factors, apolipoproteins, CRP and 
fibrinogen 
d. to characterise and compare female FH subjects and male FH subjects from the 
group of FH subjects as a whole and divided into subgroups of susceptible and 
resistant 
2.2.2 Hypotheses  
Specific hypotheses of this thesis were that 
a. susceptible FH subjects  have a more severe CHD risk factor profile in 
comparison with resistant FH subjects 
b. deceased FH subjects have a more severe CHD risk factor profile compared 
with non-deceased FH subjects 
c. FH subjects have a more CHD prone coagulation factor profile and higher 
CRP levels and fibrinogen levels than control subjects, and similarly that 
susceptible have a more CHD prone coagulation factor profile than resistant 
d. male FH subjects have a more severe CHD risk factor profile in comparison 
with female FH subjects 
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3. Subjects and methods 
The master thesis was approved by The Regional Committee of Medical Ethics, The 
Norwegian Directorate of Health and by The Privacy Ombudsman at Rikshospitalet, 
Oslo University Hospital (OUS). See appendices 1, 2 and 3, respectively.  
The thesis included two studies; one retrospective data collection study and one case-
control study. No intervention or treatment of the participants was involved. There 
were no immediate anticipated clinical benefits for the study volunteers, other than 
feedback on the anthropometric and biochemical measurements. 
Written informed consent was obtained from all of the participants. 
3.1 Subjects 
3.1.1 Retrospective data collection study 
This part of the thesis was considered a cross-sectional study. 
Susceptible and resistant FH subjects 
Inclusion and exclusion criteria 
Data on FH subjects were available from another ongoing study at the Lipid Clinic. 
The study was started in 2007, and they are still recruiting participants. The persons 
with FH classified into the ‘susceptible’ group had had a premature event of CHD and 
the FH subjects classified into the ‘resistant’ group had had a late event of CHD or no 
CHD event. It was required that all participants had genetically determined FH. The 
whole list of inclusion and exclusion criteria is shown in appendix 4 for susceptible 
individuals and in appendix 5 for resistant FH subjects.  
The cut-off of the susceptible group and the resistant group were estimated from the 
total number of individuals available in Norway, based on the FH patient registry at 
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the Lipid Clinic. By using this approach, one could be sure to find a big enough group 
of FH subjects to include in the study. First, the PHREG procedure, a tool from 
SAS/STAT that performs regression analysis of survival data based on the Cox 
proportional hazards model, was performed. The survival analysis is a so-called ‘time 
to event analysis’ which is used to observe the time to a certain event of patients, in 
this case an event of CHD. Estimates were given for the 95 %, 90 %, 85 % and 80 % 
survival points for four different combinations of gender and smoking status. Then 
one could find estimates of the age at which for instance 90 % of female non-smokers 
survive to without suffering from a CHD event. Second, the ‘non-survivors’ were 
considered all individuals of that age as well as anybody younger who had had a CHD 
event. Third, the actual choice of survival age and non-survival age depended on the 
availability of appropriate individuals in the Lipid Clinic FH registry. Different cut-
off points were given for FH men and FH women in accordance with the protective 
property of oestrogen seen in women (11). 
Data on a total of 71 subjects with early cardiovascular event and 76 subjects with late 
or no cardiovascular event had been included in the study and coded when we 
received the data file. The cut-off of early CHD in FH subjects and the cut-off of late 
or no CHD for men and women, respectively, are shown in tables 6 and 7. For both 
susceptible and resistant categories, smokers and previous smokers were considered 
those FH subjects who were a smoker or previous smoker at the time of the study.  
Table 6. Retrospective. Cut-off of early CHD event in FH patients 
    Gender 
         Female  Male 
            Smoking status    
    Smoking and previous smoking ≤47  ≤43 
    Non-smoking ≤50  ≤46 
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Table 7. Retrospective. Cut-off of late or no CHD event in FH patients  
    Gender 
         Female  Male 
            Smoking status    
    Smoking and previous smoking ≥50  ≥46 
    Non-smoking ≥53  ≥48 
        
 
Anthropometry and biochemical parameters 
Except from levels of Lp(a), physical and biochemical parameters from every patient 
were collected at study-visit. Lp(a) measurement was not a part of the ongoing study 
at the Lipid Clinic, and was not measured. Thus, the Lp(a) levels used in this analysis 
was collected from the journals of the participants. Scientific evidence suggest that 
the Lp(a) level within-person is highly consistent over time (97). Hence, one can find 
a value measured at a different time and it would still be sufficient to use in the 
analysis.  
Blood samples were undertaken in the same manner in the susceptible and resistant 
groups. The blood samples were collected by laboratory personnel at the laboratory at 
the Lipid Clinic. The accredited medical-biochemical laboratory at Rikshospitalet, 
OUS, analysed the blood samples. 
The blood pressure values presented are not comparable due to incomplete 
information in the data file. We have no information on whether the patients 
registered with hypertension were medicated for hypertension or not. Hence, the 
blood pressure could be affected and possibly confounded by medication differences 
between groups. Hypothetically, all patients in the susceptible group could be 
medicated for hypertension while nobody in the resistant group was on hypertension 
drugs. Yet, we chose to present the data to show the values of blood pressure in 
relation to other parameters. 
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Missing data 
Even though all physical and biochemical parameters theoretically were collected at 
study-visit, some of the data were missing. One explanation for the missing data could 
for instance have been that several different doctors carried out the consultations. 
Despite the fact that the doctors had the same form to fill out at the study-visit 
consultations, they were not consequent in filling out different parts in the same 
manner. Other explanations, regarding blood samples, can be that the doctors forgot 
to requisition all blood samples for all patients, that the laboratory personnel at the 
Lipid Clinic did not collect all blood samples or that the laboratory personnel 
analysing the blood samples either forgot to analyse all the samples or did not report 
all the answers. 
Deceased FH subjects 
Inclusion and exclusion criteria 
The medical records from deceased FH subjects were found from storage at the Lipid 
Clinic. Out of a total 71 journals from deceased patients, 41 were excluded on basis of 
not fulfilling the FH clinical and/or genetic diagnosis criterion. Many of the deceased 
FH subjects were not tested for genetic mutation, mainly because they died before 
their type of mutation had been discovered and added to the mutation registry. In 
those cases the master student first systematically went through the pedigree of the 
patients’ family to see if any of the first-degree relatives had a verified mutation. If 
that was not the case, the deceased FH subjects were included or excluded on basis of 
the Dutch Lipid Clinic Network criteria for FH (44). Out of the remaining 30 
deceased FH subjects, 21 were genetically verified and nine were clinically verified 
on basis of the clinical and genetic diagnosis criterion. 
Data assessment 
To get the most correct data from the deceased FH subjects, we decided to use the last 
registered medical record on each subject. The master student assessed, coded and 
filed information on the deceased subjects’ date of birth, their age at the onset of first 
CHD event, age at time of death, total number of years they had had of lipid-lowering 
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treatment, type of medication and total number of years on statin treatment. Different 
clinical information like presence of xanthomas, xanthelasms and corneal arcus, blood 
pressure, presence of diabetes type II and smoking status was registered too. The pre-
treatment plasma total cholesterol level was also collected, together with the last 
registered plasma levels of lipids.  
Non-HDL, ApoB/ApoA1, and total cholesterol/HDL-C were calculated from the 
assessed blood lipid values.  
Division of the group of deceased FH subjects into subgroups 
One can expect the group of deceased FH subjects to be as diverse as any other group 
of FH patients, except from the fact that they are all deceased. Hence, the group was 
divided into two groups based on the same criteria as the susceptible and resistant 
groups to perform different analyses of interest.  
We found it interesting to split the group of deceased FH subjects into two subgroups, 
based on the time of their first CHD event. The group then was divided into ‘deceased 
FH subjects with early CHD’ or ‘deceased FH subjects with late or no CHD’ based on 
the inclusion criteria in tables 6 and 7, from the susceptible group and the resistant 
group, respectively, used for the retrospective study. Two persons did not match the 
criteria and were excluded from the deceased FH subject data set in these analyses. 
The two subgroups each consisted of 14 subjects.  
SmartDiet food questionnaire 
SmartDiet is a food questionnaire which is developed at the Lipid Clinic. SmartDiet is 
designed to investigate a patient’s dietary habits and life style. Through the 
questionnaire, the Lipid Clinic assesses information about the FH subjects’ habitual 
food composition. It focuses mainly on intake of fat and type of fat, sugar, fibre, fruits 
and vegetables. Also, SmartDiet contains five questions on life style. The 
questionnaire is recommended in use for persons with dyslipidemia, FH and in 
general patients in need of a heart friendly diet. A patient can score a maximum of 36 
 47 
points. The reproducibility and validity of SmartDiet was tested by Svilaas et al in 
2002 (146).  
Information on the dietary habits of deceased FH subjects was in most cases collected 
at their first or second visit to the Lipid Clinic. On basis of detailed medical records 
on dietary habits, the master student calculated a SmartDiet score for each deceased 
FH subject. In comparison, in the susceptible and resistant groups the SmartDiet 
questionnaire was filled out at study-visit. Hence, the SmartDiet scores could not be 
compared between the groups of non-deceased and deceased FH subjects. 
Limitations of the data on deceased FH subjects 
We found it important to recognise potential limitations using data from medical 
records of deceased FH subjects before we performed the analyses and also for 
interpretation of the results.  
Missing values 
Not all measurements were found in all subjects, most likely due to the fact that the 
primary source of data was the patients’ medical records. Medical records are 
primarily intended for patient care and not for research purposes. Different clinicians 
have different routines and approaches regarding filling out medical records. 
Gap between last consultation and time of death 
Some patients were followed up by the Lipid Clinic for several years; others had had 
their first consultation only a short time before they died. Albeit some of the patients 
had a comprehensive follow-up history at the Lipid Clinic, not all were followed the 
last couple of years before they died.  
In addition to consultations at the Lipid Clinic, most of the patients also were 
followed up by their family doctor. Therefore, in combination with the severity of 
their CHD risk profile, the time distance between consultations at the Lipid Clinic 
varied a lot between the patients. Some had consultations several times a year; others 
had consultations with years in-between.  
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We did not have medical records from other hospitals or doctors than from the Lipid 
Clinic, hence we did not know what medication or plasma lipid values the patients 
had had between the consultations or during their last years of life.  
We do not know with certainty whether the deceased FH subjects who had not been to 
the Lipid Clinic for the last couple of years before they died had one or more CHD 
event(s) between their last visit at the Lipid Clinic and time of death. Neither do we 
have information on the cause of death in every FH subject.  
From persons who had been followed for only a few years, the medical reports were 
not very comprehensive. However, we managed to get useful information from the 
data at disposal.  
Measurements at different points of time 
In most of the deceased FH patients, not all analyses were registered at every 
consultation, and some information was not registered at all. When information of 
interest was not found in the newest medical record, we found the information from 
older medical records.  
For instance, the ApoA1 and ApoB levels were in many patients not collected every 
time they visited the Lipid Clinic. Yet, blood lipid values should be measured together 
since the plasma concentrations of apolipoproteins reflects the plasma cholesterol 
levels. In all patients where the newest apolipoprotein values and the newest 
cholesterol values were measured at different consultations, we collected the newest 
recorded cholesterol values and the cholesterol values measured at the same time of 
the latest ApoA1 and ApoB values. We then compared the latest registered 
cholesterol values with the cholesterol values registered at the time of apolipoprotein 
registration in each subject. If the difference in cholesterol values were not 
statistically significant different, we decided to use the ApoA1 and ApoB levels in our 
analysis together with the newest plasma cholesterol levels.  
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When statin use was not mentioned in the newest medical record, we assumed that the 
patients were on the same medication as their previous consultation at the Lipid 
Clinic. 
Differences between non-deceased FH subjects and deceased FH subjects  
The deceased FH subjects died within a period of 15 years, from the early 1990s to 
mid-2000. By median, they died around 1998. Hence, there was a difference of about 
ten years between the journal information on the deceased FH subjects and the non-
deceased FH subjects’ study-visit. This difference promotes challenges to the 
comparison of the groups.  
First, the last ten years new drugs have become available on the market. For instance, 
ezetimibe has been used in clinics for about eight years. Consequently, only one of the 
deceased FH subjects was treated with ezetimibe, compared to approximately three in 
four of the non-deceased FH subjects.  
Second, scientific evidence is produced continually and recommendations change 
through time. The scientists and doctors know more now than they did ten years ago. 
The goals of treatment of FH subjects ten years ago are already out of date.  
Third, like drug treatment and treatment goals, measuring methods also change over 
time. New equipment and other reagents contribute to more accurate measurements 
and results. The outcome in comparison of different parameters between deceased FH 
subjects and non-deceased FH subjects could be biased on basis of older measuring 
methods used in the analyses from the deceased FH subjects. 
Fourth, treatment of more and more FH subjects begins as a result of genetic 
verification of FH. In that way, more asymptotic persons undergo lipid-lowering 
treatment the more genetic mutations that are revealed. This could be considered a 
bias when evaluating the results from comparison of clinical features in susceptible 
and resistant FH patients with deceased FH subjects. 
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Fifth, the deceased FH subjects with late or no CHD event could have died from 
virtually anything, especially due to the fact that we do not have data on everyone 
until their time of death. Nevertheless, we chose to define the group by the same cut-
offs as the non-deceased resistant group, since we primarily compared the groups on 
basis of CHD event and blood lipid parameters. 
With these limitations in mind, we still considered it interesting to compare the 
deceased FH subjects with non-deceased FH subjects. As far as we know, few 
scientists, if anyone, have systematically according to the time of their first CHD 
event looked into deceased  FH subjects’ journals and analysed and compared the data 
with comparable patients who have not died from similar events. If there are any 
interesting findings in our study this could be considered a small pilot study, and the 
implications for further studies are present.  
3.1.2 Case-control study 
Inclusion criteria 
Susceptible and resistant FH subjects 
FH patients were identified from the medical journals at the Lipid Clinic. They were 
included or excluded on basis of similar inclusion and exclusion criteria as the FH 
patients in the retrospective data collection study, with stricter age cut-offs and with 
some additional criteria. Inclusion criteria in the first of a total of two inclusion 
processes, when finding who to invite to participate in the study, considered two 
elements; a verified genetic mutation and place of residence not more than two-three 
hours drive from the Lipid Clinic, Oslo. The project was financed solely by scientific 
funding from the supervisors and could therefore not afford to pay travelling costs for 
people living far from Oslo; consequently we invited persons living close to the 
capital area. A total of 76 persons with heterozygous FH were sent an invitation letter. 
See figure 7 for flow chart.  
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Figure 7. Flow chart showing inclusion and exclusion of susceptible and resistant in case-
control study 
 
The 76 FH subjects included in the first round were sorted into two groups according 
to age at first CHD event and smoking status. Also in the case-control study, the 
persons with FH classified into the ‘susceptible’ group had had a premature event of 
CHD and the FH subjects classified into the ‘resistant’ group had had a late event of 
CHD or no CHD event, see tables 8 and 9 for cut-off levels of ‘premature’ and ‘late 
or no’ CHD event. The inclusion criteria in both the susceptible group and the 
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resistant group were, however, stricter in the case-control study than in the 
retrospective data collection study. 
Table 8. Case-control. Cut-off of early CHD event in FH patients 
    Gender 
         Female  Male 
            Smoking status    
    Smoking and previous smoking ≤46  ≤42 
    Non-smoking ≤49  ≤45 
        
 
Table 9. Case-control. Cut-off of late or no CHD event in FH patients  
    Gender 
         Female  Male 
            Smoking status    
    Smoking and previous smoking ≥60  ≥55 
    Non-smoking ≥65  ≥60 
        
 
In the second inclusion process, after including patients by mail and phone follow-up, 
patients were excluded if they were undergoing regularly LDL aphaeresis or if they 
had rheumatoid arthritis or other autoimmune diseases. Also, patients were excluded 
if they recently had had pneumonia, a cold or other infections. One FH subject was 
undergoing LDL aphaeresis. The patient was excluded because of the variation of 
blood lipid levels before and after LDL aphaeresis; both a high and a low blood lipid 
level could affect the median of the group considered the small size of the group. One 
FH subject was also excluded because of treatment for rheumatoid arthritis. Since we 
collected blood samples to estimate levels of different inflammation markers in blood 
serum and white blood cells, there was a risk that a severe autoimmune inflammation 
could affect the inflammation markers level. Written informed consent, enclosed in 
appendix 6, was provided for all patients in the information letter and obtained from 
all of them before the consultation at the day of the study-visit.  
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At the day of the study-visit, some patients did not show up. Consequently, we ended 
up with 19 and 15 FH subjects in the susceptible and resistant groups, respectively.  
In the resistant group, three out of 15 persons had had one or more CHD event(s). 
Hence, they could be considered a group of FH subjects of relatively good health. 
The main reason that the age cut-off for the susceptible group in the case-control 
study is not more different than one year in comparison with the susceptible group in 
the retrospective data collection study is that there are not very many patients in the 
FH registry at the Lipid Clinic fulfilling those strict criteria. In comparison, it was 
much easier to find older persons to the resistant group in the case-control study than 
in the retrospective data collection study. Therefore, the difference between the two 
studies is much bigger concerning the resistant groups. 
Controls 
Control subjects were ten healthy gender- and age-matched volunteers recruited 
among friends, family, colleagues and staff at Lipid Clinic and at the University of 
Oslo, other acquaintances and friends and family of friends. This reference population 
was included in the study to map potential differences between FH subjects and 
healthy persons.  
Exclusion criteria for controls were identical to those described for cases, with the 
additional criterion that controls had no previous diagnosis of heart disease or history 
of exertional chest pain. It was also preferred that the control subjects were not 
receiving anti-hypertensiva. 
Informed consent was provided for all controls and obtained from all of them before 
the consultation. The letter is shown in appendix 7.  
Anthropometric measurements 
Body weight, height and waist circumference were measured. Measurements were 
undertaken in the same manner in FH subjects and controls. Body weight was 
measured on an electronic body weight measurement apparatus of the brand Soehnle 
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S20_2763. It is calibrated in January every year. The device measures with an 
accuracy of 0.1 kilograms. The patients were weighed without jackets and shoes. 
They were also told to empty their pockets.  
The patients’ height was measured with a manual height measurement scale of the 
brand Seca. It was last calibrated in September 2008. The scale was attached to the 
wall. Height was measured without shoes. The patients stood straight against the wall 
scale, with heels, bottom, back and head touching the wall. Then the height in 
centimetres was measured. 
Waist circumference was measured by the master student using a measuring tape. The 
measuring tape was placed around the abdomen right above the upper hip bone – or in 
patients with a wide waist circumference around the widest part. It was then held 
horizontal around the waist. The reading of waist circumference in centimetres was 
done when the tape measure was snug but not caused compressions on the patients’ 
skin. 
Weight and height were used to calculate body mass index (BMI) with the formula 
BMI = weight (kg)/height2 
Blood pressure and pulse measurement 
(m).  
The blood pressure and pulse was measured by the master student with an electronic 
blood pressure measurement apparatus of the brand Welch Allyn. Last time it was 
calibrated was in 2008. Measurements were undertaken in the same manner in FH 
subjects and controls. The registration was done on the patients’ left arm. During the 
blood pressure and pulse measurement the patients sat still in a relaxed and 
comfortable position in a chair with both legs touching the floor and both arms in a 
comfortable position. Three values were measured, with three-four minutes in-
between. The averages of the three values, both for blood pressure and pulse, were 
used in the study. The patients were told not to smoke during the morning before 
measurement. All patients avoided caffeine and smoking for at least 30 minutes prior 
to testing, as they contains substances known to increase heart rate.  
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Hypertension was defined when anti-hypertensive medication was prescribed or if 
three consecutive measurements of blood pressure were >140 mmHg systolic or >90 
mmHg diastolic. 
Biochemical parameters 
Blood samples were undertaken in the same manner in FH subjects and controls. All 
participants fasted 12 hours before the blood samples were collected.  They were also 
recommended not to drink alcohol the last 24 hours before the consultation. None of 
the patients smoked before the blood sample collection. The blood samples were 
drawn by laboratory personnel at the laboratory at the Lipid Clinic, using a vacutainer 
system.  
Routine laboratory analysis (fibrinogen, aspartate amino transferase (ASAT), alanine 
amino transferase (ALAT), creatinine, fibrinogen, fasting blood glucose, total 
cholesterol, LDL-C, HDL-C, TG, Lp(a), ApoA1, ApoB and CRP and coagulation 
parameters (APC resistance, Protein C, Protein S (total), Protein S (bound), vWF 
antigen and vWF activity) were analysed at the accredited medical-biochemical 
laboratory at Rikshospitalet, OUS. Blood samples were centrifuged and analysed 
within one hour of admission. 
Except from one missing Lp(a) value in one FH subject due to a laboratory mistake, 
all analyses were done in all subjects. Two patients were taking Warfarin, and their 
blood samples were excluded in the coagulation markers analysis. Also, two patients 
forgot to fast the entire 12 hours before blood sample collection. However, we used 
the two patients’ data because they had fasted nine and ten hours before the blood 
sample collection, respectively. One FH subject had a CRP level of 13.0 mg/L. We 
performed the analysis with and without the individual concerned. 
Non-HDL was calculated with the formula: total cholesterol – HDL-C. ApoB/ApoA1 
ratio was also calculated for use in statistical analysis.  
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Since this project is part of an ongoing large research project, together with collection 
of the above mentioned blood samples, blood samples for estimation of inflammation 
markers in blood serum and peripheral mononuclear blood cells were collected from 
the FH subjects and controls. The samples were delivered to the laboratory of 
Professor Kirsten Holven for subsequent analysis.  
SmartDiet food questionnaire 
The participants filled out a SmartDiet food questionnaire when they waited for the 
blood samples to be taken. The questionnaire was updated in 2008-2009 and a new 
and more detailed version has been used at the Lipid Clinic since July 2009. It has a 
maximum score of 41 points and not 36 points, which was the maximum score in the 
2009 version of SmartDiet. Twenty-seven points or less is considered a low score, and 
a patient could change diet and lifestyle in several ways to make it more heart-
friendly. A score between 28 and 35 points is reckoned a medium score, but a patient 
could still change diet and lifestyle in many ways to make it healthier. A high score is 
when a patient scores 36 points or more. Yet, the patients in the latter category receive 
diet recommendations to “keep up the good work”. 
The new version of SmartDiet has also been tested for reproducibility and validity but 
the data are unpublished. A copy of the latest version of SmartDiet is shown in 
appendix 8. 
3.1.3 Medication and influence on blood samples and blood 
pressure in the case-control study 
Participants remained on their usual drug treatment at study-visit, and their currently 
prescribed drug treatment regimen was registered. 
LDL-C concentration 
The levels of blood lipids in the susceptible and resistant groups measured in the case-
control study were affected of the type and level of drugs they received. Estimation of 
treatment goals and risk calculation are preferentially based on a person’s LDL-C 
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concentration without treatment – to get a proper account of the concentration of 
drugs or the degree of CHD risk. 
In order to see what approximately the FH subjects’ pre-treatment LDL-C levels were 
and thereby get an impression of the patients’ levels of CHD risk pre-treatment, we 
decided to estimate the pre-treatment LDL-C level in each FH subject.  
To calculate the pre-treatment LDL-C level we had to find the efficacy of the 
different drugs and different doses of drugs the patients used at the time of study. In 
this study, three types of statins were registered among the FH subjects; rosuvastatin, 
atorvastatin and lovastatin. Also, one patient, on basis of allergic reactions to other 
alternatives, used red yeast rice. Several scientists and study groups have investigated 
the efficacy of different statins or conducted meta-analysis on other’s results (147-
151).  
Regarding efficacy of statins we decided to use data from the newest meta-analysis on 
the topic, from 2010, by Nicholls et al (150). The meta-analysis included data on 
changes in LDL-C with increasing statin dose on rosuvastatin and atorvastatin. 
Similar data on lovastatin were found from Helfand et al (151). An overview over the 
different doses of statins and the reduction in LDL-C levels is shown in table 10. 
Table 10. Changes in LDL-C level with increasing statin dose. Adapted from Nicholls et al 
(150) and Helfand et al (151). 
                Percent reduction in LDL-C level 
                Rosuvastatin  Atorvastatin  Lovastatin 
                     Daily statin dose       
       5 mg  38.8  NA   NA 
       10 mg  44.1  35.5  21.0 
       20 mg  49.5  41.4  27.0 
       40 mg  54.7  46.2  31.0 
       80 mg  NA*  50.2  42.0 
              
* NA = Not applicable 
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Furthermore, we took into consideration the lipid-lowering effects of other 
medication as well; resins, ezetimibe and nicotinic acid. No one in the FH study group 
used fibric acids. Ezetimibe is usually given in a 10 mg dose in addition to a statin 
(71). Bays et al showed that a combination drug of the statin simvastatin and 
ezetimibe gives and additional reduction in LDL-C of 4.2 – 14.0 % compared to only 
statin (71). The middle value is an LDL-C reduction of approximately 9 %, of which 
we used in further estimations of pre-treatment LDL-C levels. Concerning the 
nicotinic acid, we used a recent study by Fazio et al (152), who estimated the added 
effect of nicotinic acid in combination with ezetimibe and statin. They showed that 
the added effect of nicotinic acid was approximately 5 %. We did not take into 
consideration different doses of resins or nicotinic acid shown in the patients using 
this drug. We estimated the efficacy of resins when combined with statin to be 
approximately 11 %, from a meta-analysis of Backes et al (153). In general, when the 
effect in percent of LDL-C lowering was given in a range, we decided to choose the 
middle value of the min and max values.  
With red yeast rice we based our estimations on 21 % reduction, as estimated from a 
newly published study of Venero et al (68). 
When the pre-treatment LDL-C levels were estimated we calculated the difference 
from pre-treatment LDL-C levels with study-visit LDL-C levels in mmol/L and 
percentage difference.  
In the retrospective data collection study pre-treatment total cholesterol levels and 
study-visit total cholesterol levels were available in the data file. Hence, we calculated 
the difference from pre-treatment total cholesterol with study-visit total cholesterol 
levels in the same manner. 
Blood pressure 
Although blood pressure was recorded both in FH subjects and controls at study-visit, 
the levels in FH subjects both in comparison with controls and when comparing 
subgroups of FH subjects with each others, would be systematically affected by the 
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medication they received, such as blood pressure medication, β-blockers, nitrates and 
angiotensin-converting-enzyme (ACE) inhibitors. Since hypertension in FH subjects 
was defined as blood pressure above 140/90 mm Hg on two or more separate 
measurements or the use of antihypertensive drugs, it could be inappropriate to 
compare blood pressure between FH subjects and controls. Yet, if controls still had 
lower blood pressure than patients with FH, one could suggest that the FH subjects 
were not well-treated. And if there were approximately the same number of persons 
receiving each of the drugs in the susceptible and resistant group, they could be 
compared to each other. However, blood pressure also naturally increases with age 
(154). With a difference between the susceptible and resistant groups regarding 
median age at study-visit, age would be a possible confounding factor.  
3.2 Statistical analysis 
All statistical analyses were performed using SPSS version 16.0 statistical package 
for Windows (SPSS, Inc., Chicago, Illinois, USA).  
A P < 0.05 was considered statistically significant. For all analyses, the upper limit 
for a tendency of difference was put at P < 0.1.  
3.2.1 Continous variables 
Histograms and Normal Q-Q plots were used to evaluate whether the data material 
was normal distributed. Most distributions were not normal. Besides, an n < 30 in 
study-groups usually indicates that one should consider using non-parametric tests 
(155). In that way, one would not miss the importance of the outliers in the material. 
Since our data material was quite small, we decided to use non-parametric tests.  
When there were three or more groups to compare, the non-parametric Kruskal-Wallis 
test was used both in the retrospective data collection study and in the case-control 
study to determine differences in lipid concentrations, dietary and anthropometric 
parameters and other continuous variables between the independent groups. The 
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significance level was considered at P < 0.05. However, one does not know which of 
the groups are statistically significantly different from one another when one obtains a 
statistical significant result from Kruskal-Wallis test (155). We then conducted a post-
hoc Mann-Whitney U test between pairs of groups. In order to adjust for the inflation 
of type I errors due to multiple comparisons, we applied a Bonferroni correction to the 
P-value level of 0.05 when performing post-hoc Mann-Whitney U test (155). With 
three and four comparisons the adjusted P-value was considered significant at P < 
0.017 and P < 0.013, respectively. 
When we compared only two groups, for instance female susceptible and female 
resistant in the retrospective data collection study or in the case-control study, the 
Mann-Whitney U test was used with a significance level of P < 0.05.  
In more or less normal distributions where the P-value was significant or between 
0.051 and 1.00, we decided to run an Independent-samples t-test to verify the 
tendency of statistically significant difference. 
Continuous data were presented as median values with range (min-max).  
3.2.2 Categorical variables 
Differences in categorical variables, such as appearance of tendon xanthomas and 
smoking status between the groups were assessed by Chi-square test for independence 
in some cases. In most cases, when the assumptions for chi-square were violated, 
Fisher’s exact two-tail probability test was used. The significance level was 
considered at P < 0.05.  
Categorical variables were presented as count with percentage.  
Some values were missing in the retrospective data collection study. We decided to 
exclude cases pairwise and not listwise since we had a quite small data material. 
Except from Bonferroni correction we have performed no adjustment for multiple 
testing.  
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4. Results 
4.1 Retrospective data collection study 
In addition to characterisation and comparison of the susceptible and resistant groups, 
we performed comparisons based on gender and on subgroups. 
4.1.1 Susceptible and resistant groups 
Characterisation of the subjects and comparison of the groups is shown in table 11. 
As expected from our inclusion criteria in the susceptible and resistant groups, age at 
first CHD event was statistically significant lower in susceptible than resistant. The 
same was the case with age at study-visit.  
The susceptible group had in general a less beneficial lipid profile than the resistant 
group, with statistically significant higher median Lp(a) level, TG level and pre-
treatment total cholesterol level. However, the individuals in the susceptible group 
were significantly supplementary medically treated; 33.8 % and 12.7 % of the 
susceptible compared to 15.8 % and 2.6 % of the resistant received resin and niacin 
treatment, respectively. The TG levels in both groups were within reference range. 
The statistically significant differences between the two groups in mmol/L reduction 
of total cholesterol level, total cholesterol/HDL ratio, ApoB level and ApoB/ApoA1 
ratio disappeared when performing Bonferroni correction on the P-values.  
Medianvise, the resistant group had smoked for six years longer than the susceptible 
group – but this association also disappeared with Bonferroni correction. 
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Table 11. Characterisation and comparison of susceptible and resistant 
 Susceptible  Resistant       
        
  n   1   n     P 
 
2,3 
       Demographics        
Total 71   76    
Female  71 23 (32.4%)  76 37 (48.7%)  0.066 
Age at study-visit 71 53 (39-73)  76 59 (47-76)  0.001 
Age at first CHD event 52 30 (22-36)  14 57 (47-68)  <0.001 
Early CHD in first-degree relative 71 54 (76.1%)  72 41 (56.9%)  0.025 
        
Classical CHD risk factors        
Smoker (both pre and now) 71 47 (66.2%)  76 51 (67.1%)  1.00 
Yrs smoking total 46 18 (2-50)  51 24 (2-47)  0.017* 
Yrs since quit smoking 34 17 (3-40)  22 18 (1-45)  0.89 
Hypertension 71 16 (22.5%)  74 17 (23.0%)  0.95 
Diabetes type II 71 7 (9.9%)  75 7 (9.3%)  1.00 
        
Drug treatment        
Statin 71 69 (97.2%)  76 73 (96.1%)  1.00 
Resin 71 24 (33.8%)  76 12 (15.8%)  0.019 
Niacin 71 9 (12.7%)  76 2 (2.6%)  0.027 
Ezetimibe 71 57 (80.3%)  76 57 (75.0%)  0.57 
Total yrs lipid-lowering treatment 52 18.0 (3.0-27.0)  60 17.0 (1.0-36.0)  0.61 
Total yrs statin treatment 56 18.0 (3.0-24.0)  63 16.0 (1.0-23.0)  0.40 
        
Diet parameters        
Omega-3 supplement 35 27 (77.1%)  56 42 (75.0%)  1.00 
SmartDiet score (out of total 36) 52 30 (22-36)  61 30 (21-36)  0.88 
        
Physical examination        
Xanthomas at study-visit 70 46 (65.7%)  75 57 (76.0%)  0.24 
Xanthelasms at study-visit  70 5 (7.1%)  75 1 (1.3%)  0.11 
Corneal arcus at study-visit 70 32 (45.7%)  75 38 (50.7%)  0.67 
BMI (kg/m2) 71 27.0 (18.0-38.6)  76 27.6 (18.4-40.2)  0.55 
Systolic BP (mmHg) 71 124 (88-176)  76 128 (96-183)  -** 
Diastolic BP (mmHg) 71 77 (56-112)  76 80 (60-96)  -** 
        
Laboratory parameters        
TC pre-treatment (mmol/L) 68 11.7 (6.7-17.0)  75 10.4 (7.5-16.0)  0.011 
TC at study-visit (mmol/L) 71 4.8 (3.1-9.2)  75 4.7 (2.8-14.9)  0.27 
Difference LDL-C (mmol/L) 68 -6.8 (-11.3- -0.4)  74 -5.9 (-11.5 - +2.8)  0.036* 
Difference LDL-C (%) 68 -57.3 (-74.4 - -5.7)  74 -57.2 (-77.9 - +23.1)  0.56 
HDL-C at study-visit (mmol/L) 71 1.2 (0.7-3.1)  75 1.3 (0.5-3.1)  0.15 
LDL-C at study-visit (mmol/L) 71 3.2 (1.7-6.6)  75 2.9 (1.4-10.9)  0.091 
TG at study-visit (mmol/L) 70 0.9 (0.4-2.4)  74 0.8 (0.3-2.7)  0.008 
Non-HDL (TC - HDL-C) (mmol/L) 71 3.7 (2.1-7.4)  75 3.3 (1.6-13.3)  0.067 
TC/HDL-C 71 4.0 (2.3-7.0)  75 3.6 (2.2-9.3)  0.016* 
ApoA1 level at study-visit (g/L) 70 1.4 (0.8-2.5)  64 1.5 (0.9-2.3)  0.47 
ApoB level at study-visit (g/L) 70 0.9 (0.6-1.6)  64 0.9 (0.5-2.6)  0.031* 
ApoB/ApoA1 70 0.66 (0.36-1.25)  64 0.61 (0.33-1.44)  0.033* 
Lp(a) (mg/L) 58 518 (60-3130)  54 170 (60-1890)  <0.001 
                
Data are given as n (%) or median (min-max)      
1   n indicates number of individuals       
2 Chi-square test for independence or Fisher's exact two-tail probability test, statistically significant when P < 0.05 
3 
* Statistic significant P-value disappears when performing Bonferroni adjustment 
Post-hoc Mann Whitney U test, statistically significant when P < 0.05 
  
** Cannot compare groups on basis of incomplete information in data file    
CHD = coronary heart disease; BMI = body mass index; BP = blood pressure; TC = total cholesterol; HDL-C =  
high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol;    
TG = triglycerides; ApoA1 = apolipoprotein A1; ApoB = apolipoprotein B; Lp(a) = lipoprotein(a)   
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Categorisation of Lp(a) values 
In figure 8a, the median level of Lp(a) of 518 and 170 mg/L in the susceptible and 
resistant groups, respectively, are shown, P < 0.001. In figure 8b, the value of Lp(a) 
is divided into three categories. The lowest category represents the smallest value 
measureable at the medical-biochemical laboratory at Rikshospitalet, OUS. A Lp(a) 
value below 300 mg/L represents the 75-percentile in the general population, and 
values above 300 mg/L are considered to increase CHD risk (104, 106). 
Fifty percent of resistant FH subjects had a Lp(a) level in the 61-299 mg/L range, 
which was a significantly greater number than that of susceptible FH subjects 
(24.1%). Conversely, the number of susceptible FH subjects with a Lp(a) level above 
300 mg/L was statistically significant greater in comparison with the number of 
resistant FH subjects, with a number of 67.2 % and 40.7 %, respectively. Both 
comparisons were statistically significant at a P-value of 0.011. There was no 
difference between the two groups regarding Lp(a) level <60 mg/L. 
 
 
Figures 8a and 8b. Categorisation of Lp(a) values. A. The median Lp(a) value of the 
susceptible and resistant groups shown in bar chart. The two groups have a median value of 
518 (60-3130) and 170 (60-1890) mg/L, respectively, * P <0.001. B. Distribution of subjects 
when Lp(a) is divided into three groups, ** P = 0.011. 
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4.1.2 Female and male 
When splitting the whole material of FH subjects into groups based on gender, one 
could potentially reveal differences that were not seen in the comparison of 
susceptible and resistant groups. 
As shown in table 12, there was a statistically significant difference between male 
and female FH subjects in the medication treatment, where more male subjects were 
treated with statins as well as resins and niacin. 
Furthermore, FH men had significantly lower median total cholesterol level at study-
visit than what FH women had. Also, male FH subjects tended towards having a 
bigger percent reduction of total cholesterol. However, not surprisingly, the women 
had significantly higher median HDL-C level and higher ApoA1 level and hence 
lower ApoB/ApoA1 ratio. The FH women also had significantly lower total 
cholesterol/HDL ratio in comparison with the FH men. 
Female FH subjects had a tendency of lower median TG concentration than male FH 
subjects, with P = 0.082.  
The age at study-visit was significantly different between the male group and female 
group; women were by median four years older than men. Also, a trend showed that 
the FH men were younger at their first CHD event in comparison with FH women. 
However, those finding were as expected, with oestrogen’s protective role in female 
before menopause (11). 
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Table 12. Characterisation and comparison of female and male 
 Female  Male       
        
  n   1   n     P 
 
2,3 
       Demographics        
Total 60   87    
Age at study-visit 60 58 (39-76)  87 54 (40-75)  0.035 
Age at first CHD event 25 45 (30-63)  60 39 (25-68)  0.076 
Early CHD in first-degree relative 57 42 (73.7%)  86 53 (61.6%)  0.19 
        
Classical CHD risk factors        
Smoker (both pre and now) 60 40 (66.7%)  87 58 (66.7%)  1.00 
Yrs smoking total 39 19 (2-40)  58 19 (2-50)  0.79 
Yrs since quit smoking 24 16 (1-45)  32 19 (2-40)  0.91 
Hypertension 58 14 (24.1%)  87 19 (21.8%)  0.90 
Diabetes type II 59 6 (10.2%)  87 8 (9.2%)  1.00 
        
Drug treatment        
Statin 60 55 (91.7%)  87 87 (100.0%)  0.010 
Resin 60 8 (13.3%)  87 28 (32.2%)  0.016 
Niacin 60 1 (1.7%)  87 10 (11.5%)  0.028 
Ezetimibe 60 45 (75.0%)  87 69 (79.3%)  0.68 
Total yrs lipid-lowering treatment 48 18 (1-36)  64 18 (3-23)  0.63 
Total yrs statin treatment 51 17 (1-24)  68 17 (3-23)  0.95 
        
Diet parameters        
Omega-3 supplement 41 30 (73.2%)  50 39 (78.0%)  0.63 
SmartDiet score (out of total 36) 48 30 (21-35)  65 31 (22-36)  0.12 
        
Physical examination        
Xanthomas at study-visit 59 40 (67.8%)  86 63 (73.3%)  0.60 
Xanthelasms at study-visit  59 2 (3.4 %)  86 4 (4.7%)  1.00 
Corneal arcus at study-visit 59 26 (44.1%)  86 44 (51.2%)  0.50 
BMI (kg/m2) 60 27.8 (18.0-40.2)  87 26.9 (18.9-38.6)  0.80 
Systolic BP (mmHg) 60 128 (88-183)  87 126 (96-176)  -* 
Diastolic BP (mmHg) 60 77 (56-98)  87 78 (57-112)  -* 
        
Laboratory parameters        
TC pre-treatment (mmol/L) 59 11.0 (7.0-17.0)  84 11.3 (6.7-16.0)  0.74 
TC at study-visit (mmol/L) 60 5.0 (3.3-14.9)  86 4.7 (2.8-7.9)  0.042 
Difference TC (mmol/L) 59 -5.9 (-11.3 - +2.8)  59 -6.6 (-11.5 - -0.7)  0.11 
Difference TC (%) 83 -54.6 (-71.3 - +23.1)  83 -57.6 (-77.9 - -10.4)  0.082 
HDL-C at study-visit (mmol/L) 60 1.4 (0.8-3.1)  86 1.2 (0.5-2.2)  <0.001 
LDL-C at study-visit (mmol/L) 60 3.2 (1.6-10.9)  86 3.0 (1.4-5.5)  0.16 
TG at study-visit (mmol/L) 59 0.8 (0.3-2.4)  85 0.9 (0.4-2.7)  0.061 
Non-HDL (TC - HDL-C) (mmol/L) 60 3.6 (2.0-13.3)  86 3.5 (1.6-6.5)  0.61 
TC/HDL-C 60 3.5 (2.2-9.3)  86 4.0 (2.3-7.6)  0.004 
ApoA1 level at study-visit (g/L) 54 1.6 (1.0-2.5)  80 1.3 (0.8-2.0)  <0.001 
ApoB level at study-visit (g/L) 54 0.9 (0.5-2.6)  80 0.9 (0.6-1.5)  0.57 
ApoB/ApoA1 54 0.58 (0.33-1.44)  80 0.68 (0.35-1.27)  0.014 
Lp(a) (mg/L) 44 276 (60-3130)  68 435 (60-2460)  0.13 
                
Data are given as n (%) or median (min-max)      
1   n indicates number of individuals       
2 Chi-square test for independence or Fisher's exact two-tail probability test, statistically significant when P < 0.05 
3  Post-hoc Mann Whitney U test, statistically significant when P < 0.05     
* Cannot compare groups on basis of incomplete information in data file    
CHD = coronary heart disease; BMI = body mass index; BP = blood pressure; TC = total cholesterol; HDL-C =  
high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol;    
TG = triglycerides; ApoA1 = apolipoprotein A1; ApoB = apolipoprotein B; Lp(a) = lipoprotein(a)   
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4.1.3 Susceptible female and resistant female 
By splitting the susceptible and resistant groups into groups based on gender, one 
could somewhat meet the challenge of gender as a confounding factor.  
Characterisation of the subjects and comparison of the groups of susceptible female 
and resistant female is shown in tables 13a and 13b, respectively.  
In general, the susceptible female group had a more atherogenic blood lipid profile 
than the group of resistant female. First of all, the susceptible women had a 
statistically significant higher median Lp(a) level. In addition, the susceptible women 
had significantly higher median total cholesterol pre-treatment level, LDL-C level, 
TG level, non-HDL level, ApoB level, ApoB/ApoA1 ratio and total cholesterol/HDL-
C ratio.  
Interestingly, the susceptible women also had medianvise significantly bigger 
reduction in total cholesterol measured in mmol/L. However, the only medication that 
differed between the two groups was resin treatment, a significantly higher number of 
persons in the susceptible women group received resins in combination with statins.  
Moreover, the amount of years of both lipid-lowering treatment and statin treatment 
were greater in the susceptible female group compared with the resistant female 
group.  
Significantly more susceptible women had early CHD in first-degree relatives than 
the resistant women. 
As expected, the susceptible women were younger at first CHD event than the 
resistant women. Furthermore, there were only two women in the resistant group who 
had had a CHD event. 
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4.1.4 Susceptible male and resistant male 
As shown in tables 13a and 13b, respectively, there were unexpectedly few 
differences between the group of susceptible male and the group of resistant male 
compared to the findings between the female groups.  
The only statistically significant finding was that more men in the susceptible male 
group medianvise received niacin treatment in comparison with the men in the 
resistant male group. 
Not surprisingly, the susceptible men were significantly younger at their first CHD 
event than the resistant men – and they also were younger at study-visit.  
Interestingly, there was a tendency of difference between the two groups considering 
the number of years they had received lipid-lowering treatment, with a median of 16.0 
years in  susceptible men and 18.5 years in resistant men, P = 0.071. At the same 
time, there was a trend towards resistant men having been smoking medianvise for 
four more years than susceptible men.  
Table 13a. Characteristics and comparison of female and male subdivided into groups of susceptible and resistant 
  Female       Male             
          
 Susceptible  Resistant    Susceptible  Resistant       
            
                    
  n   1   n     P   2,3 n     n     P   4 P   5 P 
 
6 
                   Demographics                    
Total 23   37     48   39        
Age at study-visit 23 57 (39-73)  37 58 (50-76)  0.84  48 51 (40-73)  39 60 (47-75)  <0.001  0.023  0.67 
Age at first CHD event 23 44 (30-48)  2 61 (58-63)  0.020  48 37 (25-45)  12 56 (47-68)  <0.001  0.001  0.32 
Early CHD in first degree relative 23 21 (91.3%)  34 21 (61.8%)  0.015  48 33 (68.8%)  38 20 (52.6%)  0.19  0.042  0.59 
                    
Classical CHD risk factors                    
Smoker (both pre and now) 23 14 (60.9%)  37 26 (70.3%)  0.58  48 33 (68.8%)  39 25 (64.1%)  0.82  0.60  0.74 
Yrs smoking total 13 17 (3-30)  26 25 (2-40)  0.092  33 18 (2-50)  25 22 (3-47)  0.082  0.34  0.81 
Yrs since quit smoking 11 11 (4-35)  13 17 (1-45)  0.73  23 19 (3-40)  9 18 (2-32)  0.85  0.67  0.95 
Hypertension 23 8 (34.8%)  35 6 (17.1%)  0.21  48 8 (16.7%)  39 28 (71.8%)  0.30  0.13  0.28 
Diabetes type II 23 4 (17.4%)  36 2 (5.6%)  0.20  48 3 (6.2%)  39 5 (12.8%)  0.46  0.20  0.43 
                    
Drug treatment                    
Statin 23 21 (91.3%)  37 34 (91.9%)  1.00  48 48 (100.0%)  39 39 (100.0%)  1.00  0.10  0.11 
Resin 23 6 (26.1%)  37 2 (5.4%)  0.045  48 18 (37.5%)  39 10 (25.6%)  0.34  0.43  0.025 
Niacin 23 0 (0.0%)  37 1 (2.7%)  1.00  48 9 (18.8%)  39 1 (2.6%)  0.021  0.027  1.00 
Ezetimibe 23 19 (82.6%)  37 26 (70.3%)  0.37  48 38 (79.2%)  39 31 (79.5%)  1.00  1.00  0.43 
Total yrs lipid-lowering treatment 16 20.0 (4.0-27.0)  32 15.5 (1.0-36.0)  0.009  36 16.0 (3.0-23.0)  28 18.5 (10.0-23.0)  0.071  0.003  0.063 
Total yrs statin treatment 17 19.0 (4.0-24.0)  34 15.5 (1.0-23.0)  0.004  39 16.0 (3.0-23.0)  29 17.0 (8.0-22.0)  0.18  0.029  0.057 
                    
Diet parameters                    
Omega-3 supplement 13 9 (69.2%)  28 21 (75.0%)  0.72  22 18 (81.8%)  28 21 (75.0%)  0.73  0.43  1.00 
SmartDiet score (out of total 36) 16 30 (25-35)  32 30 (21-35)  0.92  36 31 (22-36)  29 31 (26-36)  0.61  0.40  0.18 
                                        
Data are given as n (%) or median (min-max) 
1 n indicates number of individuals 
2 Mann-Whitney U test and C hi-square test for independence or Fisher's exact two-tail probability test, statistically significant when P < 0.05 were used 
3  between susceptible female and resistant female 
4 between susceptible male and resistant male 
5 between susceptible female and susceptible male 
6
CHD = coronary heart disease 
 between resistant female and resistant male 
Table 13b. Characteristics and comparison of female and male subdivided into susceptible and resistant group 
  Female       Male             
          
 Susceptible  Resistant    Susceptible  Resistant       
            
                    
  n   1   n     P   2,3 n     n     P   4 P   5 P 
 
6 
                   Physical examination                    
Xanthomas at study-visit 22 15 (68.2%)  37 25 (67.6%)  1.00  48 31 (64.6%)  38 32 (84.2%)  0.072  1.00  0.11 
Xanthelasms at study-visit  22 1 (4.5%)  37 1 (2.7%)  1.00  48 4 (8.3%)  38 0 (0.0%)  0.13  1.00  0.49 
Corneal arcus at study-visit 22 11 (50.0%)  37 15 (40.5%)  0.59  48 21 (43.8%)  38 23 (60.5%)  0.18  0.82  0.13 
BMI (kg/m2) 23 28.6 (18.0-35.6)  37 27.7 (18.4-40.2)  0.83  48 26.4 (18.9-38.6)  39 27.5 (21.6-38.0)  0.25  0.46  0.63 
Systolic BP (mmHg) 23 132 (88-165)  37 125 (99-183)  -*  48 123 (100-176)  39 137 (96-168)  -**  -*  -** 
Diastolic BP (mmHg) 23 74 (56-98)  37 80 (60-92)  -*  48 77 (57-112)  39 80 (60-96)  -**  -*  -** 
                    
Laboratory parameters                    
TC pre-treatment (mmol/l) 22 12.0 (7.0-17.0)  37 10.4 (7.5-15.7)  0.006  46 11.6 (6.7-16.0)  38 10.5 (8.5-16.0)  0.32  0.25  0.58 
TC at study-visit (mmol/l) 23 5.5 (3.7-9.2)  37 4.8 (3.3-14.9)  0.084  48 4.7 (3.1-7.9)  38 4.6 (2.8-7.4)  0.65  0.013  0.41 
Difference LDL-C (mmol/l) 22 -7.3 (-11.3 - -0.4)  37 -5.7 (-10.1 - +2.8)  0.036  46 -6.8 (-11.0 - -0.7)  37 -6.0 (-11.5 - -2.1)  0.55  0.78  0.093 
Difference LDL-C (%) 22 -56.9 (-71.3 - -5.7)  37 -54.4 (-70.8 - +23.1)  0.62  46 -57.3 (-74.4 - -10.4)  37 -58.9 (- 77.9 - -23.3)  0.86  0.47  0.13 
HDL-C at study-visit (mmol/l) 23 1.3 (0.8-3.1)  37 1.5 (0.9-3.1)  0.25  48 1.2 (0.7-2.2)  38 1.2 (0.5-2.0)  0.97  0.025  <0.001 
LDL-C at study-visit (mmol/l) 23 3.4 (1.9-6.6)  37 2.9 (1.6-10.9)  0.031  48 3.1 (1.7-5.5)  38 2.9 (1.4-5.1)  0.49  0.023  0.78 
TG at study-visit (mmol/l) 23 0.9 (0.4-2.4)  36 0.7 (0.3-2.4)  0.030  47 0.9 (0.5-2.4)  38 0.9 (0.4-2.7)  0.21  0.75  0.12 
Non-HDL (TC - HDL-C) (mmol/l) 23 4.1 (2.5-7.4)  37 3.2 (2.0-13.3)  0.013  48 3.6 (2.1-6.5)  38 3.3 (1.6-5.7)  0.72  0.039  0.49 
TC/HDL-C 23 4.4 (2.3-6.5)  37 3.3 (2.2-9.3)  0.006  48 4.0 (2.5-7.0)  38 4.0 (2.3-7.6)  0.97  0.98  0.001 
ApoA1 level at study-visit (g/l) 22 1.6 (1.1-2.5)  32 1.6 (1.0-2.3)  0.74  48 1.4 (0.8-2.0)  32 1.3 (0.9-2.0)  0.84  0.006  0.005 
ApoB level at study-visit (g/l) 22 1.1 (0.7-1.6)  32 0.9 (0.6-2.6)  0.005  48 0.9 (0.6-1.5)  32 0.9 (0.6-1.4)  0.58  0.019  0.49 
ApoB/ApoA1  22 0.66 (0.36-1.07)  32 0.53 (0.33-1.44)  0.018  48 0.66 (0.45-1.25)  32 0.69 (0.35-1.27)  0.97  0.89  0.006 
LDL-C/ApoB 22 3.6 (2.3-4.3)  32 3.4 (2.8-4.2)  0.59  48 3.4 (2.4-4.6)  32 3.3 (2.2-4.3)  0.40  0.095  0.019 
Lp(a) (mg/l) 19 953 (60-3130)  25 140 (60-606)  <0.001  39 458 (60-2460)  29 411 (60-1890)  0.25  0.32  0.014 
                                        
Data are given as n (%) or median (min-max) 
1 n indicates number of individuals 
2 Mann Whitney U test and Chi-square test for independence or Fisher's exact two-tail probability test, statistically significant when P < 0.05 were used 
3  between susceptible female and resistant female 
4 between susceptible male and resistant male 
5 between susceptible female and susceptible male 
6
* Cannot compare groups on basis of incomplete information in data file 
 between resistant female and resistant male 
BMI = body mass index; BP = blood pressure; TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TG = triglycerides; ApoA1 = apolipoprotein A1; 
ApoB = apolipoprotein B; lp(a) = lipoprotein(a) 
4.1.5 Susceptible female and susceptible male 
In tables 13a and 13b, respectively, the characterisation of the subjects and 
comparison of the groups of susceptible female and susceptible male is shown.  
Although the susceptible women had been treated with lipid-lowering drugs and 
statins significantly longer in comparison with the susceptible men, they had higher 
median total cholesterol level at study-visit, LDL-C level, non-HDL level and ApoB 
level. Furthermore, the only lipid-lowering drug significantly more used by men than 
women was niacin.  
As anticipated, median HDL-C level was significantly higher in susceptible female 
compared to susceptible male.  
Significantly more susceptible women than susceptible men had early CHD in first-
degree relatives. 
The median age at study-visit and the median age at first CHD event were, not 
unexpectedly, significantly higher in susceptible female in comparison with 
susceptible male. 
4.1.6 Resistant female and resistant male 
Characterisation of the subjects and comparison of the groups is shown in tables 13a 
and 13b, respectively. The resistant male group had statistically significant higher 
median Lp(a) level than the resistant female group. 
As expected, the women had medianvise higher level of HDL-C and ApoA1, and 
accordingly higher median ApoB/ApoA1 ratio level in comparison with the men. The 
total cholesterol /HDL-C ratio was lower in resistant women than resistant men.  
Significantly more resistant men than resistant women received resin treatment. The 
resistant male group also tended to have received lipid-lowering treatment and statin 
treatment for a greater number of years than the resistant female group. 
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The group of resistant women tended to have lower mmol/L difference in LDL-C 
levels in comparison with the group of resistant men. 
4.1.7 Deceased FH subjects with early CHD event and late or no 
CHD event 
As shown in table 14, median ApoA1 level was significantly lower in the group of 
deceased FH subjects with early CHD event compared with the group of deceased FH 
subjects with late or no CHD event. The same situation was seen for the ApoB/A1 
ratio, but the difference between the groups disappeared with Bonferroni correction. 
The other blood lipid values were not significantly different between the two groups. 
However, median total cholesterol/HDL-C ratio tended to be higher in the group of 
deceased FH subjects with early CHD event.  
In the group with early CHD event, a statistically significant lower percent of 
individuals were taking omega-3 supplements compared with the group with late or 
no CHD event.  
Interestingly, the deceased FH subjects with early CHD event died at a median age of 
45, suggesting that they did not only have a CHD incidence early; they also died from 
it. The two groups were classified into groups from the subjects’ age at first CHD 
event; yet, the deceased FH subjects with early CHD event died at a significantly 
younger median age than what the subjects in the group of FH subjects with late or no 
CHD event did.  
As expected, median age at first CHD event was significantly lower in the group of 
deceased FH subjects with early CHD event.  
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Table 14. Characterisation and comparison of deceased FH subjects with early CHD event 
and deceased FH subjects with late or no CHD event 
  Deceased FH subjects     
    Early CHD  Late/no CHD       
        
  n   1   n     P 
 
2,3 
       Demographics        
Total 14   14    
Female  14 5 (35.7%)  14 8 (57.1%)  0.45 
Age at time of death 14 45 (33-62)  14 66 (49-85)  <0.001 
Age at first CHD event 14 34 (26-46)  8 50 (46-55)  <0.001 
Early CHD in first-degree relative 13 9 (69,2%)  13 8 (61.5%)  1.00 
        
Classical CHD risk factors        
Smoker (both pre and now) 13 8 (61.5%)  14 7 (50.0%)  1.00 
Hypertension 13 5 (38,5%)  13 7 (53.8%)  0.69 
Diabetes type II 3 0 (0.0%)  4 2 (50.0%)  0.43 
        
Drug treatment        
Statin 14 14 (100.0%)  14 13 (92.9%)  1.00 
Resin 14 7 (50.0%)  14 6 (42.9%)  1.00 
Niacin 14 1 (7.1%)  14 2 (14.3%)  1.00 
Ezetimibe 14 1 (7.1%)  14 0 (0.0%)  1.00 
Total yrs lipid-lowering treatment 14 12.0 (2.0-44.0)  13 8.5 (1.0-20.0)  0.17 
Total yrs statin treatment 14 9.5 (1.5-18.0)  14 7.5 (0.0-15.0)  0.31 
        
Diet parameters        
Omega-3 supplement 13 2 (15.4%)  14 9 (64.3%)  0.028 
SmartDiet score (out of total 36) 12 25 (21-29)  12 27 (21-34)  0.28 
        
Physical examination        
Xanthomas at study-visit 13 9 (69.2%)  14 8 (57.1%)  0.70 
Xanthelasms at study-visit  13 7 (53.8%)  14 7 (50.0%)  1.00 
Corneal arcus at study-visit 13 7 (53.8%)  13 9 (69,2%)  0.69 
BMI (kg/m2) 12 23.9 (16.6-40.4)  9 28.7 (20.9-40.0)  0.20 
Systolic BP (mmHg) 10 129 (107-160)  10 124 (95-177)  -** 
Diastolic BP (mmHg) 10 80 (64-90)  10 75 (60-90)  -** 
        
Laboratory parameters        
TC pre-treatment (mmol/L) 14 13.3 (7.9-19.0)  14 13.0 (9.7-24.0)  0.98 
TC at study-visit (mmol/L) 14 7.8 (4.3-11.2)  14 6.9 (4.9-12.1)  0.33 
Difference LDL-C (mmol/L) 14 -4.1 (-14.7 - +0.5)  14 -5.4 (-16.4 - -1.9)  0.25 
Difference LDL-C (%) 14 -35.2 (-77.4 - +5.1)  14 -46.9 (-68.3 - -13.6)  0.25 
HDL-C at study-visit (mmol/L) 14 1.0 (0.6-2.5)  14 1.2 (0.8-2.9)  0.26 
LDL-C at study-visit (mmol/L) 14 5.4 (3.2-9.4)  14 4.7 (3.1-9.9)  0.22 
TG at study-visit (mmol/L) 14 1.2 (0.6-5.0)  14 1.4 (0.4-2.6)  0.58 
Non-HDL (TC - HDL-C) (mmol/L) 14 6.6 (3.7-10.2)  14 5.3 (3.9-11.1)  0.22 
TC/HDL-C 14 7.2 (2.8-11.2)  14 5.2 (2.7-12.1)  0.081 
ApoA1 level at study-visit (g/L) 10 1.0 (0.9-1.7)  11 1.5 (1.2-2.2)  0.010 
ApoB level at study-visit (g/L) 10 1.8 (1.1-2.8)  11 1.2 (1.0-2.8)  0.11 
ApoB/ApoA1  10 1.72 (0.73-2.91)  11 0.92 (0.55-2.12)  0.035* 
Lp(a) (mg/L) 11 436 (17-1119)  8 309 (24-1075)  0.74 
                
Data are given as n (%) or median (min-max) 
1   n indicates number of individuals       
2 Chi-square test for independence or Fisher's exact two-tail probability test, statistically significant when P < 0.05 
3 
* Statistic significant P-value disappears when performing Bonferroni adjustment 
Post-hoc Mann Whitney U test, statistically significant when P < 0.05 
   
** Cannot compare groups on basis of incomplete information in data file     
CHD = coronary heart disease; BMI = body mass index; BP = blood pressure; TC = total cholesterol; HDL-C =  
high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol;     
TG = triglycerides; ApoA1 = apolipoprotein A1; ApoB = apolipoprotein B; Lp(a) = lipoprotein(a)   
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4.1.8 Susceptible and deceased FH subjects with early CHD event 
Characterisation of the subjects and comparison of the two groups is shown in table 
15. In general, the non-deceased susceptible group had a more favourable blood lipid 
composition than that of the deceased FH subjects with early CHD event. 
Median total cholesterol levels at study-visit, percent reduction in total cholesterol, 
LDL-C level, non-HDL level, total cholesterol/HDL-C ratio, ApoA1 level, ApoB 
level and ApoB/ApoA1 ratio were significantly lower in the non-deceased susceptible 
group. The group of non-deceased susceptible FH subjects also had lower median TG 
level, but with Bonferroni correction the significant P-value disappeared. Lp(a) levels 
and HDL-C levels were not significantly different between the two groups. 
A significantly greater number of non-deceased susceptible had reported a regularly 
intake of omega-3 supplement in comparison to what was found in the deceased 
patients’ medical reports.  
The number of non-deceased susceptible FH subjects with xanthelasms was 
significantly lower than the number of deceased FH subjects with early CHD event 
with xanthelasms; the percentage of individuals were 7.1 % and 53.8 %, respectively.  
Median total number of years of statin treatment was significantly higher in non-
deceased susceptible compared to the deceased FH subjects with early CHD event. 
The same was the case with lipid-lowering treatment. Considering the latter, the 
significant difference between the groups disappeared after Bonferroni correction.  
Not surprisingly, taking into consideration the time difference between the two 
groups, a significantly greater number of susceptible FH subjects received ezetimibe 
treatment in comparison with the deceased FH subjects with early CHD event.  
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Table 15. Characterisation and comparison of susceptible and deceased FH subjects with 
early CHD event  
 Early CHD   
    Susceptible  Deceased FH subjects       
        
  n   1   n     P 
 
2,3 
       Demographics        
Total 71   14    
Female  71 23 (32.4%)  14 5 (35.7%)  1.00 
Age at study-visit 71 53 (39-73)  - -  - 
Age at time of death - -  14 45 (33-62)  - 
Age at first CHD event 52 30 (22-36)  14 34 (26-46)  0.13 
Early CHD in first-degree relative 71 54 (76.1%)  13 9 (69,2%)  0.73 
        
Classical CHD risk factors        
Smoker (both pre and now) 71 47 (66.2%)  13 8 (61.5%)  0.76 
Hypertension 71 16 (22.5%)  13 5 (38,5%)  0.30 
Diabetes type II 71 7 (9.9%)  3 0 (0.0%)  1.00 
        
Drug treatment        
Statin 71 69 (97.2%)  14 14 (100.0%)  1.00 
Resin 71 24 (33.8%)  14 7 (50.0%)  0.36 
Niacin 71 9 (12.7%)  14 1 (7.1%)  1.00 
Ezetimibe 71 57 (80.3%)  14 1 (7.1%)  <0.001 
Total yrs lipid-lowering treatment 52 18.0 (3.0-27.0)  14 12.0 (2.0-44.0)  0.021* 
Total yrs statin treatment 56 18.0 (3.0-24.0)  14 9.5 (1.5-18.0)  <0.001 
        
Diet parameters        
Omega-3 supplement 35 27 (77.1%)  13 2 (15.4%)  <0.001 
        
Physical examination        
Xanthomas at study-visit 70 46 (65.7%)  13 9 (69.2%)  1.00 
Xanthelasms at study-visit  70 5 (7.1%)  13 7 (53.8%)  <0.001 
Corneal arcus at study-visit 70 32 (45.7%)  13 7 (53.8%)  0.76 
BMI (kg/m2) 71 27.0 (18.0-38.6)  12 23.9 (16.6-40.4)  0.12 
Systolic BP (mmHg) 71 124 (88-176)  10 129 (107-160)  -** 
Diastolic BP (mmHg) 71 77 (56-112)  10 80 (64-90)  -** 
        
Laboratory parameters        
TC pre-treatment (mmol/L) 68 11.7 (6.7-17.0)  14 13.3 (7.9-19.0)  0.13 
TC at study-visit (mmol/L) 71 4.8 (3.1-9.2)  14 7.8 (4.3-11.2)  <0.001 
Difference LDL-C (mmol/L) 68 -6.8 (-11.3- -0.4)  14 -4.1 (-14.7 - +0.5)  0.12 
Difference LDL-C (%) 68 -57.3 (-74.4 - -5.7)  14 -35.2 (-77.4 - +5.1)  0.001 
HDL-C at study-visit (mmol/L) 71 1.2 (0.7-3.1)  14 1.0 (0.6-2.5)  0.076 
LDL-C at study-visit (mmol/L) 71 3.2 (1.7-6.6)  14 5.4 (3.2-9.4)  <0.001 
TG at study-visit (mmol/L) 70 0.90 (0-40-2.40)  14 1.17 (0.60-5.01)  0.041* 
Non-HDL (TC - HDL-C) (mmol/L) 71 3.7 (2.1-7.4)  14 6.6 (3.7-10.2)  <0.001 
TC/HDL-C 71 4.00 (2.32-7.00)  14 7.17 (2.80-11.20)  <0.001 
ApoA1 level at study-visit (g/L) 70 1.40 (0.80-2.50)  10 1.04 (0.90-1.70)  0.002 
ApoB level at study-visit (g/L) 70 0.90 (0.60-1.60)  10 1.83 (1.10-2.80)  <0.001 
ApoB/ApoA1  70 0.655 (0.360-1.250)  10 1.717 (0.725-2.913)  <0.001 
Lp(a) (mg/L) 58 518 (60-3130)  11 436 (17-1119)  0.14 
                
Data are given as n (%) or median (min-max) 
1   n indicates number of individuals       
2 Chi-square test for independence or Fisher's exact two-tail probability test, statistically significant when P < 0.05 
3 
* Statistic significant P-value disappears when performing Bonferroni adjustment 
Post-hoc Mann Whitney U test, statistically significant when P < 0.05 
   
** Cannot compare groups on basis of incomplete information in data file     
CHD = coronary heart disease; BMI = body mass index; BP = blood pressure; TC = total cholesterol; HDL-C =  
high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol;     
TG = triglycerides; ApoA1 = apolipoprotein A1; ApoB = apolipoprotein B; Lp(a) = lipoprotein(a)   
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4.1.9 Resistant and deceased FH subjects with late or no CHD 
event 
In table 16 the characterisation of the subjects and comparison of the non-deceased 
resistant group and the group of deceased FH subjects with late or no CHD event is 
shown.  
Median total cholesterol level pre-treatment and at study-visit, LDL-C level, non-
HDL level, total cholesterol/HDL-C ratio, ApoB level and ApoB/ApoA1 ratio were 
significantly lower in the group of non-deceased resistant FH subjects in comparison 
with the group of deceased FH subjects with late or no CHD event. Also, median TG 
level was significantly lower in non-deceased FH subjects, but Bonferroni correction 
eliminated the significance.  
A lower number of individuals in the non-deceased resistant group had hypertension 
in comparison with the deceased FH subjects group.  
Total number of years of lipid-lowering therapy and total number of years of statin 
treatment were significantly higher in the non-deceased resistant FH subjects 
compared to the deceased FH subjects with late or no CHD event. The number of 
resistant subjects that received resins and ezetimibe treatment was significantly higher 
than that of deceased FH subjects with late or no CHD event.  
Noteworthy, eight out of 14 deceased FH subjects had experienced a CHD event in 
the deceased FH subjects with late or no CHD event group compared with 14 out of 
76 subjects in the resistant group. The deceased FH subjects had their first CHD event 
at an earlier age than that of the resistant. However, the significance disappeared 
when performing Bonferroni correction on the P-value. 
Xanthelasms was found in a significantly lower number of the non-deceased resistant 
individuals compared to the deceased FH subjects. 
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Table 16. Characterisation of resistant and deceased FH subjects with late or no CHD event 
 Late/no CHD   
    Resistant  Deceased FH subjects       
        
  n   1   n     P 
 
2,3 
       Demographics        
Total 76   14    
Female  76 37 (48.7%)  14 8 (57.1%)  0.77 
Age at study-visit 76 59 (47-76)  - -  - 
Age at time of death - -  14 66 (49-85)  - 
Age at CHD first event 14 57 (47-68)  8 50 (46-55)  0.015* 
Early CHD in first-degree relative 72 41 (56.9%)  13 8 (61.5%)  1.00 
        
Classical CHD risk factors        
Smoker (both pre and now) 76 51 (67.1%)  14 7 (50.0%)  1.00 
Hypertension 74 17 (23.0%)  13 7 (53.8%)  0.039 
Diabetes type II 75 7 (9.3%)  4 2 (50.0%)  0.062 
        
Drug treatment        
Statin 76 73 (96.1%)  14 13 (92.9%)  0.50 
Resin 76 12 (15.8%)  14 6 (42.9%)  0.031 
Niacin 76 2 (2.6%)  14 2 (14.3%)  0.11 
Ezetimibe 76 57 (75.0%)  14 0 (0.0%)  <0.001 
Total yrs lipid-lowering treatment 60 17.0 (1.0-36.0)  13 8.5 (1.0-20.0)  0.001 
Total yrs statin treatment 63 16.0 (1.0-23.0)  14 7.5 (0.0-15.0)  <0.001 
        
Diet parameters        
Omega-3 supplement 56 42 (75.0%)  14 9 (64.3%)  0.51 
        
Physical examination        
Xanthomas at study-visit 75 57 (76.0%)  14 8 (57.1%)  0.19 
Xanthelasms at study-visit  75 1 (1.3%)  14 7 (50.0%)  <0.001 
Corneal arcus at study-visit 75 38 (50.7%)  13 9 (69,2%)  0.25 
BMI (kg/m2) 76 27.6 (18.4-40.2)  9 28.7 (20.9-40.0)  0.83 
Systolic BP (mmHg) 76 128 (96-183)  10 124 (95-177)  -** 
Diastolic BP (mmHg) 76 80 (60-96)  10 75 (60-90)  -** 
        
Laboratory parameters        
TC pre-treatment (mmol/L) 75 10.4 (7.5-16.0)  14 13.0 (9.7-24.0)  0.003 
TC at study-visit (mmol/L) 75 4.7 (2.8-14.9)  14 6.9 (4.9-12.1)  <0.001 
Difference LDL-C (mmol/L) 74 -5.9 (-11.5 - +2.8)  14 -5.4 (-16.4 - -1.9)  0.97 
Difference LDL-C (%) 74 -57.2 (-77.9 - +23.1)  14 -46.9 (-68.3 - -13.6)  0.061 
HDL-C at study-visit (mmol/L) 75 1.3 (0.5-3.1)  14 1.2 (0.8-2.9)  0.67 
LDL-C at study-visit (mmol/L) 75 2.9 (1.4-10.9)  14 4.7 (3.1-9.9)  <0.001 
TG at study-visit (mmol/L) 74 0.8 (0.3-2.7)  14 1.4 (0.4-2.6)  0.017* 
Non-HDL (TC - HDL-C) (mmol/L) 75 3.3 (1.6-13.3)  14 5.3 (3.9-11.1)  <0.001 
TC/HDL-C 75 3.6 (2.2-9.3)  14 5.2 (2.7-12.1)  0.005 
ApoA1 level at study-visit (g/L) 64 1.5 (0.9-2.3)  11 1.5 (1.2-2.2)  0.99 
ApoB level at study-visit (g/L) 64 0.9 (0.5-2.6)  11 1.2 (1.0-2.8)  <0.001 
ApoB/ApoA1  64 0.61 (0.33-1.44)  11 0.92 (0.55-2.12)  0.002 
Lp(a) (mg/L) 54 170 (60-1890)  8 309 (24-1075)  0.77 
                
Data are given as n (%) or median (min-max) 
1   n indicates number of individuals       
2 Chi-square test for independence or Fisher's exact two-tail probability test, statistically significant when P < 0.05 
3 
* Statistic significant P-value disappears when performing Bonferroni adjustment 
Post-hoc Mann Whitney U test, statistically significant when P < 0.05 
   
** Cannot compare groups on basis of incomplete information in data file     
CHD = coronary heart disease; BMI = body mass index; BP = blood pressure; TC = total cholesterol; HDL-C =  
high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol;     
TG = triglycerides; ApoA1 = apolipoprotein A1; ApoB = apolipoprotein B; Lp(a) = lipoprotein(a)   
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4.2 Case-control Study 
4.2.1 Susceptible, resistant and controls 
Characterisation of the subjects and comparison of the groups is shown in tables 17a 
and 17b, respectively.  
FH subjects and controls 
First, we compared the group of FH subjects with the group of controls. Median Lp(a) 
level was significantly higher in FH subjects compared with controls. The group of 
FH subjects also tended to have higher median ApoB level and ApoB/ApoA1 ratio. 
Interestingly, the FH subjects also had a higher median percent of both vWF activity 
and vWF antigen than that of the controls. The same was the case with Protein S 
level, both free and total, Protein C level and fibrinogen level. However, all 
coagulation parameter values and the fibrinogen level were within reference range.  
Furthermore, in comparison with the control group, the group of FH subjects had 
significantly higher median blood glucose level, median BMI and median waist 
circumference. In addition, a greater number of individuals in the FH group had a 
regularly intake of omega-3 supplement. Furthermore, in comparison to controls a 
significantly greater number of FH subjects had hypertension. 
Three in four FH subjects had experienced early CHD in first-degree relatives, which 
was a significantly larger number of people than that of the control group – where no 
one had early CHD in their closest family. 
Not surprisingly, median ASAT level and ALAT level were statistically significant 
higher in the group of FH subjects, most probably due to the lipid-lowering 
medication. 
Since the individual with CRP level of 13.00 mg/L potentially could affect the result, 
the CRP P-value was estimated without this individual. The difference was still non-
significant, with P = 0.25 (not shown in table). 
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Susceptible and resistant groups 
Second, we compared the groups of susceptible FH subjects with resistant FH 
subjects. There were unexpectedly few differences between the group of susceptible 
and the group of resistant individuals. The susceptible group tended to have higher 
median Lp(a) value than the resistant group. 
A greater number of individuals in the susceptible group were medicated with β-
blockers compared to the resistant group.  
There was a trend towards lower BMI in susceptible FH subjects in comparison with 
resistant FH subjects.  
As expected, the median age at first CHD event in the susceptible group was lower 
than that of the resistant group. Furthermore, the susceptible group had a lower 
median age at study-visit. However, the resistant group in the latter comparison only 
consisted of three individuals. 
Susceptible and controls 
Third, we compared the group of susceptible with the control group. Susceptible FH 
subjects had statistically significant higher median Lp(a) level and tended to have 
higher median ApoB level compared to controls.  
Furthermore, the susceptible group had significantly higher median percentage of 
vWF antigen and vWF activity and median level of free and total Protein S in 
comparison with the control group. However, all parameters were within the range of 
reference and the vWF antigen difference disappeared with Bonferroni correction.  
A significantly greater number of individuals in the susceptible group had early CHD 
in first-degree relatives in comparison with the controls. What is more, a greater 
number of susceptible individuals had hypertension.  
Not surprisingly, median level of ASAT and ALAT were significantly higher in 
susceptible patients.  
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Significantly more susceptible FH subjects in comparison with controls had a 
regularly intake of omega-3 supplement. In addition, the median waist circumference 
of susceptible was greater than that of controls, however when performing Bonferroni 
correction the statistically significant P-value disappeared. The susceptible also 
tended to have higher median fibrinogen level, median blood glucose level and 
median BMI. 
Resistant and controls 
Fourth, a comparison of the resistant group and the control group was accomplished. 
As registered in susceptible compared with controls, resistant also had significantly 
higher median percentage of vWF antigen, vWF activity and median level of free and 
total Protein S. The statistically significant difference between the resistant group and 
the control group disappeared with Bonferroni correction. 
Furthermore, resistant FH subjects had significantly higher median BMI and waist 
circumference in comparison with control subjects, in addition to higher median 
blood glucose level. In addition, a greater number of resistant individuals had omega-
3 intake on a regularly basis. However, with Bonferroni correction the significant 
difference in blood glucose disappeared. 
The resistant group had significantly higher median fibrinogen level compared to the 
control group, but the difference disappeared when performing Bonferroni correction 
on the P-value. 
A significantly greater number of individuals in the resistant group had early CHD in 
first-degree relatives in comparison with the controls. 
As expected, the group of resistant FH subjects had higher median ASAT and ALAT 
levels. With Bonferroni correction, the significance of the difference between the 
groups in ASAT disappeared.  
There were found no other differences in blood lipid levels. 
Table 17a. Characterisation and comparison of susceptible, resistant and controls 
              FH subjects                         
 FH subjects  Controls    Susceptible  Resistant                   
                
  (n = 34)   (n = 10)   P   1 (n = 19)   (n = 15)   P   2 P    3 P 
 
4 
               Demographics                
Female 12 (35.3%)  4 (40.0%)  1.00  7 (36.8%)  5 (33.3%)  1.00  1.00  1.00 
Age at study-visit 59 (42-77)  60 (42-74)  0.77  56 (72-43)  62 (55-77)  0.033*  0.63  0.24 
Age at first CHD event 40 (28-63)**  -  -  39 (28-48)  62 (59-63)**  0.006  -  - 
Early CHD in first-degree relative 25 (73.5%)  0 (0.0%)  <0.001  14 (73.7%)  11 (73.3%)  1.00  <0.001  0.001 
                
Classical risk factors                
Smoker (now) 3 (8.8%)  1 (10.0%)  1.00  1 (5.3%)  2 (13.3%)  0.57  1.00  1.00 
Smoker (pre and/or now) 23 (67.6%)  4 (40.0%)  0.15  12 (63.2%)  11 (73.3%)  0.71  0.27  0.12 
Hypertension 16 (47.1%)  0 (0.0%)  0.007  10 (52.6%)  6 (40.0%)  0.51  0.005  0.051 
Diabetes type II 2 (5.9%)  0 (0.0%)  1.00  0 (0.0%)  2 (13.3%)  0.19  1.00  0.50 
                
Drug treatment                
Statin 33 (97.1%)  -  -  19 (100.0%)  14 (93.3%)  0.44  -  - 
Resin 13 (38.2%)  -  -  8 (42.1%)  5 (33.3%)  0.73  -  - 
Niacin 4 (11.8%)  -  -  4 (21.1%)  0 (0.0%)  0.11  -  - 
Ezetimibe 32 (94.1%)  -  -  18 (94.7%)  14 (93.3%)  1.00  -  - 
Albyl E 27 (79.4%)  -  -  17 (89.5%)  10 (66.7%)  0.20  -  - 
Β-blockers 12 (35.3%)  -  -  11 (57.9%)  1 (6.7%)  0.003  -  - 
                
Diet parameters                
Omega-3 supplement 29 (85.3%)  4 (40.0%)  0.008  16 (84.2%)  13 (86.7%)  1.00  0.032  0.028 
SmartDiet score (out of total 41) 35 (29-41)  35 (26-37)  0.35  33 (29-41)  36 (29-40)  0.26  0.60  0.23 
                
Physical examination                
BMI (kg/m2) 27.1 (18.2-37.8)  23.3 (20.3-25.8)  0.003  26.6 (18.2-36.9)  27.9 (22.8-37.8)  0.069  0.054  <0.001 
Waist circumference (cm) 98 (65-117)  85 (70-95)  0.001  95 (65-117)  98 (88-116)  0.22  0.022*  <0.001 
Systolic BP (mmHg) 135 (106-136)  125 (113-150)  0.077  132 (106-164)  138 (109-176)  0.41  0.12  0.10 
Diastolic BP (mmHg) 86 (56-109)  81 (62-95)  0.45  85 (56-104)  87 (71-109)  0.45  0.63  0.36 
                                
Data are given as n (%) or median (min-max), n indicates number of individuals             
Post-hoc Mann Whitney U test, Chi-square test for independence or Fisher's exact two-tail probability test, statistically significant when P < 0.05, were used     
1   between FH subjects and controls               
2   between susceptible and resistant               
3   between susceptible and controls               
4   between resistant and controls               
* Statistic significant P-value disappears when performing Bonferroni adjustment             
** n = 22 among FH subjects / n = 3 among resistant due to only 3 incidents of CHD            
CHD = coronary heart disease; BP = blood pressure; BMI = body mass index             
 
Table 17b. Characterisation and comparison of susceptible, resistant and controls 
             FH subjects                          
 FH subjects  Controls    Susceptible  Resistant                   
                
  (n = 34)   (n = 10)   P   1 (n = 19)   (n = 15)   P   2 P   3 P 
 
4 
               Laboratory parameters                
Blood lipid parameters                
TC at study-visit (mmol/L) 4.9 (3.0-11.5)  4.9 (4.1-7.0)  0.81  5.3 (3.0-8.4)  4.5 (3.8-11.5)  0.97  0.96  0.60 
HDL-C at study-visit (mmol/L) 1.4 (0.7-3.2)  1.7 (0.9-2.7)  0.35  1.3 (0.7-3.2)  1.5 (0.9-2.0)  0.20  0.29  0.56 
LDL-C at study-visit (mmol/L) 3.2 (1.5-9.0)  2.9 (1.1-5.4)  0.79  3.2 (1.7-5.2)  3.2 (1.5-9.0)  0.59  0.80  0.82 
Estimated LDL-C pre-treatment (mmol/L) 9.0 (3.7-16.7)  -  -  9.1 (4.3-16.7)  8.6 (3.7-14.6)  0.40  -  - 
Difference LDL-C (mmol/L) -6.4 (-14.1 - +0.2)  -  -  -6.4 (-14.1 - +0.2)  -4.0 (-10.0 - -0.5)  0.40  -  - 
Difference LDL-C (%) -67.2 (-84.4 - +4.7)  -  -  -68.6 (-84.4 - +4.7)  -61.1 (82.6 - -11.1)  0.32  -  - 
TG at study-visit (mmol/L) 0.8 (0.3-3.7)  0.9 (0.5-2.5)  0.90  0.8 (0.4-3.7)  0.8 (0.3-3.4)  0.77  0.80  0.96 
Non-HDL (TC-HDL-C) (mmol/L) 3.5 (1.8-10.5)  3.3 (1.4-6.1)  0.71  4.0 (1.8-6.1)  3.4 (2.2-10.5)  0.51  0.51  0.96 
TC/HDL-C 3.4 (2.2-11.5)  3.0 (1.5-7.8)  0.41  3.7 (2.3-6.5)  3.3 (2.2-11.5)  0.44  0.27  0.76 
ApoA1 level at study-visit (g/L) 1.5 (0.9-2.4)  1.6 (1.0-2.2)  0.66  1.5 (0.9-2.4)  1.6 (1.0-2.1)  0.47  0.55  0.89 
ApoB level at study-visit (g/L) 1.0 (0.5-2.4)  0.8 (0.3-2.4)  0.066  1.0 (0.5-1.4)  1.0 (0.6-2.4)  0.79  0.082  0.12 
ApoB/ApoA1 0.63 (0.37-2.00)  0.48 (0.15-1.17)  0.085  0.65 (0.37-1.08)  0.63 (0.41-2.00)  0.70  0.10  0.15 
Lp(a) (mg/L) 585 (60-2460)**  172 (85-913)  0.013  1210 (60-2460)**  434 (60-1890)  0.096  0.005  0.13 
Coagulation parameters                
APC resistance  1.06 (0.63-1.15)***  1.07 (0.99-1.11)  0.23  1.06 (0.89-1.10)***  1.05 (0.63-1.15)  0.37  0.10  0.64 
Protein S (free) (%) 88 (62-105)***   75 (63-83)  0.003  89 (65-105)***  87 (62-105)  0.68  0.011  0.005 
Protein S (total) (%) 99 (85-105)***  86 (73-105)  0.001  93 (85-105)***  103 (86-105)  0.091  0.009  0.002 
Protein C (%) 128 (87-154)***  107 (82-134)  0.049  128 (87-154)***  128 (87-144)  0.84  0.92  0.067 
vWF antigen (%) 155 (61-243)***  117 (65-151)  0.011  156 (81-243)***  153 (61-236)  0.91  0.025*  0.021* 
vWF activity (%) 131 (61-266)***  95 (61-120)  0.001  157 (81-243)***  129 (61-211)  0.64  0.003  0.006 
Other laboratory parameters                
Fasting blood glucose (mmol/L) 5.5 (4.5-8.2)  5.0 (4.4-6.3)  0.031  5.5 (4.5-6.3)  5.8 (4.7-8.2)  0.36  0.069  0.037* 
Creatinine (µmol/L) 74 (48-99)  65 (54-89)  0.21  74 (55-99)  74 (48-94)  0.96  0.22  0.33 
ASAT (U/L) 34 (19-85)  24 (16-44)  0.002  37 (24-85)  32 (19-58)  0.18  0.001  0.019* 
ALAT (U/L) 37 (13-136)  22 (13-36)  0.001  43 (13-136)  33 (20-67)  0.092  0.001  0.007 
Fibrinogen (g/L) 3.4 (2.4-5.7)  3.1 (2.6-3.5)  0.026  3.4 (2.4-4.4)  3.5 (2.5-5.7)  0.18  0.089  0.017* 
CRP (mg/L) 0.6 (0.6-13.0)  0.6 (0.6-1.8)  0.20  0.60 (0.60-2.00)  0.77 (0.60-13.00)  0.15  0.42  0.11 
                                
Data are given as n (%) or median (min-max), n indicates number of individuals             
Post-hoc Mann Whitney U test, Chi-square test for independence or Fisher's exact two-tail probability test, statistically significant when P < 0.05, were used     
1   between FH subjects and controls               
2   between susceptible and resistant               
3   between susceptible and controls               
4   between resistant and controls               
* Statistic significant P-value disappears when performing Bonferroni adjustment             
** n = 33 among FH subjects / n = 18 among susceptible due to one missing value             
*** n = 32 among FH subjects / n = 17 among susceptible due to exclusion of two patients on Warfarin treatment         
TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TG = triglycerides; ApoA1/B = apolipoprotein A1/B;      
Lp(a) = lipoprotein(a); APC resistance = Activated protein C-resistance; vWF = von Willebrand Factor; ASAT/ALAT = aspartate/alanine aminotransferase; CRP = C-reactive protein  
4.2.2 Female and male 
As shown in table 18 there were unexpectedly few differences between the group of 
female FH subjects and the group of male FH subjects in the case-control study.  
The female group had significantly higher estimated median pre-treatment LDL-C 
level than what was estimated in the male group. However, there were no differences 
between the groups on other blood lipid parameters.  
A lower median creatinine concentration was registered in the group of FH women in 
comparison with the group of FH men. 
The number of female FH subjects with hypertension was significantly greater in 
comparison with then number of hypertensive male FH subjects. However, there was 
no difference in use of anti-hypertensive drugs.  
A lower number of female FH subjects tended towards using Albyl E compared to the 
male FH subjects.  
 
  
Table 18. Characterisation and comparison of female and male 
 Female  Male       
      
  (n = 12)   (n = 22)   P 
 
1 
     Demographics      
Age at study-visit 64 (42-73)  58 (44-77)  0.083 
Age at first CHD event 39 (30-48)*  40 (28-63)**  0.92 
Early CHD in first-degree relative 10 (83.3%)  15 (68.2%)  0.44 
      
Classical CHD risk factors      
Smoker (now) 0 (0.0%)  3 (13.3%)  0.54 
Smoker (pre and/or now) 7 (58.3%)  16 (72.7%)  0.46 
Hypertension 9 (75.0%)  7 (31.8%)  0.030 
Diabetes type II 0 (0.0%)  2 (9.1%)  0.53 
      
Drug treatment      
Statin 11 (91.7%)  22 (100.0%)  0.35 
Resin 3 (25.0%)  10 (45.5%)  0.29 
Niacin 0 (0.0%)  4 (18.2%)  0.27 
Ezetimibe 11 (91.7%)  21 (95.5%)  1.00 
Albyl E 7 (58.3%)  20 (90.9%)  0.070 
Β-blockers 4 (33.3%)  8 (36.4%)  1.00 
      
Diet parameters      
Omega-3 supplement 10 (83.3%)  19 (86.4%)  1.00 
SmartDiet score (out of total 41) 36 (29-39)  34 (29-41)  0.59 
      
Physical examination      
BMI (kg/m2) 27.9 (18.2-37.8)  27.0 (21.9-36.9)  0.68 
Waist circumference (cm) 97 (65-116)  99 (81-117)  0.46 
Systolic BP (mmHg) 141 (106-168)  132 (109-176)  0.35 
Diastolic BP (mmHg) 79 (56-105)  87 (71-109)  0.73 
      
Laboratory parameters      
Blood lipid parameters      
TC at study-visit (mmol/L) 5.1 (3.0-11.5)  4.7 (3.1-8.0)  0.97 
HDL-C at study-visit (mmol/L) 1.5 (0.7-3.2)  1.4 (0.9-2.2)  0.91 
LDL-C at study-visit (mmol/L) 3.0 (1.9-9.0)  3.3 (1.5-4.9)  0.93 
Estimated LDL-C pre-treatment (mmol/L) 10.8 (5.9-16.7)  7.9 (3.7-15.8)  0.042 
Difference LDL-C (mmol/L) -6.7 (-14.1 - -2.5)  -5.1 (-12.1 - +0.2)  0.21 
Difference LDL-C (%) -69.8 -(84.4 - -21.2)  -61.9 (-82.6 - +4.7)  0.33 
TG at study-visit (mmol/L) 0.8 (0.3-3.2)  0.8 (0.3-3.7)  0.61 
Non-HDL (TC - HDL-C) (mmol/L) 3.5 (1.8-10.5)  3.5 (1.9-6.4)  0.90 
TC/HDL-C 3.6 (2.3-11.5)  3.4 (2.2-6.2)  0.90 
ApoA1 level at study-visit (g/L) 1.5 (0.9-2.4)  1.5 (1.0-2.1)  0.86 
ApoB level at study-visit (g/L) 1.0 (0.7-2.4)  1.0 (0.5-1.6)  0.65 
ApoB/ApoA1 0.63 (0.46-2.00)  0.62 (0.37-0.92)  0.72 
Lp(a) (mg/L) 429 (60-1770)***  786 (60-2460)  0.35 
Coagulation parameters      
APC-resistance 1.04 (0.96-1.15)  1.06 (0.63-1.15)  0.27 
Protein S (free) (%) 82 (65-105)  90 (62-105)  0.11 
Protein S (total) (%) 98 (85-105)  100 (86-105)  0.45 
Protein C (%) 128 (94-144)  128 (87-154)  0.37 
vWF antigen (%) 155 (93-243)  154 (63-232)  0.53 
vWF activity (%) 145 (93-266)  125 (61-237)  0.51 
Other laboratory parameters      
Fasting blood glucose (mmol/L) 5.3 (4.5-6.5)  5.6 (4.5-8.2)  0.22 
Creatinine (µmol/L) 64 (48-90)  77 (63-99)  0.017 
ASAT (U/L) 35 (13-136)  43 (20-81)  0.090 
ALAT (U/L) 30 (24-85)  37 (19-58)  0.43 
Fibrinogen (g/L) 3.4 (2.4-4.7)  3.4 (2.5-5.7)  0.80 
CRP (mg/L) 0.60 (0.60-13.00)  0.60 (0.60-3.7)  0.83 
            
Data are given as n (%) or median (min-max), n indicates number of individuals   
1 
* n = 7 among female, ** n = 15 among male, *** n = 11 among female 
Mann Whitney U test, Chi-square test for independence or Fisher's exact two-tail probability test, significant when P < 0.05 
  
CHD = coronary heart disease; BMI = body mass index; BP = blood pressure; TC = total cholesterol; HDL-C = high-density 
lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TG = triglycerides; ApoA1 = apolipoprotein A1; ApoB = 
apolipoprotein B; Lp(a) = lipoprotein(a); APC-resistance = Activated protein C-resistance; vWF = von Willebrand Factor; 
ASAT/ALAT = aspartate/alanine aminotransferase; CRP = C-reactive protein 
4.2.3 Female and male subdivided into groups of susceptible and 
resistant  
Susceptible female and resistant female 
Characterisation of the subjects and comparison of the susceptible female group and 
the resistant female group is shown in tables 19a and 19b, respectively.  
The group of susceptible women had significantly lower median Protein S level, both 
free and total, in comparison with the group of resistant women. However, all values 
were within the range of reference. 
The susceptible female group had statistically significant lower median CRP level in 
comparison with the resistant group. However, the median values both were within 
reference range. Since there was one individual with a CRP level of 13.00 mg/L, 
which was considerably higher than the others in the resistant group, we also 
performed the analysis without the individual. The median value then was 0.88 mg/L 
and the range was 0.60 – 1.80 mmol/L, and there still was a trend towards the 
resistant female group having higher CRP median level than the susceptible female 
group with a P = 0.080. 
A greater number of susceptible women were medicated with Albyl E in comparison 
with resistant women, and a greater number of susceptible women also tended to use 
β-blockers.  
The group of resistant women had a median BMI of 30.3 kg/m2, which was 
statistically significant higher than the median BMI in the group of susceptible 
women, which was 25.3 kg/m2
Interestingly, there were found no differences in blood lipid levels. 
. 
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Susceptible male and resistant male  
As shown in tables 19a and 19b, respectively, there were few differences between 
the group of susceptible men and the group of resistant men. 
Susceptible men had significantly higher median level of free Protein S in comparison 
with resistant men. However, the median level in both groups is within reference 
range. 
A statistically significant greater number of susceptible men received β-blocker 
medication in comparison with the number of resistant men. In addition, there was a 
trend towards a greater number of susceptible men receiving niacin compared to 
resistant men. 
Not surprisingly, the susceptible male group were significantly younger than the 
resistant male group considering median age at first CHD event. 
No differences in blood lipid levels were found.
Table 19a. Characterisation and comparison of female susceptible and resistant and male susceptible and resistant 
  Female       Male           
 Susceptible  Resistant    Susceptible  Resistant                       
  (n = 7)   (n = 5)   P   1 (n = 12)   (n = 10)   P 
 
2 
           Demographics            
Age at study-visit 57 (42-73)  67 (62-69)  0.29  53 (44-70)  59 (55-77)  0.074 
Age at first CHD event 39 (30-48)  -*  -  39 (28-43)  62 (59-63)**  0.009 
Early CHD in first-degree relative 7 (100.0%)  3 (60.0%)  0.15  7 (58.3%)  8 (80.0%)  0.38 
            
Classical risk factors            
Smoker (now) 0 (0.0%)  0 (0.0%)  1.00  1 (8.3%)  2 (20.0%)  0.57 
Smoker (pre and/or now) 3 (42.9%)  4 (80.0%)  0.29  9 (75.0%)  7 (70.0%)  1.00 
Hypertension 6 (85.7%)  3 (60.0%)  0.52  4 (33.3%)  3 (30.0%)  1.00 
Diabetes type II 0 (0.0%)  0 (0.0%)  1.00  0 (0.0%)  2 (20.0%)  0.20 
            
Drug treatment            
Statin 7 (100.0%)  4 (80.0%)  0.42  12 (100.0%)  10 (100.0%)  1.00 
Resin 2 (28.6%)  1 (20.0%)  1.00  6 (50.0%)  4 (40.0%)  0.69 
Niacin 0 (0.0%)  0 (0.0%)  1.00  4 (33.3%)  0 (0.0%)  0.096 
Ezetimibe 7 (100.0%)  4 (80.0%)  0.42  11 (91.7%)  10 (100.0%)  1.00 
Albyl E 7 (100.0%)  0 (0.0%)  0.001  10 (83.3%)  10 (100.0%)  0.48 
Β-blockers 4 (57.1%)  0 (0.0%)  0.081  7 (58.3%)  1 (10.0%)  0.031 
            
Diet parameters            
Omega-3 supplement 6 (85.7%)  4 (80.0%)  1.00  10 (83.3%)  9 (90.0%)  1.00 
SmartDiet score (out of total 41) 35 (29-38)  36 (33-39)  0.51  33 (29-41)  36 (29-40)  0.45 
            
Physical examination            
BMI (kg/m2) 25.3 (18.2-31.8)  30.3 (27.7-37.8)  0.028  27.1 (21.9-36.9)  26.5 (22.8-31.6)  0.82 
Waist circumference (cm) 93 (65-101)  101 (94-116)  0.051  100 (81-117)  98 (88-110)  0.97 
Systolic BP (mmHg) 139 (106-164)  150 (122-168)  0.29  132 (120-146)  135 (109-176)  0.84 
Diastolic BP (mmHg) 75 (56-104)  93 (75-105)  0.16  87 (75-91)  84 (71-109)  0.67 
                        
Data are given as n (%) or median (min-max), n indicates number of individuals         
Mann Whitney U test, Chi-square test for independence or Fisher's exact two-tail probability test, statistically significant when P < 0.05, were used  
1   between female susceptible and female resistant          
2   between male susceptible and male resistant           
* n = 0 in the female resistant group due to 0 CHD incidents          
** n = 3 among male resistant due to only 3 incidents of CHD          
CHD = coronary heart disease; BP = blood pressure; BMI = body mass index         
Table 19b. Characterisation and comparison of female susceptible and resistant and male susceptible and resistant 
  Female       Male           
 Susceptible  Resistant    Susceptible  Resistant           
            
  (n = 7)   (n = 5)   P   1 (n = 12)   (n = 10)   P 
 
2 
           Laboratory parameters            
Blood lipid parameters            
TC at study-visit (mmol/L) 4.8 (3.0-8.4)  5.7 (4.0-11.5)  0.37  5.6 (3.1-6.9)  4.5 (3.8-8.0)  0.43 
HDL-C at study-visit (mmol/L) 1.3 (0.7-3.2)  1.6 (1.0-2.0)  0.19  1.3 (0.9-2.2)  1.5 (0.9-1.8)  0.55 
LDL-C at study-visit (mmol/L) 2.8 (1.9-5.2)  3.5 (1.9-9.0)  0.87  3.6 (1.7-4.5)  3.0 (1.5-4.9)  0.51 
Estimated LDL-C pre-treatment (mmol/L) 10.2 (7.4-16.7)  12.4 (5.9-14.6)  0.69  9.0 (4.3-15.8)  6.0 (3.7-12.6)  0.22 
Difference LDL-C (mmol/L) -6.4 (-14.5 - -2.1)  -7.0 (-10.0 - -3.1)  0.87  -6.4 (-12.1 - +0.2)  -3.2 (-8.2 - -0.5)  0.39 
Difference LDL-C (%) -68.6 (-84.4 - -32.5)  -71.0 (-76.9 - -21.2)  0.69  -69.1 (-80.7 - +4.7)  -53.3 (-82.6 - -11.1)  0.47 
TG at study-visit (mmol/L) 0.7 (0.5-1.4)  1.2 (0.3-3.2)  0.46  1.0 (0.4-3.7)  0.8 (0.3-3.4)  0.29 
Non-HDL (TC-HDL-C) (mmol/L) 3.3 (1.8-6.1)  3.7 (2.4-10.5)  0.69  4.3 (1.9-5.5)  3.2 (2.2-6.4)  0.28 
TC/HDL-C 4.1 (2.3-6.5)  2.9 (2.5-11.5)  0.57  3.5 (2.5-6.2)  3.4 (2.2-5.0)  0.62 
ApoA1 level at study-visit (g/L) 1.5 (0.9-2.4)  1.6 (1.2-1.9)  0.37  1.5 (1.1-2.0)  1.6 (1.0-2.1)  0.87 
ApoB level at study-visit (g/L) 0.9 (0.7-1.4)  1.0 (0.7-2.4)  0.74  1.1 (0.5-1.3)  0.9 (0.6-1.6)  0.57 
ApoB/ApoA1 0.67 (0.46-1.08)  0.63 (0.47-2.00)  0.69  0.62 (0.37-0.92)  0.65 (0.41-0.91)  0.92 
Lp(a) (mg/L) 878 (204-1770)*  370 (60-606)  0.14  1260 (60-2460)  569 (60-1890)  0.28 
Coagulation parameters            
APC-resistance  1.04 (0.97-1.09)  1.04 (0.96-1.15)  0.87  1.06 (0.89-1.10)**  1.07 (0.63-1.15)  0.32 
Protein S (free) (%) 72 (65-89)  94 (74-105)  0.023  95 (79-105)**  85 (62-95)  0.007 
Protein S (total) (%) 88 (85-99)  105 (98-105)  0.008  100 (86-105)**  100 (86-105)  0.81 
Protein C (%) 117 (94-144)  137 (120-144)  0.10  129 (87-154)**  117 (87-141)  0.52 
vWF antigen (%) 146 (93-243)  169 (137-236)  0.37  157 (81-232)**  142 (61-220)  0.35 
vWF activity (%) 121 (93-266)  149 (110-211)  0.25  148 (89-237)**  121 (61-172)  0.15 
Other laboratory parameters            
Fasting blood glucose (mmol/L) 5.2 (4.5-5.7)  5.8 (4.7-6.5)  0.33  5.6 (4.5-6.3)  5.8 (4.8-8.2)  0.87 
Creatinine (µmol/L) 64 (55-90)  63 (48-83)  0.69  77 (63-99)  76 (63-94)  0.84 
ASAT (U/L) 30 (24-85)  30 (25-33)  0.56  38 (29-47)  35 819-58)  0.45 
ALAT (U/L) 42 (13-136)  31 (26-38)  0.19  43 (23-81)  38 (20-67)  0.25 
Fibrinogen (g/L) 3.4 (2.4-4.2)  3.5 (3.3-4.7)  0.28  3.4 (2.7-4.4)  3.6 (2.5-5.7)  0.47 
CRP (mg/L) 0.60 (0.60-1.40)  0.99 (0.60-13.00)  0.037  0.62 (0.60-2.00)  0.60 (0.60-3.70)  0.83 
                        
Data are given as n (%) or median (min-max), n indicates number of individuals         
Mann Whitney U test, Chi-square test for independence or Fisher's exact two-tail probability test, statistically significant when P < 0.05, were used   
1   between female susceptible and female resistant           
2   between male susceptible and male resistant           
* n = 6 among female susceptible due to one missing value, ** n = 17 among male susceptible due to exclusion of two patients on Warfarin treatment 
TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TG = triglycerides; ApoA1/B = apolipoprotein A1/B;  
Lp(a) = lipoprotein(a); APC-resistance = Activated protein C-resistance; vWF = von Willebrand Factor; ASAT/ALAT = aspartate/alanine aminotransferase; CRP = C-reactive protein 
5. Discussion 
In this thesis, two studies have been conducted; one cross-sectional study and one 
case-control study. Both of the studies have advantages and potential limitations, 
which are discussed below.  
Subsequently, the principal results will be discussed and put into context of the 
findings in other scientific studies. 
5.1 Discussion of subjects and methods 
5.1.1 Retrospective data collection study 
Study design 
This part of the thesis was considered a cross-sectional study. 
Other studies have also investigated groups of FH subjects based on CHD event, with 
a focus on risk factors for CHD. However, no one, as far as we know, has split the 
groups of interest into ‘susceptible’ and ‘resistant’ as we have. Hopkins et al (90) 
compared in their case-control study subjects with and without CAD and included FH 
subjects in the early CAD event group on basis of CAD event occurring <55 years in 
men and <65 years in women, respectively. FH subjects with later onset of CAD were 
not included in the study.  In a retrospective cohort study to investigate the 
contribution of classical risk factors to CVD in FH, Jansen et al compared FH 
subjects with and without CVD, independent of when the FH subjects had their first 
CVD event (86). In a third similar study, a cross-sectional study by de Sauvage 
Nolting et al, FH subjects were not recruited on basis of CVD event. Instead, the FH 
subjects were split into two groups after they were recruited; one group with present 
or earlier CVD event and one group without any symptoms of CVD (94). 
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Advantages 
Cross-sectional studies can be used to study several associations at once (156). All of 
the variables were measured at one point in time. In this study, for instance, we 
examined age, gender and a great number of anthropometric and biochemical 
measurements. The aim of our study was to compare these parameters in a group of 
FH subjects with early CHD event versus a group of FH subjects with late or no CHD 
event. 
The study was relatively inexpensive in comparison to for instance cohort studies, and 
could be conducted over a short period of time. The participants only had to come on 
one study-visit and there was no follow-up period. The FH subjects were continually 
included as they came to policlinic follow-up at the Lipid Clinic.  
Limitations 
According to Lewington et al (157), on behalf of the Prospective Studies 
Collaboration, the results from retrospective studies of CHD can be distorted by 
reverse causality. Since exposure and disease are measured at the same point of time, 
one cannot be sure whether an exposure preceded or followed a health outcome. 
Blood cholesterol can affect blood pressure; however, the influence also goes in the 
opposite direction. On the other hand, prospective studies in people with no previous 
CHD history have to be very large to assess reliability concerning which one risk 
factor affects the relevance of other risk factors (157). To manage the challenge of 
this potential bias we have included both a group with early CHD event and a group 
with late or no CHD event in this study. 
There is a risk of response bias, where those individuals who wanted to participate in 
the study were systematically different from those who did not want participate. The 
individuals who wanted to participate could for instance have been more motivated on 
lifestyle changes, more concerned about health matters or more likely to follow up 
their drug regimen. Consequently, there was a potential risk that our results would not 
be representative for the entire population of FH subjects. However, to minimise this 
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risk the FH subjects were recruited in different ways; by invitation letters, by 
telephone calls or when they were at the Lipid Clinic at their regular follow-up. 
This type of study does not yield incidence or relative risk. However, in this study we 
were not looking for other findings except differences in certain parameters between 
the groups.  
Data assessment 
Susceptible and resistant groups 
One weakness of this retrospective data collection study concerning susceptible and 
resistant  FH subjects was the missing data of variables due to incomplete assessment 
of data at the study-visit, for example registration of smoking history. As pointed out 
earlier there are several potential underlying causes for the missing data. However, 
the missing data was not considered a problem since we in most parameters only 
missed data from one to three persons in each group, which was fewer than 5 % of the 
total number of participants. 
Deceased FH subjects 
Limitations of the data on deceased FH subjects were presented in the ‘subjects and 
methods’ section.  
5.1.2 Case-control study 
Study design 
This part of the thesis was considered a case-control study. At the same time it had 
similarities with the retrospective data collection study, and many of the points 
discussed in the retrospective data collection study were also applicable for this case-
control study. With that in mind, we mainly emphasise the advantages and limitations 
with case-control studies in the following. 
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Advantages 
Case-control studies also have advantages (156, 158). First, they are rapid and cost-
effective to conduct, especially compared to cohort studies (156). The case-control 
studies require less time, money and size than cohort studies (156). In a clinical 
master thesis, a study must be planned, accomplished and finished in one year. Thus, 
if a master project is not part of a bigger study or project, the most efficient study 
form to choose is a case-control study or a cross-sectional study. 
Second, case-control studies usually investigate less common diseases (158), in this 
case FH. It is generally less important to devote extraordinary resources toward 
confirming that control subjects are free of FH because the disorder is genetic 
conditioned. So, even though the controls were not randomly picked out in this study, 
the majority of potential controls would have been likely to be free of the disorder 
anyway, based on family history and incidence of CHD. 
Case-control studies can be useful for evaluating multiple risk factors for a disease 
(158).  
Limitations 
Our case-control study had several potential limitations (156, 158). First, a case-
control design does not provide incidence, relative risk or natural history of a disease 
(158) or, in this circumstance, different risk factors. We looked at a number of 
existing cases at a point of time. We compared two groups of cases, FH subjects with 
an early onset of CHD and FH subjects with late or no onset of CHD, to the same 
extent as we compared FH subjects with controls. Primarily, the healthy population of 
controls provided information on a reference level of the different parameters 
measured. In other words, both of the FH groups could have a higher or lower level 
than what was expected and also a higher or lower level than healthy controls even 
though the FH groups and subgroups between themselves did not differ. 
Second, there is a potential risk of recall bias (156, 158). Information on among other 
parameters such as physical activity, food intake, alcohol intake, smoking habits and 
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dietary supplements like omega-3 intake, was self-reported through the SmartDiet 
food questionnaire. We could not control whether the participants reported what their 
actual intake of different foods or beverages was. When one fills out a questionnaire, 
it may be difficult to remember what one usually eats or drinks. The FH-subjects had 
through their follow-up at the Lipid Clinic received dietary advice several times 
before. In comparison, no one of the controls had ever received dietary advice. Hence, 
the SmartDiet questionnaire was familiar to the FH subjects since it is a tool the Lipid 
Clinic frequently uses in treatment and follow-up. The scheme was new to the 
controls. Also, some of the patients knew how to summarize points from the 
SmartDiet questionnaire to get a good score. However, in a recent thesis by Fæhn at 
the University of Oslo (159) it was suggested that FH subjects have a healthier diet 
compared with patients with multifactorial hypercholesterolemia – suggesting that the 
FH subjects actually may be more concerned about their health – minimising the risk 
of bias concerning the FH subjects’ knowledge to SmartDiet. 
Another example is that many of the participants reported that they had a daily intake 
of cod liver oil or omega-3 FAs. Since this was a “yes or no”-question in the 
SmartDiet questionnaire, we could not see whether they had an intake of omega-3 
FAs on a regular basis or every now and then. In Norway, the tradition is to take a 
fish-oil or omega-3 supplement during the winter, but not necessarily during the 
summer months. If the study had been committed in June the frequency of omega-3 
intake might have been different from what we registered in January and February. 
However, some of these issues could be expected to affect all participants, 
independent of group, to the same extent. Nevertheless, to minimise the risk of recall 
bias the master student read through the SmartDiet questionnaire together with the 
participants.  
Most of the control subjects were working in a hospital or were colleagues of the 
master student or of persons working at the Lipid Clinic. They might have been 
biased concerning their level of knowledge and hence more conscious about their 
health than other potential controls because of their work or knowledge to our work. 
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When comparing controls with FH subjects, the group of susceptible FH subjects 
could also be more concerned about their health than controls or resistant FH subjects 
as a result of their early CHD history. The resistant FH subjects could as well be more 
concerned about their health because of their genetically increased risk of CHD. 
Third, there is always a risk of interviewer bias. We minimised this factor by using 
standardised methods for data collection in both FH subjects and controls, with the 
master student collecting all the anthropometric information on the participants. The 
inclusion of the participants was based on questions on a form to be sure all 
participants were asked the same questions. On all subjects we used the same scale, 
the same blood pressure measurement apparatus, the same height measurement scale 
and the same measuring tape. The same laboratory personnel at the Lipid Clinic 
collected all the blood samples. At the accredited medical-biochemical laboratory at 
Rikshospitalet, OUS, strict routines were followed during blood sample analysis. 
Fourth, inclusion restrictions of FH subjects may limit generalisation (156). In our 
study we found it necessary to use restriction of the two groups of FH subjects in 
order to reduce potential biases and to increase feasibility. We found restriction 
essential to ensure a valid study. 
Fifth, the control subjects were selected amongst colleagues, and are not 
representative for the population as a whole. Sampling of controls from a general 
population is expensive (156) and was not a realistic alternative in this small-scale 
study. Furthermore, they might have been more likely to cooperate than people in the 
general population since they were colleagues and acquaintances. Ideally, we could 
have selected more than one control group to see whether the selection of controls 
influenced the measured associations between FH subjects and controls. However, 
controls were recruited from the same geographical area as the FH subjects and were 
age- and gender matched to the FH subjects. It was never a precondition that they 
were supposed to be representative on basis of a population. Intentionally, the most 
important feature of the control group was to have a reference population to put the 
characteristics of the two FH groups into perspective. All routine blood parameters 
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were within the normal range in the control group, suggesting it was an appropriate 
reference group. What applies to the recruitment of all FH subjects is that most of 
them contacted us after receiving an invitation letter; consequently the FH subjects 
probably were as much likely to cooperate as the controls. 
Data assessment 
We used standardised methods for data collection in all participants. Whereas some of 
the data were assessed or measured with high accuracy (for instance blood lipid 
values), others (for instance smoking history, intake of different types of food and 
physical activity) were based on self-reporting and therefore potentially biased. Still, 
to standardise the patients’ answers as much as possible, one scheme with questions 
were used on all patients. All anthropometric measurements were done with the same 
scale, the same blood pressure measurement apparatus, the same height measurement 
scale and the same measuring tape. 
The blood lipid values in FH subjects were affected by the drugs they were on, 
compared to controls who did not report use of any lipid-lowering medication. When 
comparing FH subjects with early CHD event and FH subjects with late or no CHD 
event, they were all on medication; hence it did not matter whether the blood lipid 
values were without medication or not. To get a picture of the blood lipid 
concentrations’ influence of CHD risk we estimated the pre-treatment values of LDL-
C, since LDL-C is considered one of the most potent CHD risk factor (11). 
A possible bias regarding blood pressure registration was that some participants 
rested for a shorter time before blood pressure measurement than others. According to 
a report on CHD prevention from The Norwegian Directorate of Health, a person 
should sit still for several minutes before the blood pressure registration (23). This 
could result in somewhat higher blood pressure levels in some of the patients 
compared to their actual blood pressure level. The background for this difference was 
that the blood tests had to be delivered for analysis to the medical-biochemical 
laboratory at Rikshospitalet, OUS, within one hour after assessment. When there were 
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two participants on one day we had to follow a strict time management plan to deliver 
the blood samples within one hour. To cope with this potential bias we measured 
blood pressure three times and calculated the mean value for further analysis. 
5.1.3 Statistics 
We chose to use the non-parametric techniques Kruskal-Wallis test and Mann-
Whitney U test to compare the different groups. Non-parametric techniques take into 
consideration outliers in a small data set using median as the middle value of the data. 
Hence, the outliers did not affect the analyses as much as they potentially would with 
parametric techniques and comparison of means. However, non-parametric tests are 
less powerful than the parametric tests (160). We could risk missing statistically 
significant P-values. To approach this potential bias Independent-samples t-test was 
ran in addition to the non-parametric tests to verify the tendency of statistically 
significant difference. 
We could also have manipulated the non-parametric data into parametric data by log 
transforming them. There is some controversy concerning log transformation of data; 
the data is not raw data anymore when one uses them in further statistical analysis. 
LDL-C values are usually calculated with the Friedewald formula; total cholesterol 
level – HDL-C level – 0.45 · TG level (161). The formula assumes that the patients 
are fasting when the blood sample are retrieved. However, it is known to be less 
reliable as the TG concentration increases. Ideally, the TG level should not exceed 4.5 
mmol/L. In the group of deceased FH subjects we do not know whether the patients 
fasted or not before the blood tests were assessed. On the other hand, the Lipid Clinic 
follows strict routines in all their analyses, and one could expect that most patients 
had fasted. In a recent analysis of 300,000 people with initial vascular disease, the 
Emerging Risk Factor Collaboration suggested that blood lipids except from TGs may 
be measured without the need to fast (162). 
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The number of participants in both the retrospective data collection study and the 
case-control study was acceptable in comparison to other published studies carried out 
on FH subjects (38, 56, 163, 164). Yet, limitations were connected to the number of 
participants in several of our statistical analyses. In analyses where the group of non-
deceased FH subjects or group of deceased FH subjects have been subdivided 
according to gender or incidence of CHD event, the number of participants was too 
small to be representative. Particularly, this is pronounced among the deceased FH 
subjects where the number of subjects at some analyses, for instance Lp(a) level, 
included only eight individuals. Also, in the case-control study, when the groups were 
divided into gender, the female susceptible group and female resistant group consisted 
of seven and five individuals, respectively. The control group consisted of ten 
individuals in the first place; hence it was unsuitable for being subdivided into smaller 
groups. On basis of the small number of subjects in many of the analyses, potential 
significant results may have disappeared. However, even in some of the comparisons 
with a small number of persons significant results appeared which may suggest strong 
associations between the tested parameters and subjects.  
5.2 Discussion of results 
5.2.1 Blood lipid parameters 
Lipoprotein (a) 
In the retrospective data collection study, the median Lp(a) concentration in the 
susceptible group was considerably higher than the median level in the resistant 
group, with a level of 518 and 170 mg/L, respectively. In the case-control study there 
was a trend towards the susceptible FH subjects having higher median levels of Lp(a) 
in comparison with resistant FH subjects with a median of 1210 and 434 mg/L, 
respectively – however it was not statistically significant probably due to the small 
number of participants. In neither of our studies a significant difference was seen 
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when dividing the group of FH subjects into groups of female and male. However, the 
subgroup of susceptible women had significantly higher median Lp(a) level compared 
with resistant women, suggesting that the level of Lp(a) in susceptible women 
account for the difference registered between the susceptible and the resistant groups 
when not divided by gender.  
Our results on the differences between the susceptible and resistant groups are 
consistent with other findings. In a study of 115 FH subjects with and without CHD 
by Seed et al (40), higher Lp(a) levels were reported in patients with FH with CHD in 
comparison with those with no visible complications, with Lp(a) levels of 570 and 
180 mg/L, respectively. The same association was also seen in the study by Jansen et 
al (86). However, no difference was seen between FH subjects with and without CHD 
in two other studies (90, 94). de Sauvage Nolting et al (94) found a non-significantly 
higher Lp(a) concentration in men in comparison with women, which also is 
consistent with our findings. In a recent cross-sectional study of 811 FH subjects, 
Alonso et al (24) found no differences between female and male FH subjects. 
However, neither of the studies compared FH men and FH women divided into 
subgroups of susceptible and resistant FH subjects. 
In the case-control study, the FH subjects had significantly higher median level of 
Lp(a) in comparison with controls, with a Lp(a) level of 585 and 172 mg/L, 
respectively. In a Greek case-control study of 82 FH subjects and 82 controls, Elisaf 
et al found a similar association (164). 
According to a recent review by Chapman et al (110), niacin is the only commercially 
available drug known to specifically reduce circulating Lp(a) levels; it can lower 
Lp(a) by up to 30 %. Other studies have found similar associations (97, 165, 166). In 
our retrospective data collection study, a significantly higher number of susceptible 
FH subjects received niacin treatment in comparison to resistant FH subjects, and the 
same was the case with FH men compared to FH women. The niacin medication may 
have contributed to a lower median level than what was really the case in susceptible 
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and male FH subjects, contributing to a non-significantly higher Lp(a) in the latter in 
comparison with female FH subjects. 
In a recent meta-analysis of 36 studies by Insull et al (166), associations of Lp(a) with 
CHD was found independent of level of non-HDL-C. Accordingly, when Lp(a) is 
elevated it is even more important to reduce other potential or manifested CHD risk 
factors. 
Our results are supported by a current study examining genetic data from three 
different trials from Kamstrup and coworkers who suggested that patients must 
systematically be screened for their Lp(a) levels (167). They further suggested that 
every time the concentration of Lp(a) is doubled the cardiovascular risk is increased 
by approximately 20 % (167). 
Total cholesterol, LDL, HDL and triglycerides 
Total cholesterol 
When dividing the group of FH subjects in the retrospective data collection study into 
groups based on gender, the FH women had significantly higher median level of total 
cholesterol compared to FH men, with 5.0 mmol/L and 4.7 mmol/L, respectively. The 
same tendency was seen in female susceptible versus female resistant and in female 
susceptible versus male susceptible. In the case-control study, the susceptible group 
and the resistant group had a median total cholesterol level of 5.3 and 4.5 mmol/L, 
respectively. The deceased FH subjects, both in the group of deceased FH subjects 
with early CHD and the group of deceased FH subjects with late or no CHD, the 
median total cholesterol level was significantly higher than in the non-deceased FH 
subjects, with levels of 7.8 mmol/L and 6.9 mmol/L in the two groups of deceased FH 
subjects, respectively. There was not a statistically significant difference between-
group in the deceased FH subjects or between the susceptible and resistant groups. 
According to the European guidelines on cardiovascular disease prevention in clinical 
practice and as shown in table 2, the recommendations for subjects at high risk for 
CHD, including FH subjects, is <4.5 mmol/L (54, 55). An interpretation of the results 
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from our studies in comparison with the recommendations is that many of the subjects 
in our study do not reach the total cholesterol treatment goals. The deceased FH 
subjects had significantly higher cholesterol levels than the non-deceased FH subjects, 
suggesting that the medical treatment nowadays lowers cholesterol levels more 
effectively than the treatment that was offered ten years ago. Hopkins et al conducted 
their case-control study of 262 FH subjects in 2001, and, interestingly, the mean total 
cholesterol level in cases (FH subjects with premature CAD) and controls (FH 
subjects without CAD) were 6.7 and 7.7 mmol/L, respectively (90), which is in 
accordance with our results from the deceased population. The total cholesterol levels 
in Hopkins’ study were measured at the approximately same time as the median time 
of deceased FH subjects’ death, confirming our theory on improvement of total 
cholesterol levels with newer medication. In other studies similar to ours, FH subjects 
had had a six weeks wash-out period before their cholesterol levels were measured; 
hence, the total cholesterol values are not comparable (86, 94).  
Interestingly, in the retrospective data collection study, the susceptible group had 
significantly higher median pre-treatment total cholesterol than that of the resistant 
group, with 11.7 and 10.4 mmol/L, respectively. However, there was not a 
pronounced difference between FH men and FH women nor between deceased FH 
subjects and non-deceased FH subjects. In Jansen’s cohort study of 2,400 FH subjects 
and in de Sauvage Nolting’s cross-sectional study on 526 FH subjects where all 
participants had had wash-out periods (86, 94), the total cholesterol levels are in line 
with our findings. 
LDL cholesterol 
Regarding median LDL-C level, the same pattern as observed for total cholesterol 
was seen in both the retrospective data collection study and the case-control study. 
This is consistent with similar studies (86, 94, 168). One of the most interesting 
findings in our two studies was that the median estimated pre-treatment LDL-C level 
in the case-control study was significantly different between female FH subjects and 
male FH subjects; a median level of 10.8 mmol/L and 7.9 mmol/L was registered in 
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women and men, respectively. Since LDL-C is considered a powerful atherogenic 
lipoprotein (11) and treatment goals often consider LDL-C levels in preference to 
total cholesterol levels (23, 54, 55), we estimated the FH subjects’ pre-treatment 
LDL-C levels on basis of their dose of statins and the presence of other lipid-lowering 
drugs. The LDL-C lowering effects of the different statins were found from several 
trials and meta-analyses (147-151). However, the estimation of pre-treatment LDL-C 
levels did not take into consideration between-subjects differences. Some persons 
could react better to statin and/or combination treatment than others (35, 169). 
In the other trials studying pre-treatment LDL-C, no significant difference between 
FH subjects with and without CHD has been found (86, 94, 168). 
Triglycerides and HDL cholesterol 
According to the European guidelines on cardiovascular disease prevention in clinical 
practice, the recommended treatment goal for TG levels is <1.7 mmol/L (54, 55). The 
FH subjects in both our studies had a median TG level at study-visit below 1.0 
mmol/L, except from the deceased FH subjects where the median TG level was 1.2 
mmol/L and 1.4 mmol/L in the groups of deceased FH subjects with early CHD event 
and deceased FH subjects with late or no CHD event, respectively.  
The observed levels of TGs in FH subjects were higher than what was observed in the 
study by Hopkins et al (90), with 1.9 mmol/L and 1.8 mmol/L in FH subjects with 
early onset of CAD and with no clinical history of CAD, respectively. However, our 
results are consistent with theirs regarding the observation that there was no 
differences between the groups. In a cohort study of 1,185 FH patients, the Scientific 
Steering Committee on behalf of the Simon Broome Register Group (64) registered 
TG levels in men and women more in line with ours, with a mean TG level of 1.4 and 
1.2 mmol/L, respectively; however, no comparison test was run. On the other hand, 
both de Sauvage Nolting et al (94) and Jansen et al (86) found significantly higher TG 
levels in FH with CVD compared with FH without CVD. However, the differences 
seen in de Sauvage Nolting and Jansen’s studies are based on pre-treatment values. 
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Niacin and resins are more potent drugs than statins concerning lowering TGs (170, 
171), and more susceptible FH subjects than resistant FH subjects and more male FH 
subjects than female FH subjects received niacin in our study. Nevertheless, TG 
levels were reported to be normal in FH subjects (30, 44). 
The European guidelines on cardiovascular disease prevention in clinical practice 
recommends the HDL-C levels in high-risk individuals to be >1.0 mmol/L and >1.2 
mmol/L in men and women, respectively (54, 55). Our findings are in line with these 
recommendations and the FH subjects disregarding of subgroups both in the 
retrospective data collection study and in the case-control study had a higher median 
HDL-C level than the minimum recommended values. However, the median HDL-C 
level in deceased FH subjects was lower than in the non-deceased FH subjects, with a 
median concentration of 1.0 mmol/L and 1.2 mmol/L in the groups of deceased FH 
subjects with early CHD event and deceased FH subjects with late or no CHD event, 
respectively. As expected, FH women had significantly higher median HDL-C level 
in comparison with FH men in our retrospective data collection study; however, there 
was no significant difference in our case-control study. A possible interpretation of 
the results from our study could be that there are differences between the groups of 
deceased and non-deceased FH subjects due to the HDL-C increasing effect of 
supplemental medication (71, 170, 171).  
The three other studies comparing subjects with and without CHD found a 
significantly higher mean level of HDL-C in FH subjects with no CHD in comparison 
with FH subjects with CHD (86, 90, 94). Our findings are inconsistent with those 
findings, perhaps due to the small number of subjects in our studies.  
Other blood lipid parameters 
ApoA1, ApoB and ApoB/ApoA1 ratio 
The same pattern as observed for LDL-C and HDL-C was seen in both the 
retrospective data collection study and the case-control study. However, even though 
FH women tended to have higher total cholesterol and LDL-C levels in the 
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retrospective data collection study, their median ApoB/ApoA1 ratio was significantly 
higher than that of FH men, probably due to their increased HDL-C levels. A recent 
prospective case-control study by van der Steeg et al suggested that the ApoB/ApoA1 
ratio adds little to the existing measures for CHD risk (172). On the contrary, Rasouli 
et al suggested in a recent case-control study that the ApoB/ApoA1 ratio was suitable 
for use in clinical practices (173). However, as of today little is known regarding the 
efficacy of using the ratio in FH subjects.   
Non-HDL and total cholesterol/HDL-C ratio 
For treatment of patients with, or at risk of CHD, some guidelines focus primarily on 
total cholesterol levels and/or LDL-C levels (170). However, in both European 
guidelines on cardiovascular disease prevention in clinical practice and NCEP ATP 
III other parameters also are taken into consideration, among others non-HDL-C, 
respectively (11, 54, 55). Non-HDL-C and total cholesterol/HDL-C ratio are useful 
tools in predicting the dyslipidemic state of individuals and persons at a high risk for 
development of CHD (11, 174). As NCEP ATP III suggests, the non-HDL is 
recommended as a secondary target for persons with TG levels ≥2.3 mmol/L, and is 
hence not applicable for our studies since most of the FH subjects had TGs below the 
cut-off (11). A 2002 review by Hirsch et al suggested that non-HDL in high-risk 
subjects should be <3.4 mmol/L (175). Most of our findings are close to that value. 
The Norwegian Directorate of Health suggests total cholesterol/HDL-C should be 
≤5.0 (23). In all groups and subgroups in both our studies the median was below the 
cut-off, except from the deceased FH subjects. Our findings suggest that, even though 
the ratios have been advocated by many (174-178), it may not be the best predictor of 
risk in FH subjects.  
5.2.2 Lipid-lowering treatment treatment 
Plasma lipid levels are a major modifiable risk factor for CHD (78, 179). Several 
primary and secondary prevention trials have demonstrated that lowering cholesterol 
levels contribute to reduce the risk of CHD events (11, 52, 61, 65, 109, 180-183). 
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Lipid-lowering treatment in our two studies 
Nearly all of the patients in the studies of this thesis received statin treatment, both in 
the retrospective data collection study and in the case-control study. However, there 
were several differences between different subgroups considering the duration of 
lipid-lowering treatment and statin treatment and supplemental medication with other 
drugs in addition to statins. 
In the retrospective data collection study a significantly greater number of susceptible 
FH subjects received resin and niacin treatment in comparison with resistant FH 
subjects. This difference was not pronounced in the case-control study. Yet, that 
could be due to the low number of participants. However, when the retrospective data 
collection study group of FH subjects was split into groups of FH men and FH 
women, several differences appeared. A significantly smaller number of FH women 
received statins, resins and niacin compared to FH men. At the same time, the median 
duration of lipid-lowering treatment and statin treatment was longer in the susceptible 
female group in comparison with both the resistant female group and the susceptible 
male group. Consequently, there is a tendency towards that FH women, and especially 
women with early CHD event, do not reach target levels on lipid parameters even 
though they are under treatment for a long time. In addition, it seems that men are 
more aggressively treated with medication than women – maybe due to the inequality 
in focus on CHD between men and women. Nonetheless, an interpretation of our 
findings could be that women do not receive optimal lipid-lowering treatment 
compared to men. 
The fact that female FH subjects in general had a less beneficial lipid profile than the 
male FH subjects is noteworthy, especially as it is known that oestrogen upregulates 
the LDL-R which should contribute to lower LDL-C levels (184) in addition to 
prescribed medication. 
In the retrospective data collection study, there was no difference in medical treatment 
between the deceased FH subjects with early CHD event and the deceased FH 
subjects with late or no CHD event. Furthermore, there was no difference in number 
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of persons receiving statin treatment between deceased FH subjects and non-deceased 
FH subjects. However, in comparison with the non-deceased FH subjects, a 
significantly smaller number of deceased FH subjects with early CHD event received 
ezetimibe than susceptible FH subjects and a smaller number of deceased FH subjects 
with late or no CHD event received ezetimibe and resins than resistant FH subjects. 
This difference in medication between the groups may suggest that supplemental 
medication treatment in fact contribute to less fatal events among FH subjects. 
The median duration of lipid-lowering treatment and statin treatment was 
significantly longer in the susceptible and resistant groups (18.0 and 16.0 years, 
respectively) in comparison with the groups of deceased FH subjects with early CHD 
and deceased FH subjects with late or no CHD (9.5 and 7.5 years, respectively), 
respectively. When taking into consideration the time difference between the median 
time of death in the deceased FH subjects and the median time of study-visit in the 
non-deceased FH subjects, the time difference of ten years is reflected in the 
difference in duration of medication. This indicates that most FH subjects received 
statin treatment as soon as it became available on the market. However, we do not 
know if there was a difference in health and CHD risk between deceased and non-
deceased FH subjects when they started on statin treatment.  
Statins are shown to reduce both xanthomas (21, 74) and xanthelasms (185). A 
significantly higher number of deceased FH subjects had xanthomas compared to the 
non-deceased FH subjects. Due to the difference between the two groups regarding 
dose and duration of statin treatment, the difference in the number of subjects with 
xanthelasms in the two groups was not a surprise.  
According to Nicholls et al (150) in an individual patient data pooled analysis of 
32,258 subjects at CHD risk, the more elevated the baseline lipid levels were the 
fewer patients reached their treatment goals with statins. In our retrospective study, 
both the susceptible and resistant groups were quite similar treated with drugs, with 
the differences mentioned above, but the susceptible group did not reach the same 
cholesterol level that the resistant group did, even though the susceptible FH subjects 
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were more intensively treated with supplementary medication than the resistant FH 
subjects. Interestingly, the susceptible group had significantly higher median total 
cholesterol level in comparison with the resistant group – in accordance with 
Nicholls’ findings. 
Does the treatment of FH patients reach treatment goals? 
As discussed above, the medical treatment in our studies’ FH subjects does not seem 
to cause the FH subjects to reach the treatment goals. Nevertheless, the combination 
treatment today lowers blood lipids more effectively than what the available 
medication did ten years ago.  
According to Ballantyne (53) there are two major factors that prevent effective 
treatment of FH. The first obstacle is insufficient screening for FH in people who may 
be at increased risk. The other is the failure of common lipid-lowering therapies to 
achieve treatment goals like adequate total cholesterol or LDL-C levels in accordance 
with CHD ten-year risk level calculated according to the presence of CHD event(s) 
and/or clinical or subclinical atherosclerosis (11, 53, 65). Additionally, Frolkis et al 
(186) suggest that the use of statins in clinical practices lead to observed reductions in 
LDL-C levels that are significantly less than those projected in other clinical trials. 
The difference between clinical trials in controlled situations and clinical practices 
can be due to reduced patient compliance in the latter (186).  
The British National Institute for Health and Clinical Excellence (NICE) guidelines 
suggest that treatment should start with a high intensity statin (such as simvastatin 80 
mg or appropriate doses of atorvastatin and rosuvastatin) to achieve a >50% reduction 
in LDL-C concentrations, increasing to the maximum tolerated dose if necessary (79).  
In our case-control study, the median level of LDL-C at study-visit in the group of FH 
subjects was 3.2 mmol/L. Thirty out of 34 FH subjects received a maximum dose of 
rosuvastatin or atorvastatin. In addition, use of ezetimibe was registered in 91.4 % of 
the persons with FH. Resins and niacin was registered in 38.2 % and 11.8 % of the 
FH subjects, respectively. The estimated median level of pre-treatment LDL-C in the 
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group of FH subjects was 9.0 mmol/L. That resulted in an estimated median reduction 
of LDL-C of 67.2 %. Yet, with both statin treatment and supplemental medication, 
the group of FH subjects still did not reach the treatment goal recommended by the of 
European guidelines on cardiovascular disease prevention in clinical practice and the 
Norwegian Directorate of Health, with a LDL-C level below 2.5 mmol/L – or if 
feasible below 2.0 mmol/L (23, 54, 55). Our results are in accordance with the results 
in a study from the Netherlands by Huijgen et al, where mean treated LDL-C levels in 
781 FH subjects was 3.2 mmol/L (187). 
A recent meta-analysis by Delahoy et al (188) including 25 trials investigated the 
relationship between reduction in LDL-C by statins and reduction in risk of CVD 
outcomes. They found that there was a significant positive relationship between LDL-
C level reduction and reduction in CVD risk (188). The Heart Protection Study (HPS) 
support these findings in a randomised placebo-controlled trial in 20,536 high-risk 
individuals; they demonstrated that LDL-C reduction to levels as low as 1.7 mmol/L 
was associated with significant clinical benefit in a wide range of high-risk 
individuals irrespective of baseline cholesterol levels (180). However, one could 
discuss whether a LDL-C level of 1.7 mmol/L is achievable. Surely, statin treatment 
is not enough. In the case-control study 17 out of 34 subjects received rosuvastatin 
and 15 subjects received atorvastatin, respectively. In both groups, all subjects except 
from four received the highest dose of rosuvastatin or atorvastatin. But even in our 
case-control study, where the LDL-C was lowered by an estimated median of 67.2 %, 
the median LDL-C level was 3.2 mmol/L. This information could be used as an 
incentive upon clinicians to increase, if tolerated, supplemental medication and 
combination treatment in FH subjects. 
As earlier shown in table 3, there are differences between statins regarding their 
lipid-lowering effect. For instance, the lowest dose of rosuvastatin, 5 mg, lowers 
LDL-C levels by approximately 39 % in comparison with the highest dose of 
lovastatin, 80 mg, which lowers LDL-C levels by approximately 42 % (150, 151). 
Rosuvastatin and atorvastatin are examples of high-potency statins, and lovastatin is 
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not (189). In the retrospective data collection study, 13 out of 30 subjects received 
lovastatin in the group of deceased FH subjects. In the group of non-deceased FH 
subjects, no one received lovastatin; most of them were either using atorvastatin or 
rosuvastatin, with 90 and 36 out of 147 subjects, respectively. Hence, in addition to 
the statistically significant difference in number of years of statin treatment between 
non-deceased susceptible FH subjects and deceased FH subjects with early CHD 
event and between resistant and deceased FH subjects with late or no CHD event, the 
lipid-lowering effect of statin treatment could be lower in the deceased FH subjects in 
comparison with non-deceased FH subjects.  
In general, both in FH and the general population, men have a higher risk of CHD at 
all ages (11). In view of the fact that male gender in itself is considered CHD risk 
factor due to among other factors the protective property of oestrogen in women, this 
could probably contribute to explain the more aggressive treatment in men than in 
women. We have shown that combination of drugs in our data material is more 
common in FH men than in FH women. Yet, literature shows that women do respond 
to lipid-lowering drugs to the same extent as men do (11). Since statins contribute to 
the reduction of some potential risk factors, but does not affect others to the extent of 
which combination treatment with for instance niacin and fibrates do (110), FH 
women could be at higher risk for developing CHD. 
In addition to the effect of lowering LDL-C levels, the CHD risk in individuals is 
influenced by TG and HDL-C levels (170, 171). Statins first and foremost reduce 
total cholesterol and LDL-C levels. With combination treatment HDL-C levels 
usually are increased and TG levels are lowered more than with monotherapy of 
statins (170, 171). Therapeutic intervention should aim at focusing on correcting other 
signs of dyslipidemia in FH subjects as well as normalisation of LDL-C. For instance, 
niacin plays an important role in lowering Lp(a) levels (97, 110) and is currently the 
most effective HDL-C increasing therapy (152).  
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Omega-3 supplements 
Three out of four non-deceased FH subjects in our studies, regardless of subgroup and 
in both our studies, reported a regularly intake of omega-3 supplements. Out of the 
deceased FH subjects, especially those with early CHD event, only a small number 
(15.4 %) reported use of omega-3 supplements. Hence, there was a significant 
difference between deceased FH subjects with early CHD event and non-deceased 
susceptible FH subjects, but also towards deceased FH subjects with late or no CHD 
event in the use of omega-3 supplements. Interestingly, this was one of the few 
differences between the two groups of deceased FH subjects. Our FH population was 
not characterized by increased TG levels so even though we do not know the dosage 
of omega-3 supplements used by the FH subjects it is likely to assume that they 
followed the Lipid Clinic recommendation of daily intake of cod liver oil or capsules, 
supplying a total of 0.6-1 g EPA/DHA per day, respectively. 
The Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico–Heart 
Failure (GISSI-HF) study, a large-scale clinical trial, recently showed that omega-3 
FAs (850-882 mg/d) reduced mortality in patients with chronic heart failure who were 
already receiving recommended therapies (190, 191). The favourable effects of 
omega-3 FAs in GISSI-HF suggest that marine fish oils and omega-3 supplements 
could confer protection in heart failure mainly through their antiarrhythmic action and 
in part by influencing the mechanisms related to heart failure progression (191). In the 
GISSI-Prevenzione trial in 1999 (192) dietary supplementation with omega-3 FAs (1 
g/d) was shown to lead to a statistically significant beneficial effect on death, MI and 
stroke. Interestingly, the dose of omega-3 FAs given in both GISSI trials is somewhat 
similar to the omega-3 FA intake recommended by the Lipid Clinic. Furthermore, 
Kris-Etherton et al argue in their 2003 review that evidence from prospective 
secondary prevention studies suggests that EPA/DHA intake ranging from 0.5 to 1.8 
g/d (either as fatty fish or supplements) significantly reduces subsequent cardiac and 
all-cause mortality (193). 
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Seen together with our results, it is tempting to suggest that the intake of omega-3 
FAs can have influenced early CHD event and perhaps also early death in the 
deceased FH subjects with early CHD event. Many investigator groups and literature 
recommend omega-3 intake through the diet and/or as a supplement in subjects with 
FH; however, some of the recommendations are more well-founded than others (25, 
65). However, the NICE guidelines on FH does not support recommendation of 
omega-3 supplements in FH due to lack of adequate data (79). 
Regarding diet registered with SmartDiet, no differences were found between the 
different groups in our two studies. 
5.2.3 Factors involved in inflammation, clotting and thrombosis 
Coagulation markers 
In the case-control study no differences between the susceptible group and the 
resistant group were found regarding APC resistance, Protein S, Protein C and vWF. 
Nor were differences found between female FH subjects and male FH subjects. 
However, FH subjects had significantly higher vWF antigen and activity in 
comparison with controls. The same was the case with Protein S, both free and total, 
and Protein C. However, all values were within the range of reference, besides, low 
values of Protein S and C, respectively, are associated with increased thrombosis. Yet, 
it is somewhat interesting that the FH subjects had higher vWF antigen and activity, 
given the key role of vWF in arterial thrombus formation. However, according to 
Vischer et al in a recent review study, in the general population evidence indicates 
that vWF levels are a poor predictor of CHD (144). On the other hand, Wannamethee 
et al suggested in a recent study based on data from the British Regional Heart Study 
that vWF, among other haemostatic markers, were associated with a significant 
increased risk of death from MI/CHD (194).  
 110 
C-reactive protein 
No significant differences were found concerning median level of CRP, except 
between the susceptible and resistant female groups where the median CRP levels 
were 0.60 and 0.99 mg/L, respectively. Still, there was a tendency towards 
significance when analysis was run without the individual with CRP level of 13.00 
mg/L, P = 0.080. However, use of oestrogen and/or progesterone is associated with 
increased levels of CRP (129). We do not know to what extent female FH subjects 
used hormone contraceptives or menopause oestrogen treatment, or if there was a 
difference between the groups of female FH subjects.  
Statins and ezetimibe are shown to reduce CRP (6, 126-128, 195). Li and Fang found 
in their review a reducing effect of different statins on CRP of 15-40 % (6). In a 
recent study of 44 subjects with mild hypercholesterolemia Kostakou et al found that 
both simvastatin and ezetimibe after three months had reduced CRP significantly 
(195). However, Joynt et al found no relation between CRP level and statin use (196).  
In a 2010 meta-analysis, the Emerging Risk Factors Collaboration suggests that CRP 
levels are as consistent within individuals from year to year as blood pressure and 
other parameters (120). In addition, they emphasise the association of CRP with 
CHD, possibly suggesting that lowering CRP levels are important in preventing CHD 
(120). 
Fibrinogen 
FH subjects had significantly higher median fibrinogen level in comparison with 
controls. However, both values were within reference range.  
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5.2.4 Other parameters 
BMI 
We found a statistically significant difference in BMI between FH subjects and 
controls with a median of 27.1 kg/m2 and 23.3 kg/m2, respectively. In FH subjects in 
the retrospective data collection study a similar tendency towards elevated BMI was 
observed, with a median BMI of 27.0 kg/m2 in the susceptible group and 27.6 kg/m2 
in the resistant group. This proposes the question of whether it has been a bigger 
increase in overweight people in the FH population than people in the general 
population. A cross-sectional study by Hopkins et al (90) showed even higher average 
BMI in their FH subjects of investigation, suggesting that this is not a Norwegian 
phenomenon. On the other hand, an observation study by Meyer and Tverdal from 
2005 (197) shows that there has been a decrease in BMI in the Norwegian population 
from the 1960s to the 1990s and that adult Norwegian men in the 1990s had an BMI 
of 26.5 kg/m2
Blood pressure 
 in average. Taking into consideration that Meyer and Tverdal’s data are 
more than ten years old, the FH subject and the general population BMI average 
potentially are quite similar. Our study had few participants; hence one could consider 
it to be more probable that the ten controls had too low BMI in preference to the 
theory of the FH subject weighting too much. 
According to NCEP ATP III subjects with high-normal blood pressure defined as 
blood pressure levels at 130-139 mmHg systolic and/or 85-89 mmHg diastolic, 
respectively, are at increased risk for CHD in comparison with those with optimal 
blood pressure levels (11). The median blood pressure levels in the susceptible and 
resistant groups in the case-control study were below categorical hypertension. 
However, the median blood pressure levels in both groups fit into the NCEP ATP III 
definition of high-normal blood pressure. A significantly greater proportion of the 
susceptible subjects were medicated with β-blockers in comparison with the resistant 
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subjects; however, there was no significant difference between the groups regarding 
the number of confirmed hypertensive subjects.  
There are several potential interpretations of these findings. First, a greater number of 
persons in the susceptible group were medicated in comparison with the resistant 
group. Hence, the levels in cases would be systematically affected by the medication 
they received. Second, when the median blood pressure levels in the susceptible 
group and resistant group were not different, one could suggest that neither of the 
groups reached desirable levels of blood pressure.  
Our levels of systolic and diastolic blood pressure in FH subjects are in line with the 
findings in the cohort study on 2,400 FH subjects of Jansen et al (86). However, they 
registered a significantly higher blood pressure in subjects with CAD in comparison 
to those without CAD. 
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6. Conclusion and clinical implications 
In the present studies we have shown that 
a. in the retrospective data assessment study, susceptible FH subjects had more 
severe CHD risk factor profile in comparison with resistant FH subjects in 
terms of significantly higher median Lp(a) level, pre-treatment total cholesterol 
level and TG level even though they were more intensively medically treated 
b. deceased FH subjects had a more severe CHD risk factor profile compared 
with non-deceased FH subjects due to significantly higher median total 
cholesterol level, LDL-C level at the same time as they experienced a shorter 
duration of medical treatment, a smaller reduction in total cholesterol – and 
fewer had a regularly intake of omega-3 FAs 
c. in the case-control study FH subjects and controls did not differ in coagulation 
factor profile, CRP levels or fibrinogen levels more than within the range of 
reference, nor were there differences between susceptible and resistant patients 
d. female FH subjects had a more severe CHD risk factor profile in comparison 
with male FH subjects due to significantly higher median total cholesterol level 
and LDL-C level at the same time as they were less intensively medically 
treated  
In conclusion, our results may suggest that compared with the lipid-lowering 
treatment that was offered ten years ago today’s lipid-lowering treatment reduces the 
risk of fatal CHD in FH subjects. Furthermore, the results indicate that regularly 
intake of omega-3 FAs may contribute to a reduced risk of CHD and death. Even 
though the treatment seems to have improved substantially, there is still a potential for 
improvement concerning reaching the treatment goals. Furthermore, our results may 
also indicate that female FH subjects – and in particular susceptible female FH 
subjects (FH subjects already having suffered from a cardiovascular event) – may 
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need to be followed up more closely, and more extensively treated with lipid-lowering 
medication and combination medication. Of particular interest are the elevated Lp(a) 
values registered in susceptible women. The results may suggest that FH women with 
elevated Lp(a) levels could be at a higher risk of developing CHD than other FH 
patients. Routinely screening of Lp(a) in FH patients together with other blood routine 
parameters, especially in women, followed by early initiation of niacin treatment in 
addition to statins may be of importance to reduce the increased CHD risk possible 
mediated by Lp(a). 
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7. Future perspectives 
The present studies have generated new knowledge and hence new questions and 
hypotheses. 
Only a small number of differences in coagulation markers between the susceptible 
and resistant groups and in FH subjects versus controls were found, most likely due to 
the small number of participants included in this study. However, it has previously 
been shown that peripheral blood mononuclear cells isolated from FH patients with 
early CAD (n = 6), or with present xanthomas and xanthelasms (n = 10) release more 
proinflammatory cytokines than FH subjects without CAD (n = 16) and without 
xanthomas and xanthelasms (n = 12), respectively, indicating that by the use of more 
sensitive inflammatory markers one might be able to identify new biomarkers (163). 
We therefore wish to proceed this project by analysing the circulating level and the 
gene expression of different – more sensitive – inflammatory markers which are 
thought to contribute in the atherosclerotic process. 
It is known that the phenotypic variation between FH subjects with the same genotype 
cannot be explained solely by their cholesterol levels. Future research should 
therefore be directed at identifying and determining which FH subjects that are at 
particularly high risk of premature CHD through the investigation of which 
biochemical, genetic and environmental factors that 1) may predict risk and 2) by 
modulation of which the risk is lowered. Subsequently, individual treatment regimens 
can be developed on basis of these findings in order to implement early and more 
intensive treatment for the prevention of CHD and potential fatal events in FH 
subjects who are at the highest risk of developing premature CHD. 
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Appendix 4.  Inclusion and exclusion criteria for susceptible FH subjects 
 
Inclusion criteria susceptible group 
 
 1. Proven LDL receptor or ApoB or PCSK9 mutation 
2. Aged 18 years or older 
3. Clinical diagnosis of CHD prior to: 
• 44 years for male non-smokers 
• 41 years for male smokers / ex-smokers 
• 55 years for female non-smokers 
• 51 years for female smokers / ex-smokers 
 For susceptible, smokers / ex-smokers are those patients who were a smoker or ex-smoker 
 at the time of their CHD. 
• Smoker is defined as any cigarette smoking over the previous month 
• Ex-smoker is defined as no cigarette smoking in the previous month but has 
previously smoked 
 Clinical diagnosis of CHD is defined by the presence of at least one of the following 
 symptoms: 
a) Myocardial infarction proven by at least 2 of the following: 
I. Classical symptoms (>15 minutes) 
II. Specific ECG abnormalities 
III. Elevated cardiac enzymes (>2x upper limit of normal) 
b) Percutaneous coronary intervention or other invasive procedures 
c) Coronary artery bypass grafting 
d) Angina pectoris diagnosed as classical symptoms in combination with at least one 
unequivocal result of one of the following: 
I. Exercise test 
II. Nuclear scintigram 
III. Dobutamine stress ultrasound 
IV. More than 70 % stenosis on a coronary angiogram 
4. The volunteer, their parents and all four grandparents must be white Caucasian. All four 
grandparents must have been born in the country of study 
5. Willing to provide a blood sample 
6. Completed written informed consent, including consent for their DNA to be used for 
anonymous genotyping with a potential commercial application 
 
 
 
Exclusion criteria susceptible group 
 
 1. Diabetes mellitus prior to the diagnosis of CHD 
2. Homozygous FH 
3. Pre-treatment triglyceride levels >5mmol/L 
4. Body mass index (BMI) > 40 
5. Quarter or half blood relative (sibling (including half sibling), parent, offspring, grandparent, 
aunt or uncle) already participating in the trial in the same group (i. e. a resistant volunteer 
can not be enrolled on the study if they have a qualifying blood relative already enrolled in the 
trial in the resistant group however they may be enrolled if their relative is in the susceptible 
group) 
6. Current pregnancy (that the volunteer is aware of) or lactation 
7. A known genetic disorder other than FH or ApoB or PCSK9 mutation 
8. A medical condition that, in the opinion of the investigator, would make it inadvisable for the 
volunteer to participate in the trial 
9. Volunteers who, in the opinion of the investigator, should not participate in the study 
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Appendix 5. Inclusion and exclusion criteria for resistant FH subjects 
 
Inclusion criteria resistant group 
 
 1. Proven LDL receptor or ApoB or PCSK9 mutation 
2. No clinical diagnosis of CHD or CVD prior to 
• 49 years for male non-smokers 
• 46 years for male smokers / ex-smokers 
• 60 years for female non-smokers 
• 56 years for female smokers / ex-smokers 
For resistant, smokers / ex-smokers are those patients who are a smoker or ex-smoker at the 
time of the study 
• Smoker is defined as any cigarette smoking over the previous month 
• Ex-smoker is defined as no cigarette smoking in the previous month but has 
previously smoked 
Clinical diagnosis of CHD is defined by the presence of at least one of the following 
symptoms: 
a) Myocardial infarction proven by at least 2 of the following: 
I. Classical symptoms (>15 minutes) 
II. Specific ECG abnormalities 
III. Elevated cardiac enzymes (>2x upper limit of normal) 
b) Percutaneous coronary intervention or other invasive procedures 
c) Coronary artery bypass grafting 
d) Angina pectoris diagnosed as classical symptoms in combination with at least one 
unequivocal result of one of the following: 
I. Exercise test 
II. Nuclear scintigram 
III. Dobutamine stress ultrasound 
IV. More than 70 % stenosis on a coronary angiogram 
e) Ischaemic stroke demonstrated by CT or MRI scan 
f) Documented transient ischaemic attack 
g) Peripheral arterial bypass graft 
h) Peripheral percutaneous transluminal angioplasty or other percutaneous invasive 
intervention 
i) Intermittent claudication defined as classical symptoms on combination with at least one 
unequivocal result of one of the following: 
I. Ankle/arm index <0.9 
II. Stenosis (>50 %) on an angiogram or duplex scan 
3. Pre-treatment LDL cholesterol >6.5 mmol/L  
If no pre-treatment LDL cholesterol levels are available then one of the following criteria (in 
order of preference) may be used for selection: 
I. Off-treatment LDL cholesterol >6.5 mmol/L. Off-treatment is defined as no lipid-
lowering medication for at least 6 weeks 
II. Pre-treatment total cholesterol >9.0 mmol/L 
III. Off-treatment total cholesterol >9.0 mmol/L. Off-treatment is defined as no lipid-
lowering medication for at least 6 weeks 
4. The volunteer, their parents and all four grandparents must be white Caucasian. All four 
grandparents must have been born in the country of study 
5. Willing to provide a blood sample 
6. Completed written informed consent, including consent for their DNA to be used for 
anonymous genotyping with a potential commercial application 
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Exclusion criteria resistant group 
 
 1. Quarter or half blood relative (sibling (including half sibling), parent, offspring, grandparent, 
aunt or uncle) already participating in the trial in the same group (i. e. a resistant volunteer 
can not be enrolled on the study if they have a qualifying blood relative already enrolled in the 
trial in the resistant group however they may be enrolled if their relative is in the susceptible 
group) 
2. Current pregnancy (that the volunteer is aware of) or lactation 
3. A known genetic disorder other than FH or ApoB or PCSK9 mutation 
4. A medical condition that, in the opinion of the investigator, would make it inadvisable for the 
volunteer to participate in the trial 
5. Volunteers who, in the opinion of the investigator, should not participate in the study 
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Appendix 6. Information letter and written informed consent given the FH subjects in 
the case-control study 
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Appendix 7. Information letter and written informed consent given the control 
subjects in the case-control study 
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Appendix 8. SmartDiet food questionnaire 
 
 
26 spørsmål om ditt kosthold og din livsstil
Copyright: Lipidklinikken®, Medinnova, Rikshospitalet, Oslo Universitetssykehus. Kopiering av dette skjemaet er ikke tillatt.
Les spørsmålene og de angitte svarmulighetene nøye!
Sett kryss ved det svaret som passer best med det du vanligvis spiser.
 
Kostholdsvurdering  
27 poeng eller mindre: Du bør forbedre kostholdet ditt på mange punkter, for å gjøre det mer 
helse- og hjertevennlig.
28-35 poeng: Du kan forbedre kostholdet ditt på en del punkter, slik at det blir mer 
helse- og hjertevennlig.
36 poeng eller mer: Du har sunne kostholdsvaner.
Kommentarer:
Antall poeng:  
TM
Drikk mager melk, ½ liter skummet, søt eller sur, 
daglig. Dersom du ikke drikker melk daglig, kan det 
føre til et for lavt inntak av kalsium.
Alle fløte- og rømmetyper inneholder mye mettet fett og 
anbefales ikke i hverdagskostholdet. Cultura, skum-
met kultur, lettmelk, ekstra lett melk, skummet melk, 
yoghurt, mager Créme Fraiche (10 % fett) og Kesam  
(1 % fett) kan brukes i matlaging, til sauser og dressing.
Ost er en kilde til store mengder mettet fett. Velg  
lettere eller mager ost (ost med mindre enn 10 % fett) 
til hverdags. Ikke bruk lettere ost som pålegg på  
mer enn en tredel av dagens brødskiver. Vær også  
oppmerksom på mengde og type ost du bruker i 
matlagingen. Velg gjerne planteoljebaserte oster  
som pålegg og i matlagingen.
Fett kjøtt er også en kilde til store mengder mettet 
fett. Velg kjøtt med mindre enn 10 % fett både som 
middagsmat og som pålegg. Skjær bort alt synlig fett, 
og spis minst mulig oppblandede kjøttprodukter. Velg 
for eksempel karbonadedeig eller kylling-/ svinekjøtt-
deig fremfor kjøttdeig. Fjern skinnet på kylling, kalkun 
og annet fjærkre. Velg skinkeprodukter som pålegg 
fremfor salami, fårepølse og lignende. 
Spis alle typer fisk til middag flere ganger i uken. 
Fet fisk som makrell, sild, laks og ørret inneholder 
umettet fett (omega-3) og er derfor spesielt gunstig. 
Spis fisk som pålegg daglig. Ta i tillegg 1 skje tran, 
eventuelt 2 fiskeoljekapsler, daglig året rundt.
Bruk gjerne majonespålegg daglig, men i moderate 
mengder. De fleste majonesprodukter inneholder mye 
olje og derfor mye fett (og kalorier), men fettet  
er umettet og derfor gunstig. 
Myk plantemargarin er en god kilde til umettet fett. 
Velg typer med mer enn 70 % umettet fett. Velg 
gjerne margarin med plantesteroler. Plantesteroler er 
gunstig for kolesterolet. Ved bruk av medikamentet 
Ezetrol® (ezetimib) forventes imidlertid ikke plante-
steroler å gi noen ytterligere kolesterolreduksjon.
Bruk gjerne olje, flytende eller myk plantemargarin 
i matlagingen (velg typer med mer enn 70 % umet-
tet fett). Spis mindre stekt mat. Velg heller kokt eller 
ovnsstekt mat, da vil behovet for fett i matlagingen 
reduseres. 
Grove kornprodukter er viktig i hverdagskostholdet. 
Spis mye av alle sorter fiberrike kornprodukter. Havre 
er spesielt gunstig og bør brukes regelmessig. Brødet 
bør inneholde mer enn 6 gram fiber pr 100 gram 
brød. Se også etter Brødskala’n på emballasjen. 
Husk ”5-om-dagen”. Spis minst tre porsjoner 
 grønnsaker og to porsjoner frukt hver dag. Fyll halve 
middagstallerkenen med grønnsaker, både rå og 
lettkokte. Spis frukt og grønnsaker som mellom-
måltid, som pålegg og som pynt på pålegget. Vær 
raus med porsjonene. Erter, bønner og linser kan med 
fordel spises ofte. 
 
En porsjon poteter, ris eller pasta daglig er et fint 
tilbehør til middagen.
Bruk minst mulig sukker, sukkerholdig mat og  
drikke, som kjeks, kaker, is, søtt pålegg, sukker- 
godt, sjokolade, juice, nektar, saft og brus. Med  
unntak av fruktjuice gir disse produktene ingen  
eller få næringsstoffer, men kan bidra til økt vekt.  
Sukker (inkludert frukt sukker) kan også øke  
triglyseridverdiene. 
Nøtter og mandler inneholder gunstig umettet fett, 
men er veldig kaloririke. Bruk det derfor gjerne, men  
i begrenset mengde. Kokosnøtten og chillinøttene  
inneholder mye mettet fett og bør derfor unngås. 
Kaffebønnen inneholder fettstoffer som øker kole-
sterolet. Velg derfor pulverkaffe (inneholder ikke fett) 
eller kaffe som blir filtrert, da filteret fjerner det meste 
av fettstoffene. Husk at kaffe tilsatt melk (for eksempel  
café latte, cappuccino) kan være en kilde til mettet 
fett avhengig av melketypen som brukes og mengde 
kaffe som drikkes. 
Alkohol inneholder mye kalorier og kan derfor føre til 
vektøkning. Alkohol kan også øke triglyseridverdiene. 
Eggeplommen inneholder mye kolesterol. Begrens 
inntaket til to eggeplommer per uke. Den største 
årsaken til økning av kolesterolet i blodet er likevel 
matvarer rike på mettet fett. 
De gode rådene finner du her
Mettet fett er kolesteroløkende. Reduser derfor inntaket av matvarer med mye mettet fett. Velg i stedet 
matvarer med umettet fett som kan senke kolesterolet.
Spørreskjemaet vil ikke nødvendigvis gi et komplett bilde av ditt kosthold. Du kan få mer informasjon om 
kostholdet i heftet ”Kostbehandling ved høye blodlipider hos voksne” (Lipidklinikken 2006).
Spørsmål 1-15 med unntak av spørsmål 10 er evaluert i forhold til veid kostholdsregistrering.
Kilde: Svilaas A, Strøm EC, Svilaas T, Borgejordet Å, Thoresen M, Ose L. SmartDietTM, a health educational 
tool. Reproducibility and validity of a short food questionnaire for assessment of dietary habits. Nutr Metab 
Cardiovasc Dis 2002; 12: 60-70. Tredje revidering av skjemaet utgitt i mai 2009.
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1. Måltidsmønster
Hvor mange måltider, inkludert mellommåltider, spiser du daglig?
 1-2 måltider □ 3 måltider
 4 måltider □ 5 eller flere måltider
2. Høyde, vekt og midjemål
Høyde: …..….. cm          Vekt: …..….. kg
Ønsker du å gå ned i vekt? Nei         □ Ja 
Hvis ja, hvor mange kilo ønsker du å gå ned i vekt?  …..….. kg
Midjemål: …..….. cm (Fylles ut av helsearbeider)
3. Røyk/snus
Røyker du? Nei          □ Ja           □ Ja, selskapsrøyker
Hvis ja, hvor mange sigaretter/piper røyker du i gjennomsnitt per dag? Antall …..…..
Snuser du? Nei         □ Ja 
Hvis ja, hvor mange porsjoner snuser du i gjennomsnitt per dag?    Antall …..…..
4. Mosjon
Hvor ofte mosjonerer du i minst 30 minutter slik at du blir lett andpusten eller svett?
Eksempel: Rask gange • Løping • Skigåing • Svømming • Sykling o.l.
 Sjeldnere enn 1 gang per uke eller aldri 
 1 til 2 ganger per uke
 3 eller flere ganger per uke
Hvilken type mosjon bedriver du? ……………..…..…..…..
5. Kosttilskudd
Bruker du kosttilskudd? 
 Nei □ Tran □ Fiskeoljekapsler/omega3-kapsler
 Multivitaminpreparat □ Annet ………………………
Navn:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Fødselsdato:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   Dato for besvarelsen:  . . . . . . . . . . . . . . . . . . . . . .
Navn på fastlege:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Adresse til fastlege: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
16. Belgvekster 
Spiser du belgvekster ukentlig? □ Ja □ Nei
Eksempel: Hvite tomatbønner • Brune bønner • Kikerter • Linser • Erter • Sukkererter o.l.
17. Potet, ris og pasta
Hvor mange porsjoner poteter, ris og/eller pasta spiser du daglig? 
En porsjon tilsvarer 2 poteter eller 2 dl kokt ris eller 2 dl kokt pasta/spaghetti
 Spiser ikke 0-1 porsjon □ 2 porsjoner 3 porsjoner eller fler
Hva spiser du oftest? Potet □ Ris □ Pasta
18. Nøtter, mandler o.l.
Spiser du nøtter/mandler ukentlig? □ Ja □ Nei
Spiser du avokado eller oliven ukentlig? □ Ja □ Nei
19. Kaffe
Drikker du kaffe?  □Ja □ Nei
Hvis ja, hvilken type?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Eksempel: Cappuccino • Café latte • Presskannekaffe • Kokekaffe • Traktekaffe • Pulverkaffe o.l. 
20. Alkohol
Drikker du alkohol?  □Ja □ Nei
Hvis ja, hvor mange enheter drikker du til sammen per uke?
 Mindre enn 1 □ 1-7 
 8-14 □ 15 enheter eller flere
21. Egg
Hvor mange egg, inkludert i matlaging, spiser du per uke?  Antall……
1 enhet =
1 glass vin (125 ml)
1 glass øl (0.33 l) 
4 cl brennevin  
7. Fisk til middag
Hvor mange ganger i uken spiser du fisk, fiskemat og/eller fiskeretter?
Inntil en gang i uken eller aldri  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 ganger i uken  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 eller flere ganger i uken  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Til hvor mange av disse middagene spiser du fet fisk ukentlig? Antall:…..
Eksempel: Ørret • Laks • Makrell • Kveite • Sild
8. Majones, remulade og kaviar
Hvor ofte bruker du majonesprodukter, remulade og/eller kaviar på brødmaten?
Eksempel: Majones • Rekesalat • Italiensk salat • Crab-stick salat • Skagensalat • Frokostsalat • 
Remulade • Kaviar/kaviarmix o.l.
På inntil 1 brødskive i uken eller aldri  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
På 2-7 brødskiver i uken . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
På 8 eller flere brødskiver per uke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9. Smør eller margarin på brødmaten
Hvilken type bruker du oftest?
Meierismør og alle andre typer smør • Smøregod • Bremyk • Brelett • Brelett Oliven • 
Melange margarin • Per margarin • Soft margarin uten salt og melk • Letta  . . . . . . . . . . . . . . . . .
Soft Flora (beger) • Soft Light • Soya margarin • Soya lett margarin • Oliven margarin •  
Olivero • Solsikke margarin • Soft Ekstra • Brelett omega-3 margarin . . . . . . . . . . . . . . . . . . . .
Vita • Vita lett • Vita Pro-aktiv • Becel Pro-activ • Münsterland Organic Margarin . . . . . . . . . . . . .
Bruker vanligvis ikke smør eller margarin på brødmaten . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10. Plantesteroler
Bruker du et produkt som inneholder plantesteroler?
Eksempel: Vita Pro-aktiv • Becel Pro-aktiv □ Ja □ Nei
11. Fett i matlagingen
Hvilken type fett bruker du oftest til steking, baking, i saus, som dressing o.l.
Meierismør og alle andre typer smør • Bremyk • Smøregod • Melange margarin (kube) • 
Per margarin • Soft Flora stekemargarin (kube) • Soya stekemargarin • Palmeolje . . . . . . . . . . . .
Soft Flora (beger) • Soya margarin • Solsikke margarin • Oliven margarin • Olivero •  
Soft Ekstra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Olje • Flytende margarin • Vita  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Bruker vanligvis ikke fett i matlagingen  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12. Brød, knekkebrød og andre kornprodukter
Hvor mange skiver brød, rundstykker eller knekkebrød spiser du daglig?   Antall:…..
Hvor mange porsjoner havregrøt, kornblanding eller 
andre typer frokostblandinger spiser du ukentlig?   Antall:….. 
Hvilken type brød og kornprodukter spiser du oftest?
Kneippbrød • Firkornbrød • Landbrød • Jegerbrød • Loff • Fine rundstykker • Baguetter • 
Ciabatta • Lyst knekkebrød • Riskaker • Puffet ris • Cornflakes • Havrenøtter •  
Frokostkorn (med sjokolade, honning, sukker) o.l. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rugbrød • Pumpernikkel • Bakers havre-, spelt- og byggbrød • Vita brød •  
Goman havrebrød • Mesterbakeren grovbrød • Birkebeinerbrød • Mørke knekkebrød • 
Rugsprø • Fiberrik • Havregryn • Weetabix • Havrefras • Shredded wheat o.l. . . . . . . . . . . . . .
Spiser ikke brød, knekkebrød eller andre kornprodukter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13. Grønnsaker, frukt og bær
Hvor mange porsjoner grønnsaker, frukt og bær spiser du daglig? 
1 porsjon = 150 g som tilsvarer ca 2 gulrøtter eller ca et stort eple
Mindre enn 2 porsjoner (< 300 g) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2-4 porsjoner (300-600 g) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mer enn 4 porsjoner (> 600 g) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hvor mange av disse porsjonene er grønnsaker?  Antall:…..
Hvor mange ganger i uken spiser du salat til lunsj?  Antall:…..
14. Søtt pålegg og søt drikke
Hvor ofte bruker du søtt pålegg eller søt drikke med sukker eller fruktsukker?
Eksempel: Syltetøy • Marmelade • Prim • Geitost • Sjokoladepålegg • Honning • Brus • Saft •  
Fruktjuice/juice • Nektar o.l.
0-1 ganger daglig . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 ganger daglig . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 eller flere ganger daglig . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15. Sjokolade, snacks, kaker, kjeks o.l.
Hvor ofte spiser du snacks?
Eksempel: Sjokolade • Fløteis • Potetgull • Ostepop • Baconcrisp • Tortilla chips • Kaker •  
Kjeks • Smågodt o.l.
0-1 ganger ukentlig  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 ganger ukentlig  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 eller flere ganger ukentlig  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 Totalt antall poeng:
Sett ett kryss til hvert spørsmål ved å krysse av i sirkelen ved det alternativet som passer best 
med det du vanligvis spiser.
Vær oppmerksom på at spørsmålene veksler mellom å spørre etter daglig og ukentlig forbruk.
1. Melk (sur/søt) og yoghurt
Hvor mange glass melk drikker/bruker du daglig som drikke, i matlagingen, 
på gryn, i grøt, i dessert, i kaffe/te o.l.?  Antall:…..
Hvor mange små beger med yoghurt (ca 1 dl) spiser du i løpet av en uke?   Antall:….. 
Hvilken type melk bruker du oftest? 
Helmelk • Kulturmelk • Kefir • Kaffemelk 5 % fett  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lettmelk • Cultura • Biola naturell (syrnet lettmelk) • Ekstra Lett melk • Melk med smak  . . . .  
Skummet melk • Skummet kultur melk • Biola bærdrikk 0,1 % fett  . . . . . . . . . . . . . . . . . . . . . . .
Drikker/bruker mindre enn 1 liter melk i uken eller bruker aldri  . . . . . . . . . . . . . . . . . . . . . . . . .
2. Fløte, rømme o.l.
Hvilken type bruker du oftest i matlagingen, i dressing, i dip, i kaker, i kaffe/te o.l.
Kremfløte • Créme Fraiche • Seterrømme • Pisket krem  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Matfløte • Lettrømme • Créme Fraiche lett . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kaffefløte • Ekstra lett rømme • Vikingmelk • Kesam • Matyoghurt • Créme Fraiche 10 % fett . .
Bruker ikke dette ukentlig eller bruker aldri . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3. Ost på brødmaten, i matlaging, på pizza o.l.
Hvor mye ost som pålegg, regnet i osteskiver eller  
i spiseskjeer (for smørbar ost), spiser du daglig?   Antall:…..
Til hvor mange middager per uke bruker du ost?
(eks pizza, lasagne, i saus, i salat o.l.)  Antall:…..
Hvilken type ost bruker du oftest?
Hvitost • Nøkkelost • Gudbrandsdalsost (G35) • Ekte geitost • Fløtemysost • Edamer • 
Gräddost • "Dessert oster" • Smørbare fete oster • Mozzarella • Revet pizza-/pastaost • 
Taffelost • Burgerost • Snøfrisk • Parmesan  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Lettere hvitost • Lettere nøkkelost • Lettere fløtemysost • Lettere Gudbrandsdalsost •  
Lettere smørbare oster • Mozzarella • Fetaost • Prim med vaniljesmak  . . . . . . . . . . . . . . . . . .
Ost med raps- og solsikkeolje (Vita Gul o.l.) • Cottage cheese • Gammalost • Pultost • 
Mager mysost • Prim • Mager prim • ”Så lett” ost 10 % fett  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Bruker ost kun en gang i uken eller bruker aldri . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4. Kjøttpålegg
Hvilken type kjøttpålegg bruker du oftest? 
Salami • Lett salami • Servelat • Fårepølse • Stabburpølse • Morrpølse • Haugpølse • 
Reinsdyrpølse • Falukorv • Fleskepølse • Sylte • Lammerull • Paté • Fenalår •  
Leverpostei (vanlig) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kokt/røkt skinke • Hamburgerrygg • Krydderskinke • Pastramiskinke • Roastbiff • Bankekjøtt • 
Kylling- og kalkunpålegg • Lett servelat • Kalverull • Spekeskinke uten fettrand •  
Oljebaserte posteier (Vita, Mills, Delikat, Gilde) • Mager leverpostei . . . . . . . . . . . . . . . . . . . . . .
Bruker kjøttpålegg kun en gang i uken eller bruker aldri  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5. Kjøtt til middag
Hvilken type kjøtt bruker du oftest? 
Familiedeig • Medisterdeig • Grillpølse • Wienerpølse • Kjøttpølse • Medisterpølse • 
Knakkpølse • Nakkekoteletter med fettrand • Lammekoteletter • Medisterkake • 
Wienerschnitzel • Bacon • Flesk • Grillben • Fårekjøtt  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kjøttdeig (okse, lam) • Kyllingpølse • Lettpølse • Kjøpte karbonader • Hamburger • Kebabkjøtt • 
Kjøttkaker • Kjøttpudding • Kamkoteletter med fettrand • Nakkekoteletter uten fettrand • 
Kylling, kalkun og høne med skinn • Bayonneskinke med fettrand • 
Hamburgerrygg med fettrand  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Karbonadedeig • Kjøttdeig (svin, kylling) • Biff • Filet (kylling, svin, okse, lam) • Viltkjøtt • 
Stek uten fettrand • Bogskinke • Kamkoteletter uten fettrand • Kjøtt uten synlig fett • 
Kylling, kalkun og høne uten skinn • ”Go og mager” pølser • Vita pølser . . . . . . . . . . . . . . . . . . . .
Spiser kjøtt kun en gang i uken eller spiser aldri  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6. Fiskepålegg
Hvor ofte har du fisk som pålegg eller i salater til lunsj?
Eksempel: Laks • Makrell • Sild • Sardiner • Brisling • Tunfisk • Reker • Krabbe • Crab-sticks • 
Fiskepudding • Fiskekaker o.l.
På inntil 1 brødskive i uken eller aldri  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
På 2-4 brødskiver i uken . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
På 5 eller flere brødskiver per uke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
